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Abstract 
 
Cellular senescence, the irreversible loss of proliferating capacity of somatic 
cells, is an important tumour suppressor mechanism but also driver of ageing. 
These somehow contradictory functions are dependent on the development 
of the so-called senescent phenotype, which involves over-production of pro-
inflammatory and pro-oxidant signals, however the exact mechanisms 
underlying its induction remain incompletely understood. In this thesis we 
aimed to understand how mitochondria and pro-inflammatory factors interact 
during senescence and how they contribute to the senescent phenotype.  
Firstly, we show that mitochondria are critical for the establishment and 
maintenance of cell senescence. Elimination of mitochondria rejuvenated 
senescent human fibroblasts, abrogating the pro-inflammatory phenotype, 
heterochromatin foci and expression of cyclin-dependent kinase inhibitors 
p21 and p16. Importantly, a considerable percentage of these cells were able 
to resume proliferation. Mechanistically, we show that mTORC1 integrates 
signals from the DNA damage response towards PGC-1β-dependent 
mitochondrial biogenesis, playing a causal role in the development of 
senescence. Secondly we show that inhibition of IL-8, a prominent pro-
inflammatory cytokine of the SASP, partially abrogated the senescent 
phenotype by reducing mTOR-dependent mitochondrial mass and ROS 
production during senescence. Finally, we demonstrate that inhibition of 
mitochondrial content in vivo by either rapamycin or PGC-1β deletion 
prevents age-dependent increase in senescence in mouse liver. Our results 
suggest mitochondria as an important target for interventions aiming to 
reduce the load of senescent cells in ageing tissues.  
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Chapter 1. Introduction 
 
 
1.1 Cellular Senescence 
 
In 1961, while performing experiments with cultures of human fibroblasts, 
Hayflick and Moorhead first described cellular senescence (Hayflick et al. 1961). 
Hayflick and Moorhead have observed that human fibroblasts irreversibly lose 
the ability to divide following a fixed number of cell divisions. They also found 
that these non-dividing cells remained viable for a long period of time (many 
weeks) but failed to proliferate, despite the presence of ample space, nutrients 
and growth factors in the culturing medium. This form of senescence triggered 
by an extended period of cell divisions became known as “replicative 
senescence”. Since Hayflick´s discovery of replicative senescence, various 
reports have demonstrated that cells can also enter senescence in response to 
a variety of external stresses (Lloyd 2002). This last form of senescence has 
been termed “stress-induced premature senescence” (SIPS). The fact that 
several different stressors can lead cells to entry a senescence state supports 
the idea that the senescent phenotype represents a general cellular response 
mechanism. Therefore, as a cellular mechanism/program, senescence is likely 
to play a role in the physiology of cells within living tissues (Ben-Porath et al. 
2004). The observation that cells would not proliferate indefinitely in culture 
spawned two hypotheses: i) senescence as a cellular mechanism that 
permanently locks cells in the cell cycle preventing the spread of damage to the 
next cell generation and therefore potential malignant transformation – 
senescence as a tumour-suppressive mechanism (Sager 1991) - and ii) 
senescence as a causal factor for tissue impairment and decreased tissue 
repair and regeneration ability with age – senescence as potential cause for 
tissue dysfunction observed during ageing (Campisi et al. 2007). How this 
response is coordinated within the body is still not clear, however it could occur 
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in a pleiotropic manner, as proposed in the Antagonistic Pleiotropy Theory of 
Ageing (Williams 1957). The Antagonistic Pleiotropy Theory claims that a 
process which is beneficial to young organisms (possibly providing a 
reproductive advantage) can be harmful to old organisms. In this sense cellular 
senescence would, at first, be beneficial as tumour suppressor, but an 
accumulation of senescent cells with age would entail deleterious 
consequences to the same organism. 
 
 
1.1.1 The Senescent Phenotype 
 
Although senescent cells cannot respond to mitogenic stimuli, they have the 
ability to remain viable in culture for an extended period of time. In this state of 
perpetual cell cycle arrest or senescence, cells develop certain characteristics 
collectively known as the senescent phenotype. The long-term culture of cells 
results in a dramatic change in cellular morphology characterised by an 
increase of the cellular volume, loss of the original cellular shape and 
acquisition of a flattened cytoplasm (Bayreuther et al. 1988) (Figure 1.1). 
However, the senescent phenotype comprises not only the cellular morphologic 
changes and growth arrest, but also results in changes in the nuclear structure, 
gene expression, protein processing and metabolism and resistance to 
apoptosis (Campisi 2000, Sitte et al. 2000, von Zglinicki et al. 2000, Narita et al. 
2003). 
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Figure 1.1 | Young and old human diploid cells (MRC5 
fibroblasts). (left) Young cells at a population doubling 20; 
(right) Old cell at population doubling 55 – Replicative 
senescent cell.  
 
Typically, senescent cells present a G1 phase DNA content (Dulić et al. 1993, 
Stein et al. 1995), resulting from the fact that cells usually arrest growth in this 
phase of the cell cycle. Although, in some cases the cell cycle phase in which 
cells become permanently arrested may differ depending on species and 
genetic background of the cell (Di Leonardo et al. 1994, Ogryzko et al. 1996, 
Herbig et al. 2004). The proliferating arrest observed in senescent cells occurs 
due to expression of dominant cell cycle inhibitors (discussed below). 
Similar to senescence, apoptosis is a cellular mechanism in response to cellular 
damage resulting from intrinsic and extrinsic stresses. However, whereas 
senescence prevents propagation of damaged or stressed cells, apoptosis 
responds by permanently eliminating them (Ellis et al. 1991). Many cells types 
show resistance to apoptosis when undergoing cellular senescence; this feature 
of senescence has been argued as a putative reason for the fact that the 
number of these cells increases with age (Hampel et al. 2004). Reports have 
described that the difference between apoptosis and senescence might be due 
to different responses to the p53 pathway (Seluanov et al. 2001, Campisi et al. 
2007). However, the mechanisms behind the “decision” between apoptosis or 
senescence are not yet fully elucidated. Reports have demonstrated that it may 
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depend on the nature and intensity of damage or stress (Seluanov et al. 2001, 
Rebbaa et al. 2003). It is thought that rapid DNA repair quickly terminates p53–
p21 signalling, whereas slow, incomplete or defective repair results in sustained 
signalling and senescence (Campisi et al. 2007). In vivo, it has recently been 
suggested that induction of senescence or apoptosis depends on the cellular 
level of telomere dysfunction and differentially on p53 gene function during 
senescence. Lechel et al. showed that telomere dysfunction induced in mouse 
livers led to p53 independent apoptosis but a p53 dependent induction of 
cellular senescence, depending on the level of telomere dysfunction (Lechel et 
al. 2005).  
Furthermore, senescent cells undergo gene expression changes of a variety of 
cellular pathways. Indeed some other traits of the senescent phenotype are a 
result of those changes (e.g., cell cycle arrest and apoptosis resistance). Cell-
cycle regulating genes (inhibitors and activators) are described to be altered in 
senescence (Shelton et al. 1999, Chang et al. 2002, Zhang et al. 2003, Mason 
et al. 2004, Jackson et al. 2006, Trougakos et al. 2006). Cyclin-dependent 
kinase inhibitors (CDKIs) are often described to show increased expression 
during senescence. The CDKIs proteins p21 and p16 are expressed in 
senescence under the control of the regulatory pathways p53 and 
retinoblastoma (pRb) proteins respectively (Campisi 2001, Braig et al. 2006). 
Additionally, senescent cells are also described to repress proteins involved in 
cell-cycle progression (e.g. replication-dependent histones, c-FOS, cyclin A, 
cyclin B and PCNA) (Seshadri et al. 1990, Stein et al. 1991, Pang et al. 1994). 
Alterations in gene expression are also accountable for the increased secretion 
of certain factors, namely inflammation mediating factors, growth factors and 
extracellular matrix components (see Role of inflammatory factors in cellular 
senescence), collectively known as the senescence-associated secretory 
phenotype (SASP), that may contribute to age-related impairment of tissue 
structure and function (Campisi 2003). 
 
  Chapter 1. Introduction 
 
5 
 
1.1.2 Senescence Markers 
For many years researchers have tried to find markers specific for senescent 
cells. So far several markers have been proposed to identify senescent cells but 
none is exclusive to the senescence state. Indeed, many commonly used 
cellular markers of senescence are not robust and might over-estimate 
senescent cells present at low frequencies when used individually (Lawless et 
al. 2010, Correia-Melo et al. 2013). 
Senescent cells are unable to express genes required for cellular proliferation 
and/or DNA replication, even in the presence of pro-mitogenic factors (Dimri et 
al. 1994, Dimri et al. 1996). These features distinguish senescence from 
quiescence, another cellular non-proliferative state that is readily rescued in 
response to mitogenic stimuli. DNA replication is often detected by incorporation 
of 5-bromodeoxyuridine (BrdU) or 3H-thymidine (Sidman et al. 1959), or by 
immunostaining for PCNA or Ki67 proteins. However, these markers do not 
allow distinction between senescent, quiescent or post-mitotic cells (Scholzen et 
al. 2000, Pan et al. 2011). 
Dimri and collegues (Dimri et al. 1994) described a marker that could allow a 
more specific identification of senescent cells. They showed that several human 
cells express β-galactosidase (β-Gal) histochemically detectable at pH 6.0 upon 
induction of senescence in culture (Sen-β-Gal). They reported that Sen-β-Gal is 
expressed by senescent, but not pre-senescent fibroblasts and keratinocytes. 
The specificity of β-Gal for senescence was also observed in human tissue 
samples of skin from donors of different age, providing in situ evidence that 
senescent cells may exist and accumulate with age in vivo. β-Gal is a 
lysossomal hydrolase enzyme with optimum activity at an acidic pH of 4.0-4.5 
reflecting the natural milieu of the lysosome (Kuo et al. 1978, Zhang et al. 1994). 
The specificity of β-Gal for senescent cells at pH 6.0  has been proposed to be 
a result of augmented lysossomal activity during senescence (Cristofalo et al. 
1975). In this context, Sen-β-Gal most likely reflects the changes in cell function 
that invariably accompanies senescence. The senescence specificity of this 
marker was then put into question by later reports describing that β-Gal could 
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also be induced by stresses such as prolonged confluence in culture (Lee et al. 
2006). 
Senescence is also accompanied by nuclear changes including an increase in 
nuclear size (Narita 2007), and an increase in the density of nuclear pore 
complexes (Maeshima et al. 2006), which function is to allow transport of 
macromolecules between the nucleus and cytoplasm. Further to that, senescent 
fibroblasts accumulate a distinct chromatin structure enriched with 
heterochromatin proteins, also designated as Senescence-associated 
Heterochromatin Foci (SAHF) (Narita et al. 2003). These heterochromatin 
structures have been correlated with the irreversibility of the cell cycle arrest in 
senescence (Beausejour et al. 2003, Narita et al. 2003). SAHFs can be 
detected by DNA dyes such as the 4’,6-diamidino-2-phenylindol (DAPI) and 
also by the presence of certain heterochromatin-associated histone 
modifications such as the H3Lys9 methylation. Heterochromatin protein-1 (HP1) 
is another protein associated with SAHFs (Narita et al. 2003). Alterations in 
nuclear envelop proteins, such as lamin A and B which connect the nuclear 
envelop to the chromatin, have been implicated in senescence. While, 
decreased expression of Lamin B1 in senescent cells has been correlated with 
SAHF formation (Sadaie et al. 2013, Shah et al. 2013), lamin A repression 
activates a DDR and induces 53BP1 and γ-H2AX foci (Liu et al. 2005). 
 
Several reports have described senescence-associated DNA foci (SDFs) as a 
marker of senescence (d'Adda di Fagagna et al. 2003, Takai et al. 2003, Herbig 
et al. 2004, von Zglinicki et al. 2005, Di Micco et al. 2006), which often display 
molecular markers for DNA double-strand breaks. These markers include 
nuclear foci of phosphorylated histone H2AX (γH2AX) and their co-localization 
with DNA repair and DNA damage checkpoint factors such as 53BP1 (d'Adda di 
Fagagna et al. 2003). Telomere-induced foci (TIF), as a result of shortened 
telomeres, were also shown to be a marker of senescent cells (d'Adda di 
Fagagna et al. 2003). Recently, it was demonstrated that damage at telomeres 
can occur independently of telomerase activity and telomere length, a 
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phenomena know as Telomere-associated foci (TAF) (Fumagalli et al. 2012, 
Hewitt et al. 2012). Following these lines, telomere-initiated senescence reflects 
a DNA damage checkpoint response that is activated with a direct contribution 
from dysfunctional telomeres and both telomere-induced or associated foci (TIF 
or TAF) have been indicated as markers of senescence. 
As mentioned previously, none of these markers per se identify specifically 
senescence cells. However, it was recently proposed, by Lawless and co-
workers (Lawless et al. 2010), that Ki67 negativity (proliferation marker) and 
γH2A.X positivity (DNA damaged marker) together is a good criteria for 
quantifying the senescent state of cells both in cultured fibroblasts and in tissue 
sections.  
 
1.1.3. Causes of Senescence 
 
Telomeres have played a central role in ageing research since the early 1970’s, 
when Alexei Olovnikov predicted that a progressive shortening of telomeres 
was responsible for the “Hayflick Limit” (Olovnikov 1971). Telomere shortening 
was therefore thought to be caused by what is known as the “end replication 
problem”, a phenomenon caused by the inability of the DNA replication 
machinery, specifically DNA polymerase, to synthesise in a 3’-5’ direction 
leading to the incomplete replication of the lagging strand. Telomeres are 
repetitive DNA sequences with associated proteins located at the end regions of 
linear chromosomes. In vertebrae, telomeres are tandem repeats of the 
sequence TTAGGG, which main function is to protect chromosomes erosion 
during each cell division (Muller 1938, Blackburn 1991, d'Adda di Fagagna et al. 
2004). The protection function of these end parts of chromosomes are 
reinforced by a group of telomere-associated proteins collectively termed as 
shelterin (de Lange 2005). The shelterin complex is constituted by six proteins: 
TRF1, TRF2 and POT1, which recognise the telomeric repeat sequence, and 
TIN2, TPP1 and Rap1 (de Lange 2005), which ultimately arrange telomere ends 
into a loop structure, known as the T-loop, to cover the exposed DNA ends 
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(Griffith et al. 1999). The “end-replication” problem has been referred to as one 
of the major reasons why normal cells do not proliferate indefinitely, since 
dysfunctional telomeres trigger a classical DNA damage response (DDR) 
(d'Adda di Fagagna et al. 2003, Takai et al. 2003, Herbig et al. 2004), which 
recognise unprotected telomeres similarly to double-strand breaks (DSBs). 
Interestingly, shelterin components have been demonstrated to inhibit DNA 
repair mechanisms. It has been shown that loss of shelterin components such 
as TRF2 contributes to activation of a DDR at telomeres (van Steensel et al. 
1998). Moreover, TRF2 and its binding partner RAP1 are required to prevent 
Non-Homologous End Joining (NHEJ)-dependent telomeric DNA fusions by 
inhibiting DNA-PK and ligase IV mediated end-joining (Bae et al. 2007). 
Consistent with these observations, Fumagalli and colleagues have shown in 
budding yeast that induction of DSBs adjacent to a telomeric sequence impairs 
the recruitment of ligase IV to the site of damage (Fumagalli et al. 2012), 
suggesting that damage at telomeres, occurring in the presence of sufficient 
shelterin components including TRF2, may elicit a persistent DDR due to 
inhibition of repair. Harley and colleagues provided the confirmation the 
telomeres do shorten with successive replication (Harley et al. 1990). 
Nevertheless, it was still unclear if telomere shortening played a functional role 
in the induction of senescence, as their shortening could merely be a 
consequence of cells reaching senescence. In the late 90’s, Bodnar and 
colleagues have provided the ultimate evidence that telomere erosion can 
induce senescence, by showing that ectopic expression of the catalytic subunit 
of telomerase, the enzyme able to elongate telomeres, leads to cell 
immortalisation (Bodnar et al. 1998). However, the shortening rate of telomeres 
is much greater than what was originally accounted by the “end-replication” 
problem alone, suggesting that other factors may contribute to telomere 
shortening (Levy et al. 1992). Furthermore, originally it was suggested that 
telomeres could serve as a counting mechanism within cells that would allow a 
finite number of replications, nevertheless a set time or threshold for telomere 
length to induce senescence has not been found (Von Zglinicki 2001). The large 
heterogeneity in telomere length between cells in the same culture (Lansdorp et 
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al. 1996) and the presence of senescent cells in cultures that have undergone a 
low number of divisions suggested that telomere length is not solely a result of a 
certain number of divisions a cell has undergone (Martin-Ruiz et al. 2004). As a 
matter of fact, Reactive oxygen species (ROS) have been described to 
contribute to accelerated telomere shortening, with telomeric DNA being 
especially sensitive to damage caused by ROS (Von Zglinicki 2001). It has 
been shown that telomeres accumulate more single-stranded breaks than the 
rest of the genome resulting from oxidative damage (Petersen et al. 1998), and 
this way may act as “sensors” to oxidative stress, preventing cells that have 
been exposed to high levels of potentially mutagenic factors from replicating 
(Martin-Ruiz et al. 2004). Consistent with a role of ROS in telomere dysfunction 
it has been suggested that guanine rich regions are more susceptible to 
oxidative modification  (Grollman et al. 1993) and that oxidative modifications of 
TRF1 and TRF2 affect its binding to telomeres (Opresko et al. 2005). 
Furthermore, interventions affecting both mitochondrial function and ROS 
generation have been shown to impact on telomere-dependent senescence in 
vitro. Treatment with free radical scavengers (von Zglinicki et al. 2000), low 
ambient oxygen concentrations (Forsyth et al. 2003, Richter et al. 2007), 
overexpression of antioxidant enzymes (Serra et al. 2003), and mild chronic 
uncoupling (Passos et al. 2007) have been shown to decelerate telomere 
shortening and to extend the lifespan of cells in culture. All together these data 
has driven the current hypothesis that both the “end-replication” problem as well 
as the ROS driven stochastic damage contributes to telomere shortening 
(Figure 1.2).  
Recently, work carried out in our group and Fabrizio d’Adda di Fagagna’s group 
have shown that oxidative-stress induced telomere damage is irreparable and 
can occur irrespectively of telomere length (Fumagalli et al. 2012, Hewitt et al. 
2012). In order to establish whether telomeric location was necessary for DNA 
damage foci persistence, using live-cell imaging our group has tracked DNA 
damage foci lifespan using a AcGFP-53BP1c fusion protein in combination with 
a fluorescently labelled PNA probe which specifically tags telomere repeats. 
Using this method it was found that majority of long-lived foci in stress-induced 
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senescence co-localise with telomeres (Hewitt et al. 2012), which suggests that 
they are major contributors to a persistent DDR. These persistent irreparable 
telomeric DNA damage foci, also known as Telomere-associated foci (TAF), 
occur independently of length or telomerase activity, indicating that not only 
telomere length but damage within telomeric regions is also an important 
contributor to cellular senescence (Figure 1.2).  
 
 
 
 
Figure 1.2 | Both telomeric and non-telomeric DNA damage contribute to the 
stabilisation of cellular senescence. DNA damage at telomeres is distinct from that 
throughout the genome; it is irreparable due to the repression of DNA repair pathways 
by telomere bound proteins, known as the “shelterin” complex. This contributes to a 
permanent DNA damage response (DDR). However, continuous generation of short-
lived DDR foci by elevated reactive oxygen species (ROS) may equally contribute to 
the maintenance of the phenotype, as long as a dynamic equilibrium between damage 
induction and repair can be maintained (adapted from Correia-Melo et al. 2014). 
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Oncogene activation has been causally implicated in cellular senescence; this 
form of senescence is termed Oncogene-Induced Senescence (OIS). The term 
oncogene, as the name may suggest, is often associated with oncogenesis or 
malignant transformation of cells, indeed they are mutant versions of normal 
genes that, together with additional mutations, have the potential to transform 
cells. Ras oncogenes were first reported by Harvey and colleagues when using 
a preparation of a murine leukaemia virus, taken from a leukaemic rat, induced 
sarcomas in new-born rodents (Harvey 1964, Malumbres et al. 2003). However, 
expression of oncogenes can lead normal cells to undergo senescence, mainly 
due to an exhaustive period of cell proliferation followed by a permanent arrest. 
It had been already known that oncogenic Ras could transform cells to a 
tumorigenic state. However, the first evidence of OIS was presented by Serrano 
and colleagues (Serrano et al. 1997), when expressing an activated mutant 
form of Ras (H-RasV12), in primary human or rodent cells, they observed that 
cells permanently arrested in G1 phase. These cells also presented an 
accumulation of p53 and p16 proteins and were phenotypically indistinguishable 
from senescent cells. These observations suggested that the onset of cellular 
senescence does not simply reflect the accumulation of cell divisions, but can 
be prematurely activated in response to an oncogenic stimulus (Serrano et al. 
1997). Since OIS was first reported, other members of the RAS signalling 
pathway (e.g. RAF, MEK, MOS and BRAF), as well as pro-proliferative nuclear 
proteins (e.g. E2F ‑ 1), have been shown to cause senescence when 
overexpressed or expressed as oncogenic versions (Lin et al. 1998, Zhu et al. 
1998, Dimri et al. 2000, Michaloglou et al. 2005). Accordingly, OIS is then a cell 
response to activated oncogenes in order to counteract excessive mitogenic 
stimulation, which puts cells at risk of oncogenic transformation.  
 
Two major mechanisms have been implicated in the initiation and stabilisation 
of cellular senescence: i) the activation of a DNA damage response upon a 
genotoxic stress or telomere shortening (discussed above) and ii) perturbations 
on chromatin organisation (Di Bernardo et al. 2012). Chromatin organisation 
determines the extent to which genes are active (euchromatin) or silent 
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(heterochromatin). Alterations of chromatin structure resulting in global 
induction of heterochromatin are believed to contribute to the irreversible nature 
of the senescent state (Howard 1996). These characteristic heterochromatin 
structures, also known as senescence-associated heterochromatic foci (SAHF), 
are facultative heterochromatin whose formation is dependent on the pRb 
tumour suppressor pathway and may repress the expression of proliferation 
promoting genes, namely E2F target genes, such as cyclin A, DHFR and Mcm3 
(Narita et al. 2003). Histones variations have also been implicated in the SAHF 
transcription silencing clout. SAHF are nuclear structures comprising the 
histone H2A variant, macro-H2A (Zhang et al. 2005). There is evidence that 
support a direct role for macro-H2A in gene silencing; macro-H2A has been 
described to be resistant to ATP-dependent remodeling proteins and binding of 
transcription factors (Angelov et al. 2003). Both the cell cycle regulator p16 
(Narita et al. 2003, Narita et al. 2006) and the chromatin structure regulators 
HIRA (histone cell cycle regulation defective homologue A) and ASF1 (anti-
silencing function 1) have been described to drive formation of SAHF (Zhang et 
al. 2005). Despite the fact that SAHF have been mainly associated with gene 
silencing, chemical inhibition of histone deacetylase, which promotes 
euchromatin formation, has been shown to induce senescence (Ogryzko et al. 
1996, Munro et al. 2004). These findings that both euchromatin and 
heterochromatin can trigger senescence may appear contradictory, but one 
possible explanation is that both manipulations can cause extensive but 
incomplete changes in chromatin organisation and therefore each may alter the 
expression of different critical genes (Campisi et al. 2007).  
 
 
1.1.4. Role of a DNA damage response (DDR) in cellular senescence 
 
Cellular senescence, as a result of a persistent DDR, can be triggered by DNA 
damage such DNA single strands breaks (SSBs) and/or DNA double strands 
breaks (DSBs). There are common and specific DDR factors involved in each 
situation (Helt et al. 2005). 
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DSBs are first sensed by the Poly (ADP-ribose) polymerase (PARP) which then 
recruits the MRE11–RAD50–NBS1 (MRN) complex. The PARP-MRN complex 
functions as a lesion-specific sensor, they are one of the first factors to be 
localised to the DNA lesion (D'Amours et al. 2002). When bound to DNA, the 
MRN complex enables assembly of large macromolecular complexes (known 
as foci) that facilitate efficient DSB repair responses (van den Bosch et al. 2003). 
NBS1 then recruits the protein kinase ataxia-telangiectasia mutated (ATM) 
(Uziel et al. 2003, Lee et al. 2005). ATM is a phosphoinositol 3-kinase-like 
kinase (PIKK) that plays a central role in orchestrating a network of cellular 
responses to DSBs, including cell cycle control, DNA repair and apoptosis 
(Shiloh 2003). ATM undergoes autophosphorylation events, which leads to 
dissociation of the inactive ATM dimer into single protein molecules with kinase 
activity (Bakkenist et al. 2003, Kozlov et al. 2011). Activated ATM 
phosphorylates the histone H2AX at the site of damage (DSBs) resulting in 
γH2AX (Rogakou et al. 1999, Burma et al. 2001), which is then recognised by a 
phospho-specific domain of the mediator of DNA damage checkpoint 1 (MDC1). 
Recruitment of MDC1 to γH2AX stimulates additional accumulation of the MRN 
complex (Stucki et al. 2006), this way amplifying local ATM activity and the 
spreading of γH2AX along the chromatin from the DSBs. This increase in the 
local concentration of several DDR factors at the site of DNA damage generates 
a positive feedback loop amplifying repair signals. The DNA-damage mediator 
53BP1 (p53 binding protein 1) accumulates at the site of DNA damage as a 
result of the exposure of modified histone residues (Huyen et al. 2004, Botuyan 
et al. 2006) and establishes binding to MDC1 to further boost a downstream 
DDR (Eliezer et al. 2009). Additionally, 53BP1 is an important DDR factor 
involved in DNA repair by NHEJ (Nakamura et al. 2006), through its inhibitory 
effect on homologous recombination (Bunting et al. 2010). 
 
Alternatively, generation of local regions of replication protein A (RPA) -coated 
single-stranded DNA, caused by replication stress or UV irradiation, recruits the 
heteromeric complex that contains the ATM and rad 3 related (ATR) protein and 
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its DNA-binding subunit ATRIP to the site of damage (Namiki et al. 2006), 
activating a less defined feedback loop through the activation of the RAD9-
HUS1-RAD1 (9-1-1) and RAD17-RFC complexes, as well as TOPBP1 (d'Adda 
di Fagagna 2008). Activated by this DNA-protein structure, ATR then 
phosphorylates its downstream substrates, including the checkpoint kinase 1 
(CHK1) and 2 (CHK2) (Helt et al. 2005). Subsequently, CHK1 and CHK2 
phosphorylate and inactivate the cell division cycle 25A and C (CDC25A and 
CDC25C) proteins, members of the CDC25 phosphatase family and key 
regulators of the cell cycle (Bartek et al. 2003, Kastan et al. 2004). ATR also 
stimulates phosphorylation of H2AX and the formation of DNA damage foci 
(Iwabuchi et al. 2003). Notably, during the end stages of repair, DSBs also 
generates RPA coated ssDNA which activates ATR (Zou et al. 2003). 
 
Ultimately, CDC25 phosphatases and p53 are the bottom elements of the DDR 
signalling cascade that connects the upstream DDR pathway with the core of 
the cell-cycle progression machinery. CDC25 phosphatases are important for 
normal cell proliferation, as they activate cyclin-dependent kinases (CDKs) and 
cause their DDR-mediated inactivation, by either proteolytic degradation or 
exclusion from the nucleus (Shen et al. 2012, Neelsen et al. 2013). On the other 
hand, p53 induces cell-cycle arrest by activating the transcription of p21, a CDK 
inhibitor that blocks cell-cycle progression (Rufini et al. 2013).  
 
 
During senescence, the permanent cell cycle relies on two main molecular 
pathways: p53–p21 and p16INK4A-Rb pathways.  
 
Double-strand breaks trigger the DNA damage response (DDR) by a repertoire 
of different stressors as discussed above (see Causes of Senescence). This 
signalling cascade centred around the ATM kinase induces senescence 
primarily through the p53 pathway (Campisi 2005, Lossaint et al. 2011, Wang et 
al. 2011). p53 is a stress-activated transcription factor that controls the 
expression of hundreds of genes implicated in a variety of physiological 
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responses including responses to genome instability and DNA damage (Toledo 
et al. 2006). p53 tumour suppression function relies on its ability to cease cell 
proliferation and induce two fundamental cell responses: apoptosis (cell death) 
or cellular senescence (permanent cell cycle arrest) (Di Micco et al. 2006, Gao 
et al. 2011, Gatta et al. 2011, Osawa et al. 2011, Rufini et al. 2013). The cyclin-
dependent kinase inhibitor 1 CDKN1A/p21, a well-established p53-target gene, 
has been proved to be up-regulated during senescence being an essential 
mediator of the p53-dependent cell cycle arrest (Brown et al. 1997, Herbig et al. 
2003, d'Adda di Fagagna 2008, Passos et al. 2010). p21 is a dual inhibitor of 
cyclin-dependent kinases (Harper 1993, Xiong et al. 1993) and proliferating-cell 
nuclear antigen (PCNA) (Waga et al. 1994), which are required for passage 
through the cell cycle. Accordingly, depletion of p21 in mouse embryonic 
(Brugarolas et al. 1995) and human fibroblasts (Brown et al. 1997) compromise 
its ability to undergo p53-dependent G1 arrest following DNA damage and 
abrogates several characteristics of the senescent phenotype. Notwithstanding 
that p21 is crucial to the p53-growth arrest of senescent cells (Chang et al. 
2000), it is unlikely to be exclusively responsible for the complex changes 
underpinning senescence. Indeed, p53 is a master transcription factor involved 
in the regulation of several physiological and metabolic pathways which have 
also been heavily implicated in regulation of cellular senescence and the ageing 
process (Vousden et al. 2009). In this context, E2F7 is another p53 target that 
has recently been described to be involved in cell-cycle arrest and senescence; 
it promotes repression of several E2F target genes, including E2F1, and many 
genes essential for mitosis, such as CCNA1 (encoding cyclin A), CCNB1 
(encoding cyclin B) and CDC2/CDK1 (Aksoy et al. 2012, Carvajal et al. 2012, 
Rufini et al. 2013).  
 
Stimuli that produce a DDR can also engage the p16–pRb pathway. pRb can be 
activated by p16INK4a, hereafter p16, independently of p53 (Alcorta et al. 1996). 
In certain cell types (e.g. fibroblasts) activation of the p16–pRB pathway often 
occurs secondarily to engagement of the p53 pathway (Stein et al. 1999, 
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Jacobs et al. 2004), while in others (e.g. epithelial cells) the inducing stimuli acts 
primarily through the p16–pRB pathway (Campisi et al. 2007). Additionally, in 
mouse cells telomere dysfunction seems to primarily activate the p53 pathway, 
whereas in human cells both the p53 and p16–pRB pathways are activated 
(Smogorzewska et al. 2002). p16 is a cyclin dependent kinase inhibitor that 
localises at the perinuclear cytoplasm, which following activation translocates to 
the nucleus (Serrano et al. 1993). As a cyclin dependent kinase inhibitor, p16 is 
able to prevent phosphorylation of pRb by cyclin/cdk complexes. p16-pRb axis 
is pivotal to the establishment of cell-cycle arrest: hypophosphorylated pRb 
halts cell proliferation by inhibitory binding to E2Fs transcription factors, thus 
preventing them from stimulating transcription of genes involved in cellular 
proliferation and DNA replication (Campisi et al. 2007). While p21 has its 
maximal expression at the initiation of senescence and declines after the cell 
become senescent, p16 expression increases gradually, with barely detectable 
levels at the early stages of senescence, and then persists for months after 
induction of senescence (Alcorta et al. 1996, Stein et al. 1999). p16 expression 
has been shown to increase as a result of oncogene activation (Serrano et al. 
1997). During OIS, suppression of pRb abolishes the establishment of 
senescent phenotype, but it is not sufficient to overcome cell-cycle arrest; this 
depends on the concomitant p53-dependent cell-cycle arrest (Aksoy et al. 2012). 
Additionally, p16 has also been shown to be upregulated following oxidative 
damage (Chen et al. 2004), radiation (Meng et al. 2003) and telomere 
dysfunction (Jacobs et al. 2004). The mechanisms by which senescence-
causing stimuli induce p16 expression are thought to occur due to reduced 
expression of Polycomb INK4a repressors such as BMI1 and CBX7 (Itahana et 
al. 2003, Gil et al. 2004, Bracken et al. 2007). Supporting this idea, it is reported 
that BMI1 or CBX7 overexpression extends the replicative lifespan of human 
and mouse fibroblasts (Jacobs et al. 1999, Itahana et al. 2003, Gil et al. 2004). 
The p16–pRB pathway is also involved in SAHFs generation (Narita et al. 2003), 
this may be due to pRB ability to complex with histone modifying enzymes that 
form repressive chromatin (Macaluso et al. 2006).  
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Another possibility is that DNA damage signals activate p38MAPK signalling 
which then activates p16 (Iwasa et al. 2003, Bulavin et al. 2004, Ito et al. 2006). 
 
The p38 mitogenic-activated protein kinase (p38MAPK) has also been 
described to be important for the senescence growth arrest, it can activate both 
the p53-p21 and p16-pRb growth arrest pathways (Iwasa et al. 2003). 
p38MAPK inhibition moderately delays replicative senescence and the rapid 
entry into senescence of cells from patients with Werner’s syndrome, a 
premature aging disorder caused by a defective DNA repair protein (Davis et al. 
2009). Additionally, p38MAPK activity is required for the senescence arrest 
caused by oncogenic RAS, and constitutive p38MAPK activity can induce a 
growth arrest in normal human cells (Wang et al. 2002, Deng et al. 2004). 
Recently, p38MAPK has also been described as a key factor for secretion of 
inflammatory factors by senescent cells (Freund et al. 2011). Passos et al. 
(2010) have shown that p38MAPK enhances mitochondrial ROS generation, 
thereby contributing to the stabilisation of a DDR during senescence (Passos et 
al. 2010).  
 
 
 
1.2 Role of Mitochondria and ROS in cellular senescence 
 
The first evidence of mitochondria as sub-cellular organelles occurred in the 
19th century, when Richard Altmann and Carl Benda argued for the existence of 
sub-cellular structures that sometimes appeared threadlike and at other times 
more granular. These features gave rise to the name “mitochondria” from the 
Greek words mitos (thread) and chondrion (granule) (Bechtel et al. 2007). From 
a structural perspective, the mitochondrion (the basic unit of mitochondria) 
contains two membranes that separate four distinct compartments: the outer 
membrane, the inner membrane, the inter-membrane space and the matrix. The 
inner membrane is highly folded into cristae and harbors the electron transport 
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chain and ATP synthase responsible for the cellular energy supply (McBride et 
al. 2006). Mitochondria are central organelles to cellular metabolism and have 
been shown to become altered during cellular senescence.  
In 1956, Denham Harman proposed the Free Radical Theory of Ageing 
(Harman 1956), in which reactive oxygen species (ROS) would form inside the 
cells, as a by-product of normal redox reactions, which could in turn cause 
damage to surrounding structures and or molecules, such as DNA, lipids and 
proteins. Many reports have since supported Harman’s theory, showing 
correlative evidence that oxidative damage increases during ageing (Oliver et al. 
1987, Fraga et al. 1990, Hamilton et al. 2001). In the 1970’s, Harman 
introduced a modification to the Free Radical Theory of Ageing, suggesting that 
mitochondria would play a central role on ageing (Harman 1972), since these 
organelles are the main producers of ROS in cells (Chance et al. 1979), in what 
was then termed as the Mitochondrial Theory of Ageing (MTA). In the past 
years, it has been shown that mitochondria are indeed the major source of ROS 
within the cell (confirming the modified proposal of Harman), but also that 
mitochondrial DNA (mtDNA) deletions and mutations can be a result of 
oxidative stress, and that mitochondrial oxidative damage can accumulate with 
age in organisms ranging from worms to humans (Golden et al. 2001, Yui et al. 
2003). It has been shown that mtDNA is more susceptible to ROS mediated 
damage than nuclear DNA; these subcellular structures, contrary to their 
nuclear counterpart, lack histones and instead form protein-DNA complexes 
(nucleoids) in the mitochondrial matrix, which can protect them against oxidative 
damage, but not in the same extent as histones (Gilkerson 2009). However, 
lately the MTA has been questioned, with several reports suggesting an inverse 
relationship between mitochondrial biogenesis and ageing (discussed below) 
and genetically manipulated animal models where mitochondrial function and 
oxidative stress were targeted showing conflicting results (Muller et al. 2007). 
For instance, studies in mice have shown that heterozygous deletion of the 
mitochondrial superoxide dismutase, an enzyme able to convert superoxide 
anion into hydrogen peroxide and water, showed that increased oxidative stress 
does not accelerate ageing in mice (Van Remmen et al. 2003). Furthermore, 
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interventions promoting longevity, namely CR and sirtuin activators, have been 
linked with increased mitochondrial biogenesis (Baur et al. 2006, Lopez-Lluch et 
al. 2006). A recent study has also shown that elevated mitochondrial ROS 
levels promote extension of lifespan in Caenorhabditis elegans (C. elegans) by 
protecting from the consequences of mitochondrial dysfunction via triggering of 
a unique pattern of gene expression that modulates stress sensitivity and 
promotes survival (Yee et al. 2014).  
Notwithstanding that the role of mitochondria and ROS during ageing is 
conflicting, in senescence mitochondrial dysfunction seems to be a general 
feature and has been reported to occur independent of the nature of the 
senescence stimuli (e.g. genotoxic stress, telomere dysfunction and oncogene 
activation) (Allen et al. 1999, Hutter et al. 2002, Zwerschke et al. 2003, Hutter et 
al. 2004, Passos et al. 2007, Moiseeva et al. 2009). Mitochondrial dysfunction 
during senescence has been characterised by an increase in mitochondrial 
mass and decreased mitochondrial membrane potential, leading to metabolic 
inefficiency and increased generation of ROS (Saretzki et al. 2003, Ramsey et 
al. 2006, Passos et al. 2007, Lu et al. 2008). The mechanisms by which 
mitochondrial homeostasis is maintained are complex and involve regulation of 
mitochondrial number and function in response to a variety of environmental 
cues. The Peroxisome Proliferator-Activated receptor (PPAR)-γ co-activator 
(PGC)-1 family of transcription co-activators are master regulators of 
mitochondrial homeostasis (Lin et al. 2005). These transcription co-activators 
regulate mitochondria numbers and function by interacting with a broad range of 
transcription factors that are involved in a wide variety of biological responses 
including adaptive thermogenesis, mitochondrial biogenesis and glucose/fatty 
acid metabolism (Wu et al. 1999). The PGC-1 family comprises three homologs: 
PGC-1α (Puigserver et al. 1998), PGC-1β (Kressler et al. 2002) and PGC-
related co-activator (PRC) (Andersson et al. 2001). It has been described that 
PGC-1 co-activators factors stimulate mitochondrial biogenesis via induction of 
the uncoupling protein 2 (UCP-2) and regulation of the nuclear respiratory 
factors (NRFs). PGC-1 co-factors also regulate mitochondrial DNA 
replication/transcription through binding and co-activation of the transcriptional 
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factor NRF-1 on the promoter of the mitochondrial transcription factor A (mtTFA) 
(Lin et al. 2005). The role of PGC-1 transcriptional co-activators on the ageing 
process seems to be controversial. Several reports have suggested an inverse 
relationship between mitochondrial biogenesis and ageing. Mitochondrial 
density in skeletal muscle gradually declines during age (Crane et al. 2010), 
suggesting a decrease in mitochondrial biogenesis possibly via an age-
dependent reduction in levels of PGC-1α (Wenz et al. 2009). Studies on 
mitochondrial-myopathy mouse models have suggested that a compensatory 
mitochondrial mass increase is beneficial by partly compensating for the 
reduced function of the respiratory chain and maintaining overall ATP 
production in skeletal muscle (Wredenberg et al. 2002). However, the same 
group has later reported that beneficial effects of mitochondrial mass increase 
seems to be tissue specific, since it contributes to aggravate heart failure 
progression in the same mouse model (Hansson et al. 2004). Furthermore, 
genetically induced mitochondrial biogenesis has been associated with age-
related diseases such as cardiomyopathy (Lehman et al. 2000), renal fibrosis 
(Hickey et al. 2011) and diabetes (Sawada et al. 2014), all of which have been 
associated with cellular senescence (Sussman et al. 2004, Testa et al. 2007, 
Yang et al. 2010). Increased mitochondrial content has also been associated 
with osteoarthritis, particularly Kashin-Beck Disease (KBD), where articular 
chondrocytes present increased mitochondrial mass (Liu et al. 2010). While 
there is some evidence for a role mitochondrial homeostasis deregulation 
during senescence, the mechanisms by which mitochondria become impaired is 
still not clear. 
ROS have been implicated in both the induction and stabilisation of cellular 
senescence, with several studies showing that ROS can accelerate telomere 
shortening (von Zglinicki 2002) and induce DNA damage and thus activate a 
DDR and senescence (Chen et al. 1995, Lu et al. 2008, Rai et al. 2009) (Figure 
1.3A). Evidence indicates that activation of major downstream effectors of the 
DDR in senescence result in elevated ROS. Activation of a DDR by genotoxic 
stress or telomere uncapping (Passos et al. 2010), over-expression of activated 
RAS (Lee et al. 1999), BRAFV600E (Kaplon et al. 2013), p53 (Macip et al. 2003), 
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p21 (Macip et al. 2002) and p16 (Takahashi et al. 2006) all resulted in elevated 
ROS generation. In most of the above reported cases treatment with 
antioxidants, such as N-acetyl cysteine (NAC), was able to prevent the cell-
cycle arrest supporting a causal role for ROS in the process (Figure 1.3B and 
1.3C). Together these observations indicate that elevated ROS are a 
consequence of the activation of the senescence programme. Indeed ROS has 
been proposed to act as signalling molecules during cellular senescence 
(Passos et al. 2006). Mechanistically, it is still unclear how these pathways 
contribute to mitochondrial dysfunction and ROS generation. Takahashi and 
colleagues, using human fibroblasts expressing a temperature-sensitive simian 
virus 40 large T antigen, connected p16 with ROS production via protein kinase 
C signalling (Takahashi et al. 2006). Protein kinase C has been shown to 
activate a non-mitochondrial source of ROS, generated by NADPH-oxidase 
through phosphorylation of p47phox, an essential component of NADPH oxidase 
(Talior et al. 2005). Consistent with this study, NADPH oxidases have been 
shown to limit the replicative lifespan of human endothelial cells in culture via 
ROS generation (Lener et al. 2009). 
Oncogene-induced senescence has been associated with mitochondrial 
dysfunction and ROS production, which is dependent on intact p53 and Rb 
tumour suppression pathways. Mitochondrial dysfunction resulted in the loss of 
ATP and activation of AMPK; in addition, mitochondrial-derived ROS were 
shown to contribute to the oxidation of DNA (Moiseeva et al. 2009). In a recent 
study, it was shown that BRAFV600E-induced senescence was accompanied by 
the activation of pyruvate dehydrogenase, which resulted in the enhanced use 
of pyruvate by the tricarboxylic acid (TCA) cycle followed by increased 
respiration and ROS generation (Kaplon et al. 2013).  
The role of p53 and p21 in ROS generation during senescence is still not well 
understood. An association between p53 and transcriptional activation of genes 
involved in mitochondrial apoptosis has been demonstrated (Polyak et al. 1997), 
as well as a stress-induced translocation of p53 to mitochondria resulting in 
increased outer membrane permeabilisation (Moll et al. 2006), however, a direct 
role of mitochondrial p53 in cellular senescence has not yet been demonstrated. 
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In contrast, transcriptional regulation of mitochondrial genes by p53 has been 
reported to impact on mitochondrial function and contribute to ageing. p53 
knock-out mice exhibited reduced expression of the Sco2 gene, which is 
required for the assembly of the mitochondrial DNA-encoded COX II subunit 
(Matoba et al. 2006). In late generation telomerase knock-out mice that have 
critically short telomeres, activation of p53 has been shown to repress the 
promoters of PGC-1α and PGC-1β genes, master regulators of mitochondrial 
biogenesis and function, thereby contributing to decreased mitochondrial 
function (Sahin et al. 2011). 
 
 
 
 
Figure 1.3 | Two different models by which reactive oxygen species can impact 
on cellular senescence. (A) Reactive oxygen species (ROS) produced via 
mitochondrial and non-mitochondrial sources can induce genomic DNA damage and 
accelerate telomere erosion/damage, both of which contribute to activation of a DNA 
damage response (DDR). (B) ROS can act as signalling molecules in senescence: 
activation of “senescence signals” has been shown to result in increased ROS 
generation (mitochondrial and non-mitochondrial). ROS has been shown to impact on a 
A B 
C 
  Chapter 1. Introduction 
 
23 
 
variety of pathways which may help stabilise the senescence growth arrest. (C) 
Simplified feedback loop model involving ROS and DNA damage. Telomere uncapping 
or general DNA damage triggers a DDR which culminates through yet unidentified 
processes to ROS generation. ROS generation leads to additional DNA damage to the 
genome, stabilising the DDR and leading to a stable senescence arrest (adapted from 
Correia-Melo et al. 2014). 
 
Knockdown of both p53 and p21 by RNA-mediated interference (RNAi) has 
been shown to reduce ROS generation in both telomere-dependent and -
independent senescence (Passos et al. 2010). Our group has found that ROS 
levels increase in senescent cells as a result of signalling through p21, and feed 
back into DNA damage induction and the DDR, generating a stable, self-
sustaining feedback loop (Figure 2c). This feedback loop persists even in 
irreversibly deep senescence. Moreover, p21 appears to be the critical mediator 
between the DDR and MAPK and TGF- stress-induced signalling cascades, 
which have been shown to contribute to ROS generation (Torres et al. 2003, 
Koli et al. 2008, Passos et al. 2010). Consistently, in vivo a p21 knockout 
rescued at least some accelerated ageing phenotypes in telomerase (mTERC) 
knockout mice (Choudhury et al. 2007), as well as markers of oxidative stress 
and DNA damage foci (Passos et al. 2010). ROS has also been shown to 
impact on the DDR and ultimately senescence in a non-cell-autonomous 
fashion. A recent study has shown that senescent cells can induce a DDR in 
neighbouring cells via a gap junction-mediated cell-cell contact and processes 
involving ROS (Nelson et al. 2012). 
ROS have also been implicated in organismal ageing, with countless reports of 
associations between oxidative damage and the ageing process (Oliver et al. 
1987, Fraga et al. 1990, Hamilton et al. 2001); however, genetically 
manipulated animal models where mitochondrial function and oxidative stress 
were targeted have generated conflicting results (Muller et al. 2007).  
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1.3. Role of Inflammatory factors in cellular senescence 
 
The senescence phenotype is not limited to an arrest of cell proliferation. 
Indeed, a senescence cell is metabolically active and encompass widespread 
changes in protein expression and secretion, ultimately developing a 
Senescence-associated Secretory Phenotype or SASP (Shelton et al. 1999, 
Krtolica et al. 2001, Krtolica et al. 2002, Campisi et al. 2007, Kuilman et al. 
2009). Current data suggests that one of the primary functions of the SASP is to 
allow communications both within and between cells. Because of this ability to 
establish intra- and inter- cellular connections, senescence-associated secreted 
factors have also been termed as “senescence-messaging secretome” (Kuilman 
et al. 2009). Cellular senescence has long been recognised as a potent tumour-
suppressive mechanism that arrests growth of cells in risk for malignant 
transformation (Braig et al. 2005, Collado et al. 2005, Michaloglou et al. 2005, 
Narita et al. 2005, Courtois-Cox et al. 2006, Ventura et al. 2007, Xue et al. 
2007). However, some studies have shown that senescent cells may also 
induce changes in the tissue microenvironment which encourages 
tumorigenesis (Krtolica et al. 2001, Coppe et al. 2008, Green 2008, Kuilman et 
al. 2008). Consistent with a pleiotropic role of senescence, the SASP has been 
shown to have a series of somehow contradictory roles with important 
consequences for ageing and cancer: i) It can contribute to the surveillance and 
elimination of senescent cells by the immune system as several studies indicate 
(Xue et al. 2007, Kang et al. 2011); ii) it can be pro-tumorigenic. Both cell 
culture experiments and studies involving co-transplantation of senescent and 
cancer cells in recipient mice, have shown that senescent fibroblasts stimulated 
hyperproliferation of cancer cells, neoplastic progression and tissue damage 
(Krtolica et al. 2001, Liu et al. 2007); iii) it can contribute to the reinforcement of 
oncogene-or stress induced senescence in a cell-autonomous fashion (Acosta 
et al. 2008, Kuilman et al. 2009) and iv) it can induce senescence in 
neighbouring cells via a bystander effect both in vitro and in vivo (Acosta et al. 
2013). In order to understand how the SASP harbours such diverse effects it is 
important to first comprehend what is the SASP. The SASP includes several 
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families of soluble and insoluble factors. While the soluble factors include 
signalling factors such as growth factors, chemokines and interleukins, and 
secreted proteases, the insoluble factors comprise insoluble secreted proteins 
and extracellular matrix (ECM) components (Coppé et al. 2010).  
 
1.3.1Senescence-associated inflammatory phenotype (SAIF) 
 
The senescence secretory phenotype involves the secretion of several 
inflammatory and cancer-related factors, including interleukins. The involvement 
of interleukins in senescence was first described by Maier et al., who reported a 
positive correlation between IL-1α transcript level and the control of cellular 
proliferation in human endothelial cells (Maier et al. 1990). Since then, many 
other interleukins have been shown to be secreted by senescent cells, being IL-
6 and IL-8 some of the most prominent interleukins of the SASP (Acosta et al. 
2008, Kuilman et al. 2008). The repertoire of inflammatory factors secreted by 
senescent cells will be here designated as the senescence-associated 
inflammatory phenotype (SAIF). 
Interleukin 6 (IL-6) was originally identified as a B-cell differentiation factor 
(Hirano et al. 1986). At the same time that IL-6 is produce by various cell types 
it can also induce a response in different cell types, through its unique receptor 
(IL-6R). This interleukin has multiple functions including regulation of the 
immune response and haemotopoiesis and more recently has been implicated 
with senescence and cancer (Davalos et al. , Hong et al. 2007, Kuilman et al. 
2008, Mihara et al. 2012). Using genetic and bioinformatic analysis, Kuilman et 
al. found that OIS is specifically linked to the activation of an inflammatory 
transcriptome (Kuilman et al. 2008). They found that senescence-associated 
cytokines, included the pleiotropic cytokine interleukin-6 (IL-6), can act in a pro-
mitogenic paracrine way. In this study, IL-6 was implicated in senescence entry 
and maintenance, via a pathway co-regulated by the transcription factor 
C/EBPβ to amplify the activation of the inflammatory network, including IL-8. 
Interestingly, in human colon adenomas IL-8 specifically co-localised with 
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arrested, p16INK4A-positive epithelium, suggesting that the context-dependent 
cytostatic and pro-mitogenic functions of specific interleukins contribute to 
connect senescence with an inflammatory phenotype and cancer (Kuilman et al. 
2008). 
Interleukin-8 (IL-8), alternatively known as CXCL8, belongs to the CXC (two N-
terminal cysteines are separated by one amino acid, represented with an "X”) 
amino acid motif family of pro-inflammatory chemokines (Thelen 2001), that are 
highly secreted by senescent cells (Coppé et al. 2010). This chemokine 
activates multiple intracellular signalling pathways downstream of two cell-
surface G protein-coupled receptors: CXCR1 (IL-8RA) and CXCR2 (IL-8RB) 
(Holmes et al. 1991, Murphy et al. 1991).  IL-8 is a chemotactic factor whose 
main functions are to stimulate cell proliferation, angiogenesis and migration 
(Waugh et al. 2008, Ning et al. 2011). This chemotactic factor was first 
described to promote the directional migration and activation of neutrophils in 
response to inflammatory and infectious diseases (Baggiolini et al. 1989, 
Baggiolini et al. 1997). Nevertheless, more recent studies have recognised IL-8 
as an important factor in cancer by promoting tumorigenesis (cell proliferation), 
tumour maintenance (angiogenesis) and progression/invasiveness (migration) 
(Waugh et al. 2008). Given the above mentioned functions of IL-8, this 
interleukin seems to play fundamental roles as a regulatory factor within the 
inflammatory, tumour and senescence milieus.  
CXCR2 is a promiscuous receptor that transmits signals from several CXC 
chemokine family members (CXCLs), including IL-8. Acosta et al. conducted a 
screen for small hairpin RNAs to identify genes controlling senescence in 
primary human fibroblasts. They reported that the knocking down of CXCR2 
alleviates both replicative and oncogene-induced senescence (OIS) and 
diminishes the DNA-damage response. Conversely, ectopic expression of 
CXCR2 resulted in premature senescence via a p53-dependent mechanism. 
They further found that cells undergoing OIS activate NF-B and C/EBPβ 
transcription factors to regulate expression of CXCR2 and multiple CXCR2-
binding chemokines. The authors concluded that senescent cells activate a self-
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amplifying secretory network in which CXCR2-binding chemokine reinforce the 
growth arrest (Acosta et al. 2008). 
 
1.3.2 Pathways controlling secretion of inflammatory factors in cellular 
senescence 
 
The pathways regulating the growth arrest and the SASP during senescence 
are often coordinately induced but do not completely overlap. For instance, both 
p16 and p53 expression are required to induce a senescence growth arrest, but 
do not induce or modify the SASP (Coppe et al. 2008, Coppe et al. 2011). The 
DDR is the most prominent initiator of senescence and persistence of a DDR 
during senescence has been shown to be essential for the development of a 
SASP, particularly for the induction of inflammatory cytokines such as IL-6 and 
IL-8 (Rodier et al. 2009). The p38 mitogen-activated protein kinase (p38MAPK) 
has been described to upregulate expression of specific cytokines such as IL-6, 
IL-8, and TNFα in some biological contexts (Ono et al. 2000, Zhang et al. 2007). 
In senescence, a study by Freund et al. showed that p38MAPK activity is 
necessary and sufficient for expression of SASP cytokines via NF-B 
transcriptional activity, in cells induced to senesce by direct DNA damage or 
oncogenic RAS (Freund et al. 2011).  
 
Cellular senescence is a complex mechanism, in which multiple stimuli can 
promote the development of a complex phenotype termed senescence 
phenotype. Although much is known about the pathways that regulate the 
senescence growth arrest, the pathways that regulate the SASP remain poorly 
understood. As described above ROS appears to add an extra layer of 
complexity to the intricate senescence phenotype. It is likely that ROS is the 
missing link between the secretory phenotype and its proposed role in the 
reinforcement of the senescent phenotype.  
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1.4. Synergistic interactions between inflammatory factors and ROS 
during senescence 
 
Mechanistically, it is still not entirely understood how the SASP contributes to 
the reinforcement of senescence, however several lines of evidence suggests 
the existence of synergistic interactions between the DDR, ROS and 
inflammatory signals (Figure 1.4). Kinetically, ROS has been observed to 
increase 2-3 days following activation of a DDR (Passos et al. 2010), while the 
SASP occurs 7-10 days later (Coppé et al. 2010). Some of the similarities 
between both pathways and potential interactions will be examined thereafter. 
Induction of both ROS and SASP in stress-induced senescence has been 
shown to be dependent on activation of the DDR (Rodier et al. 2009, Passos et 
al. 2010). Consistent with this, recent investigations have reported that 
progeroid mouse models driven by DNA damage are associated with activation 
of NF-B chronic inflammation and senescence (Osorio et al. 2012, Tilstra et al. 
2012). Interestingly, in a murine model of XFE progeroid syndrome, Ercc1–/Δ 
mice, inhibition of NF-B signalling not only reduced the onset of several age-
related pathologies, but also both DNA and proteins oxidation (Tilstra et al. 
2012), suggesting a potential link between inflammation and ROS pathways. 
Another link between ROS and the SASP during senescence involves 
p38MAPK pathways. p38MAPK has been shown to regulate the SASP in 
senescence mainly through NF-B transcriptional activity (Freund et al. 2011). 
Similarly, p38MAPK pathway has been shown to be important for ROS 
generation in both stress-induced and replicative senescence and for the 
stability of the DDR (Passos et al. 2010). 
Acosta and colleagues have shown that inhibition of CXCR2, a promiscuous 
receptor that transmits signals from several CXC chemokine family members 
(CXCLs), including IL-8, delayed the onset of both replicative and oncogene-
induced senescence and lead to decreased activation of a DDR (Acosta et al. 
2008). Mechanistically, the authors proposed that inhibition of CXCR2 reduced 
DDR potentially by impacting on ROS (Acosta et al. 2008).  
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Interpheron beta (β-IFN) has been shown to induce senescence through ROS 
activation and subsequent activation of a DNA damage response, which could 
be inhibited using the antioxidant NAC (Moiseeva et al. 2006).  
Transforming growth factor beta (TGF-β), another secreted protein, has also 
been implicated in senescence. Inactivation of TGF-β1 secretion in mouse 
keratinocytes was enough to prevent oncogene induced senescence (Tremain 
et al. 2000). In human fibroblasts, blocking TGF-β1 receptor II activity has been 
shown to prevent UVB and hydrogen peroxide induced senescence (Frippiat et 
al. 2001, Debacq-Chainiaux et al. 2005). Recently, it was demonstrated that the 
TGF-β pathway had a strong effect in paracrine induced senescence (Acosta et 
al. 2013). Interestingly, the TGF-β pathway has also been identified as an 
important link between telomere-dependent and –independent DDR and ROS 
production (Passos et al. 2010). 
Another potential link between the SASP and ROS is the fact that several 
studies indicate that NF-B (the main regulator of the SASP) is also a major 
player in the regulation of mitochondrial function and oxidative stress. Firstly, 
several reports associate NF-B with regulation of mitochondrial function. NF-
B is present in mitochondria of yeast (Bottero et al. 2001) and mammalian 
cells and is able to regulate expression of mitochondrial encoded genes in 
mammalian cells (Cogswell et al. 2003). Bakkar and colleagues reported that 
activation of the NF-B alternative pathway during myogenesis is important for 
mitochondrial biogenesis (Bakkar et al. 2008). More recently it was 
demonstrated that IKKα and alternative NF-B regulate the transcription co-
activator PGC-1β (a master regulator of mitochondrial biogenesis and function) 
to promote oxidative muscle metabolism (Bakkar et al. 2012). Secondly, it has 
also been reported that NF-B is involved in the transcriptional regulation of 
both anti-oxidant and pro-oxidant genes (Morgan et al. 2011). A recent study on 
a mouse model of type II diabetes-cardiac dysfunction has shown that 
enhanced NF-B activity is associated with increased oxidative stress. The 
authors demonstrate that chemical inhibition of NF-B alleviates oxidative 
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stress, improves mitochondrial structural integrity and ultimately restores 
cardiac function in type II diabetes (Mariappan et al. 2010). 
In contrast, numerous reports have implicated ROS in the activation of NF-B 
(Gloire et al. 2006). DNA binding and transactivation by NF-B have been 
shown to be strongly activated by ROS such as hydrogen peroxide (Meyer et al. 
1993). Overall, this suggests that NF-B and ROS pathways are tightly 
interconnected and may together impact on the stabilisation of senescence 
(Figure 1.4). 
 
 
 
Figure 1.4 | Senescence is a multi-layered process involving interactions 
between the DNA damage response, reactive oxygen species and the 
senescence-associated secretory phenotype. Initially, stressors such as telomeric 
and non-telomeric DNA damage can lead to activation of a DNA damage response 
(DDR) and cell cycle arrest. Following activation of the DDR, p53, p21 and p38MAPK 
pathways have been shown to enhance NF-B transcriptional activity. NF-B activation 
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is both responsible for the senescence-associated secretory phenotype (SASP) and 
can induce (and be activated) by reactive oxygen species (ROS). p16 has been shown 
to induce ROS generation via NADPH oxidases (Takahashi et al. 2006); however, it 
has been shown to be unrelated to the SASP (Coppe et al. 2011). Secretion of 
bioactive molecules such as ROS and SASP factors contribute not only to reinforce 
senescence in an autocrine fashion, but also to induce paracrine senescence. 
Components of the SASP, such as IL-8, β-IFN and transforming growth factor (TGF)-β, 
have been shown to reinforce the senescence arrest via ROS through yet unidentified 
mechanisms (Moiseeva et al. 2006, Acosta et al. 2008, Passos et al. 2010). NF-B 
transcriptional activity has been shown to be dependent on the DDR and ROS. 
However, NF-B activation has been shown to increase ROS generation via regulation 
of mitochondrial, antioxidant and pro-oxidant genes (Morgan et al. 2011, Bakkar et al. 
2012) (adapted from Correia-Melo et al. 2014). 
 
 
 
1.5. mTOR Signalling: Sensing nutrient availability and managing stress in 
senescence and ageing 
 
1.5.1 mTOR kinase and complexes 
 
The mechanistic target of rapamycin (mTOR) protein was first discovered by 
Heitman et al. when analysing yeast mutants resistant to the growth-inhibitory 
properties of rapamycin (Heitman et al. 1991). mTOR is a highly conserved 
serine/threonine kinase belonging to the PI3K-related family of protein kinases, 
which also includes ATM, ATR and DNA-dependent protein kinase. The mTOR 
kinase can be found in two structurally and functionally distinct multiprotein 
complexes: mTOR complex 1 (mTORC1) and 2 (mTORC2) (Laplante et al. 
2012). mTORC1 is a six protein complex formed by: the mTOR kinase, the 
mammalian lethal with sec-13 protein 8 (mLST8, also known as GβL), (Kim et al. 
2003, Jacinto et al. 2004) , the DEP domain containing mTOR-interacting 
protein (DEPTOR) (Peterson et al. 2009), the Tti1/Tel2 complex (Kaizuka et al. 
2010), the regulatory-associated protein of mammalian target of rapamycin 
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(raptor) (Hara et al. 2002, Kim et al. 2002) and  the proline-rich Akt substrate 40 
kDa (PRAS40) (Sancak et al. 2007, Vander Haar et al. 2007, Wang et al. 2007). 
The reported functions of the mTORC1 pathway involve integrating inputs from 
growth factors, stress, energy status, oxygen, and amino acids to control 
regulation of cell growth via protein (Averous et al. 2006, Ma et al. 2009), 
nucleotide (Ben-Sahra et al. 2013, Robitaille et al. 2013) and lipid synthesis, 
glycolysis (Laplante et al. 2009, Peterson et al. 2011) and autophagy (Ganley et 
al. 2009, Hosokawa et al. 2009). Whereas mTORC2 is composed by seven 
proteins including: the mTOR kinase, mLST8, DEPTOR, the Tti1/Tel2 complex, 
the rapamycin-insensitive companion of mTOR (rictor) (Jacinto et al. 2004, 
Sarbassov et al. 2004), the mammalian stress-activated map kinase-interacting 
protein 1 (mSin1) (Frias et al. 2006, Jacinto et al. 2006) and the protein 
observed with rictor 1 and 2 (protor1/2) (Pearce et al. 2007, Pearce et al. 2011). 
The role of mTORC2 is less well understood when compared to mTORC1, but it 
is known that this mTOR complex receives signals from growth factors to 
regulate glucose metabolism, lipogenesis (Garcia-Martinez et al. 2008, 
Hagiwara et al. 2012, Yuan et al. 2012), the actin cytoskeleton and apoptosis 
(Oh et al. 2011). Both mTORC complexes share common proteins but also 
include specific proteins that contribute to their distinct functions and sensitivity 
to chemical inhibitors/drugs. 
 
 
1.5.2 Signalling to and from mTORC1 
 
The mechanisms regulating the mTOR pathway are complex, owing this 
complexity to the numerous different signals that converge and diverge to and 
from this pathway. A brief summary will be described to highlight some of the 
most important and better known functions of mTORC1. Mechanistically, the 
tuberous sclerosis 1 and 2 (TSC1/TS2) complex functions as a GTPase-
activating protein (GAP) for the Ras homolog enriched in brain (Rheb) GTPase 
(Inoki et al. 2003) and negatively regulates mTORC1 activity by converting 
Rheb into its inactive form GDP bound sate (Inoki et al. 2003, Tee et al. 2003). 
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Conversely, the GTP-Rheb form is a positive regulator of mTORC1 and when 
bound to this complex strongly stimulates its activity. Growth factors signals (e.g. 
insulin and insulin-like growth factor 1 (IGF1)) induce inactivation of the 
TSC1/TSC2 complex via direct phosphorylation by the protein kinase B 
(Akt/PKB) and promote mTORC1 activation (Inoki et al. 2002, Manning et al. 
2002, Potter et al. 2002). However, Akt can also phosphorylate, PRAS40, 
another negative regulator of mTOR, and activate mTORC1 independently of 
the TSC1/TSC2 complex (Sancak et al. 2007, Vander Haar et al. 2007, Wang et 
al. 2007). Other kinases such as the extracellular-signal-regulated kinase 1/2 
(ERK1/2) and ribosomal S6 kinase (RSK1) can also phosphorylate the 
TSC1/TSC2 complex and activate mTORC1 downstream of growth factors 
stimulation (Roux et al. 2004, Ma et al. 2005). The TSC1/TSC2 complex can 
also be inhibited through phosphorylation by the inhibitor of NF-B (IB) kinase 
β (IKKβ) following pro-inflammatory cytokines stimuli (Lee et al. 2007). 
Conversely, the adenosine monophosphate - activated protein kinase (AMPK), 
following inhibitory signals downstream of Wnt, phosphorylates TSC2 and 
activates the TSC1/TSC2 complex promoting inhibition of mTOR and 
downstream pathways involved in the regulation of cell growth, proliferation, 
polarity, differentiation, and development (Inoki et al. 2006). The mechanisms 
by which mTOR senses intracellular aminoacids are not fully elucidated but it is 
described that the Ragulator-Rag complex is a master regulator in this process 
by promoting mTORC1 translocation to the lysosomal surface and allowing 
interaction with GTPases such as the Rheb GTPase (Sancak et al. 2010), in a 
process that seems to be independent of the TSC1/TSC2 complex (Smith et al. 
2005). 
One of the most well described signalling downstream of mTORC1 involves the 
70kD protein S6 kinase (p70-S6K) and the eukaryotic translation initiation factor 
4E (eIF4E) binding protein 1 (4EBP1) to regulate anabolic processes such as 
protein synthesis. mTORC1 phosphorylates the p70-S6K which upon 
phosphorylation can also phosphorylate the S6 ribosomal protein. In this 
process mTORC1 can also phosphorylate and inactivate the (4EBP1) with 
release of eIF4E promoting increased translation through the eIF4F complex 
  Chapter 1. Introduction 
 
34 
 
(Fingar et al. 2002) Alternatively, mTORC1 is also involved in the control of 
catabolic processes by negatively regulating autophagy via phosphorylation of 
ULK1 (Lee et al. 2010).  
 
1.5.3 Implications of mTOR on ageing and senescence 
mTOR has been shown to play a role on the onset of ageing and age-related 
diseases including cancer, possibly via its critical role on the regulation of cell 
growth and proliferation (Menon et al. 2008, Laplante et al. 2012). Dietary 
restriction (DR) is the most robust intervention able to prolong lifespan and slow 
down the progression of age-related diseases with reproducible results across a 
variety of species ranging from yeast to primates (Kapahi et al. 2010). During 
DR, a particular or total nutrient availability is reduced with a consequent impact 
on the activation of nutrient sensing signalling including the mTOR pathway. 
Consistent with a beneficial role for decreased mTOR activity on ageing, mTOR 
inhibition by genetic or pharmacological means led to lifespan extension of 
different organisms including yeast, worms, fruit flies and mice, similarly to DR 
(Fabrizio et al. 2001, Vellai et al. 2003, Jia et al. 2004, Kapahi et al. 2004, 
Kaeberlein et al. 2005, Harrison et al. 2009, Bjedov et al. 2010). Rapamycin, a 
compound found in the soil bacterium in the Rapa Nui Island (also known as 
Easter Island) (Vezina et al. 1975), is a chemical inhibitor of mTORC1 activity 
by forming a complex with the intracellular 12-kDa FK506-binding protein 
(FKBP12) (Brown et al. 1994, Sabatini et al. 1994). The exact mechanisms by 
which the binding of FKBP12-rapamycin to mTORC1 inhibits its activity is 
unknown, but it has been described that rapamycin may compromise the 
structural integrity of mTORC1 and the specific activity of its kinase domain (Yip 
et al. 2010). More recent studies have described that prolonged treatment with 
rapamycin may also disrupt mTORC2 assembly and function in some cells 
types (Sarbassov et al. 2006). An important study conducted in mice has 
demonstrated that mTOR inhibition via a rapamycin supplemented diet results 
in increased maximal and median lifespan even when the treatment was started 
later in life (Harrison et al. 2009). 
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Studies exploring a role for mTOR during senescence have been somewhat 
contradictory. During oncogene-induced senescence, spatial coupling of 
catabolic and anabolic processes via mTOR may facilitate the mass synthesis 
of secretory proteins (Young et al. 2009, Narita et al. 2011). Supporting a pro-
senescence role for autophagy, Kennedy et al. recently showed that rapamycin, 
a mTOR inhibitor and activator of autophagy, promotes oncogene-induced 
senescence in a mouse model of pancreatic cancer (Kennedy et al. 2011). In 
contrast, in other models of senescence, including replicative senescent rodent 
fibroblasts (Pospelova et al. 2012), mTOR activity promotes senescence and 
senescence is inhibited by rapamycin. Consistently, it has been described that 
inhibition of mTOR induces quiescence, while its hyper-activation promotes 
senescence in a p53-dependent manner (Demidenko et al. 2010, Korotchkina 
et al. 2010). Nevertheless, there is indirect evidence that suggest a role for 
mTOR during cellular senescence. Many stressors described to induce 
senescence, including DNA damage, can also activate the mTOR pathway in 
part via the TSC1/TSC2 complex. mTORC1 receives DNA damage signals 
through multiple mechanisms, all of which require p53-dependent transcription 
(Feng et al. 2005). Another important feature of senescence is the SASP with 
NF-B signalling being a master regulator of the senescence-associated 
inflammatory phenotype (Acosta et al. 2008, Kuilman et al. 2008). It has been 
shown that activation of mTOR downstream of Akt regulates NF-B activity 
(Dan et al. 2008). Such regulatory control of mTOR over inflammatory pathways 
may contribute to the understanding of the mechanisms regulating the SASP.  
 
 
1.6. Cellular Senescence and Ageing 
 
Despite being discovered over 50 years ago, cellular senescence remains an 
intriguing biological process and whether senescence exists to any significant 
extent in vivo has been the subject of a longstanding debate (Ben-Porath et al. 
2005). In the past decade, remarkable advances have been made 
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demonstrating that senescence plays an important role in vivo. Several studies 
suggest that senescence can act as a tumour suppressor mechanism (Braig et 
al. 2005, Chen et al. 2005, Collado et al. 2005, Michaloglou et al. 2005). On the 
other hand, numerous lines of evidence indicate that senescence can, in the 
long run, have adverse effects, by impairing organ regeneration and releasing a 
host of bioactive molecules, including ROS and a wide variety of pro-
inflammatory cytokines, chemokines and growth factors (collectively referred to 
as the SASP) that impact on the surrounding tissue. 
In 2006, Herbig et al. showed that the amount of cells containing telomere-
induced foci (TIF), a well-known marker of senescence, increase with age in the 
skin of baboons, primates with similar telomere length to humans and absence 
of telomerase activity (Herbig et al. 2006). In mice, cells bearing senescent 
markers have been reported to increase with age in a variety of tissues 
(Krishnamurthy et al. 2004, Wang et al. 2009, Hewitt et al. 2012), including 
post-mitotic neurons (Jurk et al. 2012). Moreover, senescent cells have been 
associated with several age-related diseases, such as diabetes (Sone et al. 
2005) and atherosclerosis (Minamino et al. 2007). While noteworthy, this data 
does not provide causality. A major challenge in the field has been to determine 
if and how senescent cells contribute to age-related tissue dysfunction, or if they 
merely correlate with it.  
Mounting evidence indicates that activation of pathways involved in cellular 
senescence impacts on mammalian lifespan (Rudolph et al. 1999, Tyner et al. 
2002, Choudhury et al. 2007). Recently, the van Deursen’s group has shown 
that inducible elimination of p16Ink4a-positive senescent cells from the eye, 
adipose and skeletal tissues in the BubR1 progeroid mouse model, delayed 
acquisition of age-related pathologies in these tissues. They showed that 
elimination of p16Ink4a-positive cells also attenuated the progression of already 
established age-related disorders, suggesting that cellular senescence may 
have a causal role in age-related tissue impairment (Baker et al. 2011). 
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1.7 Aims 
 
Although several mechanisms responsible for the activation of senescence 
have been identified, it is still unclear how a cell “commits” to becoming 
irreversibly arrested. Recent studies have revealed that the SASP, as well as 
mitochondrial/ROS may contribute to the reinforcement of the growth arrest via 
a series of positive feedback loops involving a persistent activation of the DDR 
(Acosta et al. 2008, Kuilman et al. 2008, Passos et al. 2010). The general aim 
of this thesis was to understand how mitochondria and inflammatory factors act 
together in cellular senescence and how these interactions may contribute to 
the stabilisation of the senescent phenotype. 
 
Specific Aims 
 
1. To investigate the role of mitochondrial density (mass) during the 
development of cellular senescence, both in vitro and in vivo; 
 
2. To understand the mechanisms downstream of a DNA damage response 
driving mitochondrial alterations during cellular senescence and potential 
links to the mTOR signalling pathway; 
 
3. To understand the mechanisms by which pro-inflammatory cytokine 
receptor CXCR2 helps maintain cellular senescence and investigate 
potential links to mitochondrial function. 
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Chapter 2. Material and Methods 
 
 
2.1 Chemicals and Reagents 
 
Unless otherwise stated, the chemicals used in these studies were obtained 
from Sigma-Aldrich Company Ltd (Poole, Dorset, UK). 
 
2.2 Cell Culture 
 
2.2.1 Cell lines  
 
 
Prokaryotic cell lines 
NEB 5-alpha Competent Escherichia coli, (Cat. Number C2987, New 
England Biolabs). 
 
Eukaryotic cell lines 
Human cell lines 
Human embryonic lung MRC5 fibroblasts (ECACC, Salisbury, UK), YFP-
Parkin-expressing MRC5 fibroblasts, human embryonic kidney HEK293, 
Phoenix amphotropic (human embryonic kidney HEK293 transformed with 
adenovirus E1a and carrying  a temperature sensitive T antigen), human 
breast cancer MCF7, human primary glioblastoma U87, Human colon 
carcinoma HCT116, human osteosarcoma 143B, rho 0 143B (mtDNA 
depleted human osteosarcoma 143B cells), Ataxia Telangiectasia (AT) 
patients human fibroblasts, T19 (TRF2BM) and HeLa cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, Cat. Number D5796, Sigma, 
Dorset, UK) supplemented with 10% heat inactivated foetal bovine serum 
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(BioSera, Ringmer, UK), 100 units/ml penicillin, 100 μgml-1 streptomycin 
and 2 mM glutamine, at 37oC in a humidified atmosphere with 5% CO2. 
 
T19 cells containing a doxycycline inducible TRF2BM were a kind gift from 
T. de Lange, Rockefeller University, NY, USA (van Steensel et al. 1998). 
Osteosarcoma 143B and Rho 0 143B cell lines were kind gifts from Dr. 
Robert Lightowlers, Mitochondrial Research Group, Newcastle University, 
UK. AT patient fibroblasts were kind gifts from Dr Lisa Woodbine, 
University of Sussex, UK. Phoenix amphotropic cells were a kind gift from 
Dr. Stephen Tait, Institute of Cancer Sciences, University of Glasgow, UK. 
Human embryonic kidney HEK293 cells were a kind gift from Dr. Glyn 
Nelson, Institute for Ageing and Health, Newcastle University, UK. 
 
Human fibroblasts (MRC5 fibroblasts and YFP-Parkin expressing MRC5 
fibroblasts) were used for cellular and molecular biology analysis at a 
population doubling (PD) level of 20-30 for stress-induced senescence or 
after reaching replicative exhaustion (replicative senescence). 
 
Mouse cell lines 
Mouse embryonic fibroblasts (MEFs) were obtained from C57BL/6 wild-
type mice. MEFs from Atg5-/-, PGC-1β-/-, matched wild-type, Mouse 
hepatocyte cell-line MIH and 3T3 embryonic fibroblasts were cultured in 
Advanced DMEM/F-12 (Invitrogen, Cat. Number 12634) plus 10% heat 
inactivated foetal bovine serum (BioSera, Ringmer, UK), 100 units/ml 
penicillin, 100 μgml-1 streptomycin and 2 mM glutamine, at 37oC in a 
humidified atmosphere with 5% CO2 and 3% oxygen. 
 
Atg5-/- MEFs were kind gifts from Dr.Noboru Mizushima, Tokyo University, 
Japan (via Viktor Korolchuk, Institute for ageing and Health, Newcastle 
University, UK). PGC-1β-/- MEFs were kind gifts from Dr. Sergio 
Rodriguez-Cuenca, Metabolic Research Laboratories, University of 
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Cambridge, UK. 3T3 embryonic fibroblasts were a kind gift from Dr. 
Stephen Tait, Institute of Cancer Sciences, University of Glasgow, UK. 
 
 
2.2.2 Cryogenic storage 
 
Exponentially growing adherent cells were trypsinised with Trypsin-EDTA 
(Sigma, Cat.Number T3924) and centrifuged at 150g for 5 minutes at room 
temperature. The supernatant was removed and cells were re-suspended in 
foetal calf serum (FCS) containing 10% (v/v) dimethyl sulfoxide (DMSO) at a 
density of 1x106 cells/ml. One mL aliquots of cell suspension were immediately 
transferred to cryo-vials and placed in a NalgeneTM Cryo freezing container 
filled with isopropanol. Cells were kept for 24 hours in a -80°C freezer to allow 
slow freezing, before being stored in liquid nitrogen. 
 
2.2.3 Resuscitation of frozen cells 
 
Cryo-vials were removed from the liquid nitrogen bank and quickly thawed for 1-
2 min at 37°C. Thawed cells were immediately seeded into a 75 cm2 flask with 
20 mL pre-warmed medium. Medium was replaced with fresh media 24 hours 
after seeding to remove DMSO and cell debris.  
 
2.2.4 Calculating cell density and population doublings 
 
To determine the concentration of cells within the cell suspension, following 
trypsinisation 20 µL of cells suspension were placed on a Fuchs Rosenthal 
haemocytometer (VWR International, UK). Cells were counted on 8 smallest 
squares of the haemocytometer under a standard microscope (DMIL, Leica 
Microsystems, UK). The average of four counts of 8 squares is equivalent to the 
number of cells x104/mL. The total number of cells was calculated by multiplying 
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the volume of cell suspension (mL) with the cell concentration (cells/mL). On 
human primary cell lines the population doubling (PD) level was calculated by 
comparing the amount of cells seeded with the number of cells obtained, using 
the following equation: PD)=X+Ln( N1/N2)/Ln2 
 
where, PD = population doublings 
  X   = previous PD 
N1 = number of cells harvested 
N2 = number of cells seeded 
 
 
2.3 Creating stably expressing YFP-Parkin-MRC5 fibroblast cell lines 
 
2.3.1 Bacterial Transformation  
 
NEB5-alpha competent Escherichia Coli (NEB; Cat. Number C2987) were 
transformed with a LZRS-YFP-Parkin plasmid (kind gift from Dr. Stephen Tait, 
Institute of Cancer Sciences, University of Glasgow, UK): 
 
Plasmid DNA (50 ng) was added to a 50μL of NEB5-alpha highly 
competent E. coli and incubated on ice for 30 minutes. The mixture was 
then subjected to heat shocking at 42oC for 30 seconds, before five 
minutes incubation on ice. 250μL SOC medium (Invitrogen, Cat. Number 
15544-034) was then added and cells were incubated at 37oC for 1 hour 
with shaking vigorously at 250rpm. Cells were then spread on agar 
selection plates containing lysogeny broth (LB) medium plus ampicillin 
(15g agarose to 1L LB (10g bacto-tryptone, 5g bacto-yeast extract, 10g 
NaCl made up to 1L H2O) and autoclave. Once cool enough to hold, add 
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50μg/ml ampicillin selection agent, mix thoroughly and pour into plates), 
and incubated at 37oC overnight. Individual colonies were then grown 
overnight in 5mL selective LB (LB+ampicilin). DNA was purified using the 
QIAprep Spin Miniprep kit (Qiagen, Cat. Number 27104) as described in 
the provided protocol. 
 
Transformed bacteria stocks  
Glycerol stocks were made of transformed bacteria. 800μL LB containing 
transformed bacteria were mixed with 200μl 80% glycerol, then snap frozen in 
liquid nitrogen, and stored at -80oC.  
 
 
2.3.2 Plasmid Analysis  
 
Following DNA purification using QIAprep Spin Miniprep kit, the Plasmid DNA 
was digested with the HindIII restriction enzyme (NEB, Cat. Number R0104S) to 
confirm purity of the Plasmid DNA. Plasmid DNA fragments were the right size, 
with 10.48 Kb and 2.61 Kb fragments. Non digested Plasmid DNA showed no 
fragmentation with a band size of 13.09 Kb, indicating integrity and correct 
purification of the Plasmid DNA (Figure 3.1).  
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Figure 2.1 | LZRS-YFP-Parkin plasmid. (A) Purified LZRS-YFP-Parkin plasmid map; 
(B) Purified LZRS-YFP-Parkin plasmid was digested with HindIII restriction enzyme. 
M= DNA ladder, 1= digested LZRS-YFP-Parkin (fragment size: 10.48 Kb and 2.61 Kb) 
plasmid and 2=undigested ZRS-YFP-Parkin plasmid (fragment size: 13.09 Kb). 
 
 
2.3.3 Transfection and Transduction Protocols  
 
Retroviral plasmid transfection and viral production was performed following 
class II safety procedures. 5×106 Phoenix amphotropic cells were seeded in a 
10cm dish and incubated for 24 hours in antiobiotic free medium. Cells were at 
90% confluency before proceeding to Invitrogen Transfection using 
LipofectamineTM 2000 (Invitrogen, Cat. Number 11668-019) as described in the 
ViraPower Lentiviral Expression systems user manual (Invitrogen). The day 
after transfection medium was removed and replaced with 10mL fresh medium 
without antibiotics. Viral particles containing medium were collected 48 hours 
A B 
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after initial transfection, centrifuged at 4oC and filtered through a 0.45μm pore 
PVDF filter. The purified media with 10μg/ml polybrene was then added to 
MRC5 fibroblasts at 70-90% confluence. ZeocinTM (Invitrogen, Cat. Number 
R25001) was added to cells at a final concentration of 500µM for six days, 
concentration was then reduced to 200μM to maintain selection for another 10 
days. Transduction efficiency was confirmed by fluorescence microscopy: cells 
expressing Parkin were YFP positive. 
 
 
2.4 Induction of Senescence 
 
MRC5 fibroblasts (PD 20-30) were seeded in 6-well plates (100,000 cells) and 
allowed to grow for 24 hours. Cells were then induced to senesce. 
Stress-induced senescence was induced by: 
 X-ray irradiation (X-Rad 225, Precision X-Ray INC, N-BRANFORD, CT 
USA) with 10 or 20Gy (depending on cell-line); 
 80ng/ml neocarzinostatin (Sigma; Cat. Number N9162) for 1 hour; 
 400µM H2O2 (Sigma, Cat. Number H1009) in serum free media for 1 
hour; 
 50µM Etoposide (Sigma; Cat. Number E1383) containing medium was 
replenished every 3 days for 10 days. 
Following treatments, culture medium was refreshed (except for the Etoposide 
treatment. 
 
Replicative senescence was achieved through replication exhaustion and 
confirmed by >70% of cells being positive for Sen-β-Gal and less than 0.5 
Population doublings for at least 4 weeks. 
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2.5 Treatments: 
 
2.5.1 NAC treatment 
 
MRC5 fibroblasts at a confluency of 70-90% were irradiated with 20Gy X-ray 
and treated with 2.5mM of NAC (Sigma; Cat. Number A7250) for 3 days before 
being harvested for analysis. Control non-irradiated MRC5 fibroblasts were also 
treated with 2.5mM of NAC for 3 days before being harvested for analysis. 
 
2.5.2 CCCP treatment 
 
Stably expressing YFP-Parkin human MRC5 or 3T3 fibroblasts were irradiated 
with 20 Gy (MRC5) and 10Gy (3T3) X-ray and treated 2 days after with 12.5 µM 
CCCP (Sigma; Cat number C2759) for 48 hours (refreshed every 24 hours). 
Control non-irradiated fibroblasts were treated with 12.5 µM CCCP for 48 hours 
(refreshed every 24 hours). 
Replicative senescent YFP-Parkin-MRC5 fibroblasts were treated with12.5 µM 
CCCP for 48 hours (refreshed every 24 hours). Control proliferating fibroblasts 
(PD=20-25) were treated with 12.5 µM CCCP for 48 hours (refreshed every 24 
hours). 
Fresh media (no CCCP) was replaced 48h after treatment; cells were then 
collected at the indicated time points for analysis. 
 
2.6 Treatment with pathway inhibitors 
 
2.6.1 Inhibition of mTORC1 
 
MRC5 fibroblasts were induced to senesce by X-ray irradiation with 20Gy X-ray, 
neocarzinostatin (80ng/ml) for 1 hour and H2O2 (400µM) in serum free media for 
1 hour. Following treatment, culture medium was refreshed with 100nM 
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rapamycin (Sigma, Cat. Number R8781). Etoposide treatment (50µM) was 
performed continuously every 3 days for 10 days with simultaneous 100nM 
rapamycin treatment. Cells were collected at different time points after 
treatment to kinetically understand the effect of mTORC1 inhibition on the 
development of the senescence phenotype. Replicative senescent MRC5 
fibroblasts were treated with 100nM rapamycin for 10 days before being 
harvested for analysis. Rapamycin supplemented media was always refreshed 
24h prior cells collection to avoid starvation confounding effects on mTORC1 
activity. 
 
2.6.2. Inhibition of ATM 
 
MRC5 fibroblasts at a confluency of 70-90% were irradiated with 20Gy X-ray 
and treated with 10µM of the ATM chemical inhibitor KU55933 (R&D; Cat. 
Number 3544). Control non-irradiated fibroblasts were also treated with 10µM of 
the ATM chemical inhibitor KU55933. Cells were collected at different time 
points to kinetically understand the effect of ATM inhibition on the development 
of the senescence phenotype and respective activated pathways. The ATM 
chemical inhibitor KU55933 also inhibits other PIKK proteins when used in 
higher concentrations (as described in the MSDS of the product (R&D; Cat. 
Number 3544)). We have used Ataxia Telangiectasia (AT) patient human 
fibroblasts (mutated non-functional ATM protein kinase) to confirm the results 
observed with the ATM chemical inhibitor KU55933. 
 
2.6.3 Neutralisation of CXCR1 and CXCR2 
 
Control (0Gy) or irradiated (20Gy) MRC5 fibroblasts were treated with 10ug/mL 
of neutralising antibodies against CXCR1 (BD Biosciences, Cat. Number 
555937) and/or CXCR2 (BD Biosciences, Cat. Number 555932). Replicative 
senescent MRC5 fibroblasts were treated with 10ug/mL of neutralising 
antibodies against CXCR1 and/or CXCR2. Cells were collected at different time 
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points after treatment to kinetically understand the effect of IL-8 signalling 
inhibition on the development of the senescence phenotype and respective 
activated pathways. 
 
2.6.4 Inhibition of mTORC1 plus NAC treatment 
 
Control (0Gy) or irradiated (20Gy) MRC5 fibroblasts were treated with 100nM of 
rapamycin and 2.5mM of NAC. Cells were collected 3 days after irradiation for 
ROS and DDF analysis to understand the effect of mTORC1 inhibition with 
additional antioxidant treatment on ROS and DDR suppression. 
 
2.6.5 Inhibition of ATM and mTOR 
 
Control (0Gy) or irradiated (20Gy) MRC5 fibroblasts were treated with 10µM of 
the ATM chemical inhibitor KU55933 and 100nM of rapamycin. Cells were 
collected at different time points after treatment to kinetically understand the 
effect of simultaneous inhibition ATM and mTORC1 on the development of the 
senescence phenotype and respective activated pathways. 
 
 
2.7 Knock down by small interfering RNA 
 
MRC5 cells at a population doubling (PD) level of 20-25 were transiently 
transfected with siRNAs using the HiPerFect Transfection ReagentTM (Qiagen, 
Cat. Number 301707). Cells were transfected with 10nM siRNA following the 
HiPerFect Transfection Reagent Handbook instructions. Cells were transfected 
24 hours prior to 20Gy X-radiation and harvested for analysis 72 hours after 
transfection (2 days after IR). siRNA transfection efficiency was performed by 
qPCR and/or Western Blotting. 
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Table 2.1 FlexiTube siRNAs  
FlexiTube siRNAs from Qiagen 
     
Protein siRNA Reference/Manufacturer 
scramble Negative Control siRNA SI03650325 - Qiagen 
mTOR 
Hs_FRAP1_4 FlexiTube siRNA  
Hs_FRAP1_6 FlexiTube siRNA  
SI00070462 -  Qiagen 
SI02662009 - Qiagen 
IL-8 
Hs_IL-8_5 FlexiTube siRNA  
Hs_IL-8_6 FlexiTube siRNA 
SI02654827 - Qiagen 
SI02654834 - Qiagen 
CXCR1 
Hs_CXCR1_1 FlexiTube siRNA  
Hs_CXCR1_2 FlexiTube siRNA 
SI00013258 -  Qiagen 
SI00013265 - Qiagen 
CXCR2 
Hs_CXCR2_2 FlexiTube siRNA  
Hs_CXCR2_4 FlexiTube siRNA 
SI00447083 - Qiagen 
SI00447097 - Qiagen 
 
 
 
2.8 Flow cytometry 
 
The flow cytometer (Partec, http://www.partec.com) was first calibrated using 
fluorescent beads to ensure optimum performance and reproducibility. In each 
independent experiment measurements were performed in duplicate and 1x104 
cells were analysed per measurement. 
 
2.8.1 DHE staining 
 
Dihydroethidium (DHE) is a blue fluorescent dye that when oxidised through 
binding to superoxide anions forms a red fluorescent product which intercalates 
with DNA. MRC5 fibroblasts were stained with 10µM of DHE (Invitrogen, Cat. 
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Number D1168) in serum free DMEM for 30 min at 37oC in the dark. Red (FL3 
channel) median fluorescence intensity was measured by flow cytometry. 
 
2.8.2 NAO staining 
 
The fluorescent dye 10-n-nonyl-acridine orange (NAO) binds specifically to the 
negatively charged cardiolipin (diphosphatidylglycerol) in the inner mitochondrial 
membrane independently of the membrane potential and can be used to 
monitor the mitochondrial mass. MRC5 fibroblasts were stained with 10 μM of 
NAO (Invitrogen, Cat. Number A1372) in serum-free DMEM and incubated for 
10 min at 37oC in the dark. NAO (Green - FL1 channel) mean fluorescence 
intensity was measured by flow cytometry.  
 
 
2.9 Mice 
 
2.9.1 Mice Groups, Treatments and Housing 
Mice Groups and Treatments 
C57/BL6 mice were split into 4 groups (n=10/group) according to age and diet: 
1) 3 months old young mice months fed with Control diet; 2) 9.5 months old 
mice fed with Rapamycin or Control diet for 6.6 months; 3) 15 months old mice 
fed with Rapamycin or Control diet for 12 months and 4) 16 months old mice fed 
with Rapamycin or Control diet for 4 months. The different mice groups were 
matched for age and randomly assigned for the treatments. Control and 
Rapamycin diets were purchase from TestDiet - Control diet: 5LG6/122 PPM 
EUDRAGIT 3/8 #1814831 (5AS0) and Encapsulated Rapamycin diet: 5LG6/122 
PPM ENCAP RAP 3/8 #1814830 (5ARZ). Mice were fed ad libitum and 
monitored weekly.  
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PGC-1β−/− mice were generated and provided by Transgenic RAD, Discovery 
Science, Astrazeneca. .Animals were fed ad libitum on a normal chow diet (10% 
of calories derived from fat; D12450B, Research Diets). Wild-type and PGC-1β-
/- C57/BL6 mice were sacrificed at 18 months of age. Mouse liver tissues were a 
kind gift from Dr Sergio Rodriguez-Cuenca, Institute of Metabolic Science, 
Cambridge University, UK. 
Liver tumours were induced in C57/BL6 mice by IP injection of 30mg/kg N-
Nitrosodiethylamine (den) in wild-type mice. Tumour and normal liver tissues 
were a kind gift from Dr Derek Mann, Institute of Cellular Medicine, Newcastle 
University, UK. 
Mice Housing 
Animal procedures were performed in accordance with the UK Home Office 
regulations and the UK Animal Scientific Procedures Act [A(sp)A 1986]. Animals 
were housed in a temperature-controlled room with a 12-h light/dark cycle. No 
statistical method was used to predetermine sample size. No animals or 
samples were excluded from the analysis. 
 
2.9.2 Mice tissues collection and preparation 
Tissues were collected during necrospsy and fixed with either 4% formaldehyde 
aqueous solution buffered (VWR; Cat. Number 9713.9010) and paraffin 
embedding for histochemical analysis or with glutaraldehyde (Sigma, Cat. 
Number G5882) for T.E.M. (morphometric analysis). Part of the tissues were 
also frozen in liquid nitrogen and stored at -80oC for biochemical analysis. 
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2.10 Mitochondrial Functional analysis 
 
2.10.1 Mitochondrial Isolation 
 
Liver mitochondria were isolated by the method described by (Chappell et al. 
1972) in medium comprising 0.25 M sucrose, 5 mM Tris/HCl and 2 mM EGTA 
(pH 7.4 at 4 °C) (STE buffer). The crude mitochondria were purified by adapting 
the method described in (Pagliarini et al. 2008). Essentially, 0.5mL of crude 
mitochondria (about 30-40mg/mL) were carefully layered on top of a stepwise 
density gradient of 2 mL 80%, 6 mL 52%, and 6 mL 26% Percoll in a 50 mL 
centrifuge tube. The gradient was centrifuged at 41,100 g for 45 minutes in a 
Beckman Coulter Avanti® J-E centrifuge, using JA-20 rotor. Mitochondria were 
collected from the interface of the 26%-52% interface, diluted to capacity in a 2 
mL microcentrifuge tube with STE buffer, and centrifuged at 12,000g in a 
refrigerated table top centrifuge for 10 minutes. The supernatant was carefully 
discarded, and the mitochondria were washed with an additional 2 mL of STE 
and centrifuged again. The resulting pellet was re-suspended in a small volume 
of STE for functional experiments. 
 
2.10.2 Mitochondrial Oxygen Consumption analysis 
 
Mitochondrial oxygen consumption rates were measured using the Seahorse 
XF analyser (Seahorse Biosciences) based on the method described in (Rogers 
et al. 2011), with adjustment explained in the Comments to the articles 
published in PLoS online (A source of data variation in mitochondrial respiration 
measurements). The mitochondria were energized with 5mM pyruvate (Sigma; 
Cat. Number S8636) and 5mM malate (Sigma; Cat. Number M6413), and state 
3 respiration was obtained by adding 4mM ADP (Sigma; Cat.Number A2754). 
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2.11 Fluorescence staining on life cells 
 
TMRM/ Mito Tracker Green 
Dyes stock solutions 
 1µg/µL Mitotracker green (Invitrogen, Cat. Number M7514);  
 50mM TMRM (Invitrogen, Cat. Number  T668); 
 100 µg/mL Hoechst 33342 (Invitrogen, Cat. Number H3570).  
 
Dyes working solutions 
 1:1000 Mitotracker green: 1 µL in 999 µL serum free DMEM 
 1:3000 TMRM: 1 µL in 3 mL serum free DMEM 
 MitoT/TMRM plus Hoechst solution: 1 µL of TMRM working 
solution, 200 µL of Mitotracker green working solution and 30 µL of 
Hoechst (1:100) in 3 mL serum free DMEM. 
 
Mitochondrial Membrane potential (MMP) was measured using the red-
orange fluorescent dye Tetramethylrhodamine methyl ester (TMRM), 
cationic and mitochondria selective probe that can be assessed by several 
fluorescence analysis methods (including fluorescence microscopy) 
(Floryk et al. 1999). Because TMRM changes the intensity but not the 
emission spectra in response to membrane potential it is a good marker of 
mitochondrial membrane potential in combination with Mito Tracker Green, 
a marker of mitochondrial mass (TMRM/MitoT Green). Hoechst is a blue 
fluorescence dye when bound to DNA commonly used for nuclear 
counterstain. Cells seeded in coverslips (2.5x104) were washed with PBS 
and incubated with MitoT/TMRM plus Hoechst solution at 37oC for 30 
minutes. Cells were then washed once with medium and mounted on 
glass slides with ~10 µl PBS. Cells were imaged immediately on a Leica 
DM5500B microscope using a DFC360FX camera and the LASAF 
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software (Leica). Coverslips were stained one at the time and imaged for 
not longer than 20 minutes after mounting, since MitoTracker green tends 
to leak out after a while. 
 
 
2.12 Immunostainings 
 
Cells 
 
2.12.1 Immunofluorescence staining on fixed cells 
 
Fixation 
Cells grown in coverslips were fixed in 1 mL of 2% Paraformaldehyde in 
PBS (500µL of 4% formaldehyde (VWR; Cat. Number 9713.9010) plus 
500µL of PBS) for 10 minutes at room temperature. Paraformaldehyde 
was removed and cells were washed twice with PBS. 
 
Permeabilisation 
Cells were incubated for 45 minutes at room temperature with 1mL PBG-
Triton (0.2% cold water fish gelatine, 0.5% BSA and 0.5% Triton in PBS). 
 
Immunofluorescence staining 
A primary antibody (diluted in PBG –Triton) was added to the cells for 1 
hour at room temperature with gentle agitation or overnight at 4oC without 
gentle agitation. Cells were washed twice with PBG-Triton for 5 minutes. 
Cells were incubated for 45 minutes to 1 hour with fluorescein-conjugated 
secondary antibody (1/4000) diluted in PBG–Triton and then washed three 
 Chapter 2. Material and Methods 
 
54 
 
times with PBS for 5 minutes. Cells were stained for 10 minutes with 400μl 
of DAPI (Partec; Cat. Number 05-5001) and washed 3 times in PBS 
before mounting cells on slides using an anti-fade Vectashield mounting 
medium (Vector Lab, Cat. Number H-1000). Slides were analysed using a 
Leica DM5500B microscope and fluorescence images were captured with 
a DFC360FX camera using LASAF software (Leica). 
 
 
2.12.2 ImmunoFISH on cells (H2AX-TeloFISH) 
 
Cells grown on coverslips were fixed and -H2A.X immunofluorescence 
staining was performed as described above. After application of the 
secondary antibody, cells were washed with PBS and FISH was 
performed. 
 
FISH 
Cells were fixed for 10 minutes with 4% PFA and then washed with dH2O 
for 5 minutes twice. Cells were dehydrated with 70%, 90%, 100% ethanol 
for 3 minutes each and air dried  before denaturation for 10 minutes at 
80°C in hybridisation buffer [70% deionised formamide (Sigma), 25 mM 
MgCl2, 1 M Tris pH 7.2, 5% blocking reagent (Roche,Welwyn, UK)] 
containing 4ng/µL Cy-3 labelled telomere specific (CCCTAA) peptide 
nuclei acid probe (Panagene, Cat. Number F1002-5), followed by 
hybridisation for 2 hours at room temperature in the dark. Cells were 
washed for 10 minutes with 70% formamide in 2xSSC (17.53g of NaCl 
and 8.82g of sodium citrate in 1L of H2O, adjust pH to 7.0), following by a 
10 minutes wash in 2xSSC and a final wash in PBS for 10 minutes. Nuclei 
were stained by DAPI for 10 minutes and washed 3 times in PBS for 5 
minutes, before being mounted and imaged in a Leica DM5500B 
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fluorescence microscope. In depth Z stacking was used (a minimum of 40 
optical slices with 100× objective) followed by Huygens (SVI) 
deconvolution. Telomere-associated foci were analysed blinded by several 
analysts. 
 
Table 2.2 Primary antibodies for Immunofluorescence on cells 
Primary antibodies 
     
Protein Species Host Dilution Reference/Manufacturer 
Ki67 
Human 
Mouse 
Rabbit 
polyclonal 
1:250 ab15580 - Abcam 
γ-
H2A.X(Ser139) 
Human 
Mouse 
monoclonal 
1:2000 05-636 -  Millipore 
53BP1 Human 
Rabbit 
polyclonal 
1:500 4937 - Cell signalling 
53BP1 
Human 
Mouse 
Rabbit 
polyclonal 
1:200 NB100-305 - Novus Biologicals 
MT-CO1 
Human 
Mouse 
Mouse 
monoclonal 
1:500 ab45918 - Abcam 
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Table 2.3 Secondary antibodies for Immunofluorescence on cells 
Secondary antibodies 
     
Protein Species Host Dilution Reference/Manufacturer 
Anti-mouse 
Fluorescein-
conjugated secondary 
antibody AlexaFluor 
488 
Mouse Goat 1:4000 A21042 -Invitrogen  
Anti-mouse 
Fluorescein-
conjugated secondary 
antibody AlexaFluor 
594 
Mouse Goat 1:4000 A21044 - Invitrogen 
Anti-rabbit 
Fluorescein-
conjugated secondary 
antibody AlexaFluor 
488 
Rabbit Goat 1:4000 A21212 - Invitrogen 
Anti-rabbit 
Fluorescein-
conjugated secondary 
antibody AlexaFluor 
594 
Rabbit Goat 1:4000 A21213 - Invitrogen 
Anti-rabbit 
Fluorescein-
conjugated secondary 
antibody AlexaFluor 
637 
Rabbit Goat 1:2000 A21244 - Invitrogen 
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Tissues 
 
2.12.3 Immunostainings on paraffin embedded tissues 
 
Dewax and Hydration 
 
Paraffin tissue sections of 3µm thickness were deparaffinised in Histoclear 
(National Diagnostics; Cat. Number HS-200) for 10 minutes twice and 
hydrated in graded concentration of ethanol solutions: 100% (2x 5 
minutes), 90% (5 minutes), 70% (5 minutes) and H2O (10 minutes). 
 
Antigen Retrieval  
 
Antigens were retrieved by incubation tissues sections with 0.01M citrate 
buffer pH 6.0 (29.41g of trisodium citrate in 1L of distilled water, adjust pH 
to 6.0) in the microwave: high power (800W) for 5 minutes until boiling 
followed by 10 minutes at medium power (400W). Tissues sections were 
let to cool down for 20 minutes on an ice bath. Sections were then washed 
twice in H2O for 10 minutes. 
 
Immunohistochemistry staining 
 
Protocol for rabbit primary antibodies 
Slides were incubated in blocking buffer (1:60 Normal Goat Serum 
(NGS) (Vector Lab, Cat. Number PK-6101) and 0.1% BSA in PBS) 
for 30 minutes at room temperature. Primary antibodies were applied 
overnight at 4°C and then washed for 5 minutes three times with PBS. 
Tissues sections were incubated with biotinylated anti-rabbit antibody 
(Vector Lab, Cat. Number PK-6101) diluted in blocking buffer for 30 
minutes at room temperature. Sections were washed twice for 5 
minutes in PBS and blocked for endogenous peroxidase activity with 
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0.9% H2O2 in H2O (7.5 mL of 30% H2O2 in 250mL H2O). Tissues 
were then washed 3 times in H2O for 5 minutes. Secondary 
antibodies were detected using the rabbit peroxidase ABC kit (Vector 
Lab. Cat. Number PK-4001) according to the manufacturer’s 
instructions. Substrate was developed using the NovaRed kit (Vector 
Lab, Cat. Number SK-4800) following the manufacturer’s instructions. 
Sections were counterstained with haematoxylin [5g Haematoxylin 
(Sigma, Cat. Number H3136), 300mL Glycerin (Sigma, Cat. Number 
G2289), 50g Aluminium potassium sulphate (Sigma, Cat. Number 
7210), 0.5g Sodium iodate (Sigma, Cat. Number S4007), 40mL 
glacial acetic acid (Sigma, Cat. Number 537020) in 700mL H2O] and 
washed 3 times in H2O for 5 minutes. Tissue sections were then 
dehydrated and mounted with DPX mounting medium (Thermo 
Scientific; Cat. Number LAMB-DPX). Slides were analysed using a 
NIKON ECLIPSE-E800 microscope and images were captured with a 
Leica DFC420 camera using the LAS software (Leica). 
 
Protocol for mouse primary antibodies 
Immunohistochemistry stainings using mouse antibodies on mouse 
tissues were performed using the Mouse on Mouse (M.O.M) basic kit 
(Vector Lab, Cat. Number BMK-2202) according to the 
manufacturer’s instructions. Substrate was developed using the 
NovaRed kit (Vector Lab, Cat. Number SK-4800) following the 
manufacturer’s instructions. Sections were counterstained with 
haematoxylin and washed 3 times in H2O for 5 minutes. Tissue 
sections were then dehydrated and mounted with DPX mounting 
media. Slides were analysed using a NIKON ECLIPSE-E800 
microscope and images were captured with a Leica DFC420 camera 
using the LAS software (Leica). 
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Immunofluorescence staining 
 
Protocol for rabbit primary antibodies 
Slides were incubated in blocking buffer (1:60 NGS and 0.1% BSA in 
PBS) for 30 minutes at room temperature. Primary antibodies were 
applied overnight at 4 C and then washed three times with PBS for 5 
minutes. Tissues sections were: i) incubated for 30 minutes with 
fluorescein-conjugated anti-rabbit secondary antibody diluted in 
blocking buffer or ii) incubated 30 minutes with biotinylated anti-rabbit 
antibody (Vector Lab, Cat. Number PK-6101) diluted in blocking 
buffer at room temperature, before incubation with Fluorescein Avidin 
DCS (Vector Lab, Cat. Number A-2011) diluted in PBS for 30 
minutes at room temperature. Sections were washed three times with 
PBS for 5 minutes followed by DAPI staining (nuclear counterstain) 
for 10 minutes. Tissues sections were washed 3 times in PBS for 10 
minutes, before being mounted using an anti-fade VectaShield 
mounting medium (Vector Lab; Cat. Number H-1000). Slides were 
analysed using a Leica DM5500B microscope and fluorescence 
images were captured with a DFC360FX camera using LASAF 
software (Leica). 
 
Protocol for mouse primary antibodies 
Immunofluorescence stainings using mouse antibodies on mouse 
tissues were performed using the Mouse on Mouse (M.O.M) basic kit 
(Vector Lab, Cat. Number BMK-2202) according to the 
manufacturer’s instructions. After primary antibody incubation 
sections were washed 3 times in PBS for 5 minutes, before 
incubation with fluorescein-conjugated anti-mouse secondary 
antibody diluted in diluents buffer for 30 minutes at room temperature 
Sections were washed three times with PBS for 5 minutes followed 
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by DAPI staining (nuclear counterstain) for 10 minutes. Tissues 
sections were washed 3 times in PBS for 10 minutes, before being 
mounted using an anti-fade VectaShield mounting medium (Vector 
Lab, Cat. Number H-1000). Slides were analysed using a Leica 
DM5500B microscope and fluorescence images were captured with 
a DFC360FX camera using the LASAF software (Leica). 
 
 
2.12.4 ImmunoFISH on tissues (H2AX-TeloFISH) 
 
Immunofluorescence staining was performed as described above. 
Following incubation with avidin–DCS (diluted to 1:500; Vector Lab) for 30 
minutes, tissue sections were washed 3 times in PBS and fixed in 4% 
formaldehyde aqueous solution buffered for 20 minutes. Tissue sections 
were then dehydrated with 70%, 90%, 100% ethanol for 3 minutes each. 
Sections were air dried and then denatured for 10 minutes at 80°C in 
hybridisation buffer [70% deionised formamide, 25 mM MgCl2, 1 M Tris pH 
7.2, 5% blocking reagent (Roche,Welwyn, UK)] containing 4ng/µL Cy-3 
labelled telomere specific (CCCTAA) peptide nuclei acid probe (Panagene, 
Cat. Number F1002-5), followed by hybridisation for 2 hours at room 
temperature in the dark. The slides were washed for 10 minutes with 70% 
formamide in 2xSSC (17.53g of NaCl and 8.82g of sodium citrate in 1L of 
H2O, adjust pH to 7.0), following by a 10 minutes wash in 2xSSC and a 
final wash in PBS for 10 minutes. Nuclei were stained by DAPI for 10 
minutes and washed 3 times in PBS for 5 minutes, before being mounted 
and imaged in a Leica DM5500B fluorescence microscope. In depth Z 
stacking was used (a minimum of 40 optical slices with 100× objective) 
followed by Huygens (SVI) deconvolution. Telomere-associated foci were 
analysed blinded by several analysts. 
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Table 2.4 Primary antibodies for Immunostainings on Mouse Tissues 
Primary antibodies 
     
Protein Species Host Dilution Reference/Manufacturer 
γ-H2A.X(Ser139) 
Human 
Mouse 
Mouse 
monoclonal 
1:2000 05-636 -  Millipore 
53BP1 
Human 
Mouse 
Rabbit 
polyclonal 
1:100 4937 – Cell signalling 
4-HNE 
Human 
Mouse 
Mouse 
polyclonal 
1:50 MHN-020P – Cosmo Bio Co 
MT-CO1 
Human 
Mouse 
Mouse 
monoclonal 
1:500 ab45918 - Abcam 
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Table 2.5 Secondary antibodies for Immunostainings on Mouse Tissues 
Secondary antibodies 
     
Protein Species Host Dilution Reference/Manufacturer 
Anti-mouse Fluorescein-
conjugated secondary 
antibody AlexaFluor 594 
Mouse Goat 1:4000 A21044 - Invitrogen 
Anti-rabbit Fluorescein-
conjugated secondary 
antibody AlexaFluor 488 
Rabbit Goat 1:4000 A21212 - Invitrogen 
Anti-mouse IgG 
Biotinylated 
(M.O.M. basic kit) 
Mouse Goat 1:200 
BMK-2202 – Vector 
Laboratories 
Anti-rabbit IgG Biotinylated 
(VECTASTAIN Elite ABC 
Kit) 
Rabbit Goat 1:200 PK-6101 – Vector Laboratories 
Fluorescein Avidin DCS   1:500 A-2011 - Vector Laboratories 
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2.13 Transmission electron microscopy (T.E.M.) 
 
2.13.1 T.E.M. on cells  
 
Cells were trypsinised and centrifuged for 5 minutes at 150 g. Supernatant was 
discarded and cells were washed twice with PBS, before fixation in 2% 
glutaraldehyde (Sigma, Cat. Number G5882) in 0.1M Phosphate buffer (Sigma) 
for 1 hour at 4oC in a 15mL falcon. After fixation, the cell pellet was removed 
from the tube and placed in a glass vial. Fixation continued for 1 hour at room 
temperature, followed by washes with 0.1M Phosphate buffer for 2 hours (3 
changes). Cell pellets were then post-fixed with 1% osmium tetroxide (Sigma, 
Cat. Number O5500) in the same buffer for 1 hour at room temperature, mixing 
periodically. The osmium tetroxide solution was removed and pellets were 
washed for 1 hour with 0.1M Phosphate buffer (2 changes). Cell pellets were 
then dehydrated in graded ethanol 70%, 90% for 15 minutes and then in 100% 
ethanol for 15 minutes (2 changes) and then exposed to propylene oxide 
(Sigma, Cat. Number 471968) for 10 minutes (2 changes), extra careful was 
taken in order for the pellet not to dry. Cell pellets were then embedded in 50% 
epoxy resin in propylene oxide for 1 hour. Fresh epoxy resin from the Agar 100 
resin kit (Agar Scientific, Cat. Number R1031) was added and vials were placed 
in shaker overnight. The next day, the epoxy resin was substituted for fresh one 
and the cap of the vial was removed to allow any propylene oxide still present to 
evaporate. Embedment continued for 8 more hours, before placing cell pellets 
in BEEM® embedding capsules (Ted Pella, Cat. Number 130-SPC) containing 
fresh epoxy resin. Cell pellets were then incubated at 60oC for 48 hours. 
Sections were cut, stained with uranyl acetate and lead citrate and examined 
using a transmission electron microscope in the Newcastle University EM 
facility. Randomly, 12 fields were selected and morphometrically analysed for 
mitochondria volume fraction, number and area. 
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2.13.2 T.E.M. on tissues  
 
Mouse liver tissues were fixed in 3% glutaraldehyde in 0.1M Phosphate buffer 
overnight at 4oC. Tissues were washes with 0.2M Phosphate buffer (Sigma) for 
1 hour (2 changes), before being post-fixed with 1% osmium tetroxide in 0.1M 
Phosphate buffer for 1 hour at room temperature, in a shaker. The osmium 
tetroxide solution was removed and tissues were washed for 1 hour with 0.2M 
Phosphate buffer (4 changes) in a shaker. Tissues samples were then 
dehydrated in graded ethanol of 50%, 70%, 90% for 15 minutes in each solution 
and then in 100% ethanol for 30 minutes (2 changes) and then exposed to 
propylene oxide for 30 minutes (2 changes), extra careful was taken in order for 
the tissues not to dry. Tissues were then embedded in 50%, 75% and 100% 
epoxy resin in propylene oxide for 30 minutes in each solution in a shaker. for 8 
more hours, Tissue samples were placed in BEEM® embedding capsules 
containing fresh epoxy resin from the Agar 100 resin kit (Agar Scientific, Cat. 
Number R1031) and embedment continued overnight at 37oC (during this 
period tissues are also allowed to sink to the bottom of the capsule). Tissues 
were then incubated at 60oC for 48 hours. Sections were cut, stained with 
uranyl acetate and lead citrate and examined using a transmission electron 
microscope in the Newcastle University EM facility. Randomly, 30 fields were 
selected and morphometrically analysed for mitochondria volume fraction, 
number and area. 
 
 
2.14 Senescence Associated-β galactosidase (Sen-β-gal) staining 
 
After washing with PBS, cells in coverslips were fixed with 2% formaldehyde in 
PBS for 10 minutes. Cell were then stained in the Sen-β-Gal solution (150mM 
NaCl, 2mM MgCl2, 40mM Citric Acid, 12mM NaPO3, 400 µg/mL X-gal, 
2.1mg/mL Potassium hexacyanoferrat(II)trihydrate and 1.65mg/mL Potassium 
hexacyanoferrat(III) trihydrate), pH 6.0 (human cells) or pH 5.5 (mouse cells or 
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tissues) for 24 hours at 37oC. Coverslips were washed two times in PBS and 
then mounted on VectaShield mounting media with DAPI (Vector Lab, Cat. 
Number H1200). Cells showing Sen-β-Gal staining (dark blue staining) and total 
number of cells (evaluated through DAPI staining) were counted in 10 randomly 
chosen fields (20x objective) per experiment using a Leica DM5500B 
microscope and images were captured with a Leica DFC420 camera using 
LASAF software (Leica). 
Mouse tissues were fixed for 24 hours in 10% buffered neutral formalin and 
washed 3 times for 10 minutes in a shaker before incubation in the Sen-β-Gal 
solution. Tissues were washed for 10 minutes 3 times and then photographed 
using a conventional camera. 
 
 
2.15 SASP analysis 
 
2.15.1 Antibody Array 
 
A Quantibody Human Cytokine Array for 20 cytokines (RayBiotech, Cat. 
Number QAH-CYT-1) was performed. Conditional media was collected prior to 
irradiation (time 0) and 3 and 10 days after irradiation (20Gy X-ray) following 
24h serum deprivation. Conditional media was then sent to RayBiotech for 
analysis using the Quantibody Human Cytokine Array. Limit of detection for this 
assay was 10 g/ml-1. 
 
2.15.2 ELISAs 
 
Concentrations of IL-6 and IL-8 in cell culture media were determined using a 
sandwich ELISA system (R&D Systems; DY206/DY208) according to the 
manufacturer’s instructions. Conditional media was collected prior to irradiation 
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(0Gy) and 10 days after irradiation (20Gy) following 24h serum deprivation. 
Limit of detection for this assay was 10 g/ml-1. 
 
 
2.16 Protein expression analysis 
 
2.16.1 Protein Extraction 
 
Protein Extraction from cells 
 
Cells were washed with ice cold PBS before being lysed with ice cold RIPA 
buffer (150 mM NaCl, 1% NP40, 0.5% NaDoC, 0.1% SDS, 50 mM Tris pH 7.4 
and 1x phosphatase and protease inhibitors cocktail (Thermo Scientific; Cat. 
Number 78442) and scrapped using a rubber policemen. Samples were 
collected into 1.5 mL microcentrifuge tubes and immediately stored at -80oC 
(alternatively samples could be immediately used for protein quantification and 
further analysis). 
 
Protein Extraction from mouse tissues 
 
Liquid nitrogen frozen tissues were powdered and kept on dry ice before adding 
300µL of RIPA buffer to 20 mg of tissue powder (remaining tissue powder was 
stored at -80oC). Samples were then homogeneised and further lysed by 
vigorous vortexing. At this stage samples were either stored at -80oC or used 
immediately for protein quantification and further analysis. 
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2.16.2 Protein quantification 
 
Cell lysates were defrosted on ice before being centrifuged for 10 minutes at 
16100g at 4oC. Protein quantification was performed using a colorimetric Bio-
Rad DC Protein Assay (Bio-Rad; Reagent A Cat. Number 500-0113, Reagent B 
Cat. Number 500-0114, Reagent S Cat. Number 500-0115) according to the 
manufacturer’s instructions. Protein Absorbance was measured on the Fluostar 
Omega plate reader (BMG Labtech) Considering protein absorbance, protein 
concentration of each sample was calculated and normalised by mixing 
adjusted volumes of protein lysate and loading buffer [950 µL of 2xLaemmli 
buffer (Bio-Rad; Cat. Number 161-0737) plus 50 µL of mercaptoethanol (Sigma; 
Cat. Number M6250). Protein denaturation was achieved by incubating samples 
at 100°C for 5 minutes. Samples were immediately placed on ice after 
denaturation. At this stage samples were either stored at -80oC or used 
immediately for western blotting. 
 
2.16.3 Western blotting 
 
Electrophoresis 
 
Acrylamide gels were prepared as following:  
1. A running gel was prepared according to the protein size of the target 
proteins being analysed (lower protein size higher the percentage of 
the acrylamide gel and vice versa) and poured into a cassette 
(Invitrogen; Cat. Number NC2015 or NC2010) (see Table 3.6 for gel 
preparation); 
2. After the running gel has polymerised, a 5% acrylamide staking gel 
was prepared, poured into the cassette and allowed to polymerizse 
(see Table 3.6 for gel preparation). 
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Table 2.6 Acrylamide gels for Western Blotting analysis 
Acrylamide gels 
     
1 Gel 10ml 5% 10% 12% 15% 
Sterile H20 6.8mL 5.1mL 4mL 3.3mL 
30% Acrylamide 
(Severn Biotech; Cat. Number 20-
2100-10) 
1.7mL 2.6mL 3.3mL 4mL 
1.5M Tris pH 8.8 
(Sigma; Cat.Number T6066) 
2.5mL 2.5mL 2.5mL 2.5mL 
10% SDS 
(Sigma; Cat.NumberL4390) 
100 µL 100 µL 100 µL 100 µL 
10% Ammonium Persulphate 
(Sigma; Cat.Number 215589) 
100 µL 100 µL 100 µL 100 µL 
TEMED 
(Sigma; Cat.Number T9281) 
8µL 4µL 4µL 4µL 
 
 
Gels were placed in a XCell SureLockTM Mini-Cell Electrophoresis System 
(Invitrogen) covered by Tris-Glycine running buffer (250µM Tris, 1.92mM 
Glycine and 0.1% SDS). Samples were loaded side by side into wells alongside 
with a Protein standard (Bio-Rad; Cat. Number 161-0374) and electrophoresis 
was performed at 120V, 35mA for 90 minutes. 
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Protein transfer to membrane 
 
Proteins were transferred from the gel to a 0.45µm polyvinylidene difluoride 
(PVDF) membrane (Millipore; Cat. Number IPVH00010). Both the membrane 
and the gel were placed between transfer pads (VWR; Cat. Number 732-0594) 
soaked in transfer buffer (250µM Tris, 1.92mM Glycine). Transfer was 
performed using the Trans-Blot® SD Semi-Dry Transfer Cell (BioRad) at 20 
volts for 1 hour. The membrane was then stained with Ponceaux solution (0.5% 
Ponceaux and 5 % Acetic Acid in H2O) for detection of protein bands. 
 
Antibody Blotting 
 
The membrane was incubated for 1 hour in blocking buffer (5% Milk in 0.05% 
PBS-Tween) at room temperature in a shaker. The membrane was then 
incubated overnight at 4oC while shaking gently with the required concentration 
of primary antibody diluted in blocking buffer (antibodies against phosphorylated 
proteins were diluted in 5% BSA in 0.05% PBS-Tween). Membrane was 
washed 3 times in sterile H2O before incubation with the secondary antibody 
diluted in blocking buffer for 1 hour at room temperature while shaking gently. 
Membranes were washed 3 times with sterile H2O followed by a 5 minutes 
wash in 0.05% PBS-Tween at room temperature while shaking gently, before 
the final wash in sterile H2O (5 times). 
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Table 2.7 Primary antibodies for Western Blotting 
Primary antibodies for Western Blotting 
     
Protein Species Host Dilution Reference/Manufacturer 
γ-H2A.X(Ser139) 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9718 - Cell Signalling 
p21 Human 
Rabbit 
monoclonal 
1:1000 #2947 - Cell signalling 
PGC-1β 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 ab61249 - Abcam 
NDUFB8 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab110242 - Abcam 
UQCRC2 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab14745 - Abcam 
MT-CO1 
Human 
Mouse 
Rabbit 
monoclonal 
1:250 ab14705 - Abcam 
MT-CO2 Human 
Mouse 
monoclonal 
1:1000 ab110258 - Abcam 
SDHA 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab14715 - Abcam 
TOMM20 
Human 
Mice 
Mouse 
monoclonal 
1:1000 ab56783- Abcam 
VDAC1/Porin 
Human 
Mouse 
Mouse 
monoclonal 
1:1000 ab14734 - Abcam 
S6 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #2217- Cell signalling 
S6(Ser235/236) 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #4858- Cell signalling 
p70S6K 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9202 - Cell signalling 
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p70S6K(Thr389) 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9205 - Cell signalling 
TSC2 
Human 
Mouse 
Rabbit 
monoclonal 
1:1000 #4308 - Cell signalling 
Akt 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9272 - Cell signalling 
p-Akt(S473) 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 #9271 - Cell signalling 
β-tubulin 
Human 
Mouse 
Rabbit 
polyclonal 
1:2000 #2146 - Cell signalling 
α-tubulin 
Human 
Mouse 
Mouse 
monoclonal 
1:2000 T9026 Sigma Aldrich 
GAPDH 
Human 
Mouse 
Rabbit 
monoclonal 
1:5000 #5174 - Cell signalling 
FLAG - Mouse 1:1000 F316- Sigma Aldrich 
FLAG - Rabbit 1:1000 F7425-Sigma Aldrich 
Atg5 
Human 
Mouse 
Rabbit 
polyclonal 
1:1000 A0856-Sigma 
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Table 2.8 Secondary antibodies for Western Blotting 
Secondary antibodies for Western Blotting 
     
Protein Species Host Dilution Reference/Manufacturer 
Goat anti-rabbit 
IgG -HRP 
conjugated 
Rabbit Goat 1:5000 A0545 - Sigma-Aldrich 
Goat anti-mouse 
IgG -HRP 
conjugated 
Mouse Goat 1:5000 A2554 - Sigma-Aldrich 
 
 
Chemiluminescence and evaluation 
 
The blot was incubated with the chemiluminescence agent ClarityTM Western 
ECL substrate (Bio-Rad; Cat. Number 170-5060) for 5 minutes. The blot was 
visualised using Fuji film Intelligent Dark box II and Image Reader Las-1000 
Software. The protein of interest was confirmed by size comparison of the 
protein bands to the Protein standard loaded during electrophoresis. ImageJ 
analysis software was used to quantify the intensity of signal on the blot. 
Intensity quantification of the protein of interest of calculated after Background 
subtraction and normalisation to a loading control (GAPDH or β-tubulin). 
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2.17 Gene expression analysis 
 
2.17.1 RNA extraction 
 
Cells were trypsinised and centrifuged at 150g for 5 minutes at 4oC. Cells were 
washed in PBS and centrifuged at 150g for 5 minutes at 4oC. The supernatant 
was discarded and cell pellets were used for RNA extraction using the RNeasy 
Mini Kit (Qiagen, Cat. Number 74106) following the instructions described on 
the RNeasy® Mini Handbook – Qiagen. Assessment of RNA quality and 
quantification was performed using the Nanodrop® 1000 spectrophotometer 
(Thermo Scientific). 
 
2.17.2 Reverse trancriptase reaction (RT-PCR) 
 
Total RNA was reverse transcribed into cDNA using the Omniscript RT Kit 
(Qiagen, Cat. Number 205110) as described on the Omniscript® Reverse 
Transcription Handbook – Qiagen.  
 
2.17.3 Real-time PCR for gene expression analysis 
 
The real-time PCR was conducted using the Power Syber® Green PRC Master 
Mix (Invitrogen, Cat. Number 4367659). The real-time PCR reaction mix 
included: 4µL of cDNA (200-800ng) plus 6µL of PCR master mix (5µL of Power 
Syber® Green PRC Master Mix, 0.2µL of 10 µM Primers and 0.8µL H2O), 
performing a 10µL final reaction volume. Each sample was run in triplicate in a 
C1000TM Thermal Cycler, CFX96TM Real-Time System (Bio-Rad) and Bio-Rad 
CXF Manager software. 
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Table 2.9 Primer sequences for cDNA real-time PCR 
Primers sequences for cDNA real-time PCR  
    
Gene Species Sequence 
PGC-1β Human 
Forward 5’ AGTCAACGGCCTTGTGTTAAG 
Reverse 5’ ACAACTTCGGCTCTGAGACTG 
PGC-1α Human 
Forward 5’ TGAGAGGGCCAAGCAAAG 
Reverse 5’ ATAAATCACACGGCGCTCTT 
IL-6 Human 
Forward 5’CAGGAGCCCAGCTATGAACT 
Reverse 5’GAAGGCAGCAGGCAACAC 
IL-8 Human 
Forward 5’GAGTGGACCACACTGCGCCA 
Reverse 5’TCCACAACCCTCTGCACCCAGT 
COX5A Human 
Forward 5’CAAAGTGTAAACCGCATGGAT 
Reverse 5’TCCAGGTAACTGTTCACACTCAA 
NDUFS8 Human 
Forward 5’GTGCAGGACCTCCTGGTG 
Reverse 5’TCTCGGGATCCTGCATGT 
ATP5G1 Human 
Forward 5’ TGCAGGGTAGTAGGAGTGCAG 
Reverse 5’ TTAGACCCCTGGTACAACAGC 
GAPDH Human 
Forward 5’AAATCCCATCACCATCTTCC 
Reverse 5’ GACTCCACGACGTACTCAGC 
CXCL1 Mouse 
Forward 5’ GACTCCAGCCACACTCCAAC 
Reverse 5’ TGACAGCGCAGCTCATTG 
IL-6 Mouse 
Forward 5’ CTACCAAACTGGATATAATCAGGA 
Reverse 5’ CCAGGTAGCTATGGTACTCCAGAA 
p16 Mouse 
Forward 5’ TTGCCCATCATCATCACCT 
Reverse 5’GGGTTTTCTTGGTGAAGTTCG 
β-actin Mouse 
Forward 5’ TAAGGCCAACCGTGAAAAG 
Reverse 5’ ACCAGAGGCATACAGGGACA 
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Thermo cycler real-time PCR conditions were the following: 
 
1. 95oC  10 minutes 
2. 95oC  15 seconds 
3. 60oC  60 seconds 
4. Repeat 39X steps 2 and 3. 
 
Primer specificity was confirmed using a dissociation step with calculation of a 
melting curve. Relative quantification of mRNA expression was determined by 
relative comparison to the levels of an internal control mRNA, usually a 
housekeeping gene (e.g. GAPDH and β-actin). To calculate mRNA expression 
we used the ΔΔC(t) method. 
 
 
2.18 Mitochondrial DNA (mtDNA) copy number analysis 
 
2.18.1 DNA extraction 
 
Cells were trypsinised and centrifuged at 150g for 5 minutes at 4oC. Cells were 
washed in PBS and centrifuged at 150g for 5 minutes at 4oC. The supernatant 
was discarded and cell pellets were used for DNA extraction using the 
DNeasy® Blood and Tissie Kit (Qiagen, Cat. Number 69504) following the 
instructions described on the DNeasy® Blood and Tissie Kit Handbook – 
Qiagen. Assessment of DNA quality and quantification was performed using the 
Nanodrop® 1000 spectrophotometer (Thermo Scientific). 
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2.18.2 Real-time PCR for mtDNA copy number analysis 
 
The real-time PCR was performed as described above (3.17.3). Relative 
expression were calculated using the ΔΔC(t) method. 
 
 
Table 2.10 Primers for mtDNA real-time PCR 
Primers sequences mtDNA real-time PCR  
    
Gene Species Sequence 
B2M human 
Forward 5’ CCAGCAGAGAATGGAAAGTCAA 
Reverse 5’ TCTCTCTCCATTCTTCAGTAAGTCAACT 
ND1 human 
Forward 5’ CCCTAAAACCCGCCACATCT 
Reverse 5’ GAGCGATGGTGAGAGCTAAGGT 
ND1 Mouse 
Forward 5’ ACACTTATTACAACCCAAGAACACAT 
Reverse 5’ TCATATTATGGCTATGGGTCAGG 
ND5 Mouse 
Forward 5’ CCACGCATTCTTCAAAGCTA 
Reverse 5’ TCGGATGTCTTGTTCGTCTG 
 
 
 
2.19 Comet Assay 
 
The comet assay was conducted under alkalin conditions according to Singh et 
al. (Singh et al. 1988). For each sample, 100 randomly captured comets from 
slides (50 cells on each of 2 comet slides) were examined at ×400 magnification 
using an epifluorescence microscope connected through a black and white 
camera to an image analysis system (Comet Assay II; Perceptive Instruments 
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Ltd., Haverhill, Suffolk, United Kingdom). Images acquired by the computerised 
image analysis system were used to compute the integrated intensity profiles 
for each cell, estimate the comet cell components, and evaluate the range of 
derived parameters. To quantify DNA damage, the tail moment (TM) was 
calculated as the product of the tail length and the fraction of DNA in the comet 
tail. A single reader, who was blind to the status of subjects, scored all slides. 
 
2.20 Statistical analyses 
 
We conducted One-Way ANOVA, two-tailed t test, linear and non-linear 
regression analysis and Gehan-Breslow test using Sigma Plot vs11.0. 
Wilcoxon-Mann-Whitney tests were conducted using IBM SPSS Statistics 19. 
 
2.21 Ethics statement 
 
All work complied with the guiding principles for the care and use of laboratory 
animals. The project was approved by the Faculty of Medical Sciences Ethical 
Review Committee, Newcastle University. Project license number 60/3864. 
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Chapter 3. Mitochondria are essential for the establishment and 
maintenance of senescence 
 
 
Previous studies have associated mitochondrial dysfunction and concomitant 
ROS production with cellular senescence (Passos et al. 2007, Passos et al. 
2010). While mitochondrial ROS have been causally implicated in the 
stabilisation of the permanent cell growth arrest, the role of mitochondria in 
cellular senescence is still largely unknown: How do mitochondria change 
following senescence stimuli? Do mitochondria themselves integrate 
senescence-inducing stimulus? Are mitochondria required to the establishment 
and maintenance of cellular senescence? 
The work performed in this chapter aimed to understand mitochondria dynamics 
in cellular senescence. Firstly, we kinetically analysed mitochondrial mass and 
ROS production following senescence stimuli. Secondly, we eliminated 
mitochondria from cells and assessed for its impact on the establishment and 
maintenance of the senescent phenotype. 
 
 
3.1. Mitochondrial content increases during senescence 
 
Persistent DNA lesions are a major trigger of cellular senescence by 
continuously signalling and activation of cyclin-dependent kinase inhibitors 
(responsible for the cycle arrest) through response pathways, together known 
as DNA damage response (DDR). In order to understand how mitochondria 
change during senescence, we kinetically analysed mitochondrial mass 
following activation of a DDR by genotoxic stress (generated by X-ray irradiation, 
Etoposide, Neocarcinostatin (NCS) and H2O2) or telomere dysfunction 
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(TRF2BM) in a variety of cells lines. In collaboration with Rhys Anderson and 
Francisco Marques in our lab, we observed that regardless of the DNA 
damaging agent, activation of a DDR invariably results in mitochondrial mass 
increase 2-4 days following genotoxic stress (Figure 3.1A). Protein expression 
analysis shows that kinetically mitochondrial proteins expression increase and 
reach a maximum between 2 and 3 days following a DDR (Figure 3.1B). These 
changes occurred in parallel with ROS generation and basal oxygen 
consumption rates (OCR). Nevertheless, when ROS (or basal OCR) are 
normalised per unit of mitochondrial mass no changes are observed upon 
induction of senescence, indicating that ROS increase during senescence is a 
result of mitochondrial mass increase (Figure 3.1C). The OCR analysis was 
performed in collaboration with Satomi Miwa in the von Zglinicki lab. Previous 
results in the lab have shown that addition of the free radical scavenger N-tert.-
butyl-alpha-phenylnitrone (PBN) and the antioxidant N-acetyl cysteine (NAC) 
significantly reduce ROS per cell but do not affect mitochondrial mass. Together, 
these observations suggest that changes in mitochondrial mass are not an 
adaptive process driven by ROS, but potentially the drivers of ROS generation 
in senescence. To further confirm that mitochondrial content increases 
downstream of a DDR we performed morphometric analysis by transmission 
electron microscopy (T.E.M) on MRC5 fibroblasts and found that mitochondrial 
volume fraction and numbers increased upon irradiation (Figure 3.1D). T.E.M 
analysis on MRC5 fibroblasts was performed by Michelle Charles in our lab. 
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Figure 3.1 | Mitochondrial content increases downstream of a DDR. (A) 
Mitochondrial mass increases 2-4 days following genotoxic stress (generated by X-ray 
irradiation, Etoposide, Neocarcinostatin (NCS), H2O2 or telomere dysfunction 
(TRF2BM) in a variety of cell lines (data are from 3 independent experiments per cell 
line or treatment); (B) (top) Representative western blots showing expression of 
mitochondrial proteins until 10 days after 20Gy (data are representative of 3 
independent experiments; (bottom) Expression of mitochondrial proteins (NDUFB8, 
SDHA, UQCRC2, TOMM20) following activation of a DDR using 20Gy in MRC5 
fibroblasts (data are representative of 3 independent experiments); (C) (top) Kinetic 
analysis of mitochondrial mass (NAO fluorescence); ROS (DHR fluorescence) and 
ROS per unit of mitochondria after activation of a DDR in MRC5 fibroblasts using 
A B C 
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20Gy. Data were obtained by flow cytometry and are mean±S.E.M n=3-4 independent 
experiments; (bottom) Oxygen Consumption Rate (OCR) in moles/min per cell was 
conducted in parallel with mitochondrial mass measurements using NAO by flow 
cytometry. Data are mean±S.E.M, n=3 independent experiments; (D) (left) 
Representative electron micrographs of human young proliferating MRC5 fibroblasts 
(0Gy) and 3 days after 20Gy (senescent), mitochondria are labelled in pink; (right) 
Quantification of mitochondrial volume fraction %Vv and mitochondrial number per 
cross section (T.E.M mitochondrial analyses are mean±S.E.M of 24 electron 
micrographs per condition); Scale bar = 2µm Asterisk denotes statistical significant 
P<0.05 using two-tailed t-test.     
 
 
 
High doses of X-ray irradiation have been reported to completely abolish cell 
proliferation and induce both Sen-β-Gal activity (Passos et al. 2010) and the 
SASP (Rodier et al. 2009). In order to test the dependency of mitochondrial 
mass on the DDR, we treated MRC5 human fibroblasts with increasing doses of 
X-ray irradiation. Work done, in collaboration with Rhys Anderson in our lab, 
has shown that mitochondrial mass increases proportionally to the irradiation 
dose (Figure 3.2A) and directly correlates with DNA damage foci, induction of 
Sen-β-Gal and activation of the cyclin-dependent kinase inhibitor p21 and 
inversely correlates with the proliferation marker Ki67 (Figure 3.2B). 
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Figure 3.2 | DDR-dependent mitochondrial mass increase correlates with 
senescence markers. (A) Mitochondrial mass increases proportionally to irradiation 
dose (representative histograms of NAO fluorescence measured by flow cytometry); (B) 
Graphs showing correlation between mitochondrial mass, Senescence-associated β-
Galactosidase (Sen-β-Gal), Ki67, p21 expression (measured by western blot) and 
number of H2A.X foci. Data are mean±S.E.M of n=3 independent experiments. 
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The peroxisome proliferator-activated receptor co-activator 1 (PGC-1) family 
includes PGC-1α, PGC-1β and the PGC-1-related co-activator (PRC) 
(Puigserver et al. 1998, Andersson et al. 2001, Lin et al. 2002), well known co-
activators in the regulation of metabolic pathways. These proteins are strong 
activators of mitochondrial function including regulation of mitochondrial 
biogenesis and oxidative metabolism in a variety of tissues (Handschin et al. 
2006). We questioned if PGC-1 co-activators were increased downstream of a 
DDR activating mitochondrial biogenesis in senescence. In collaboration with 
Michelle Charles in our group, we found that an increase in the mRNA levels of 
PGC-1α and PGC-1β in irradiation-induced senescent fibroblasts (Figure 3.3), 
corroborating the observed increase in mitochondrial mass following a DDR. 
 
 
 
 
Figure 3.3 | Mitochondrial regulators PGC-1α and PGC-1β expression increases 
following a DDR. (A) mRNA expression of PGC-1α and (B) PGC-1β after 20Gy X-
radiation in MRC5 human fibroblasts; Expression was normalised to mRNA levels of 
GAPDH. Data are mean±S.E.M of n=3 independent experiments. Asterisk denotes 
statistical significant P<0.05 One-way ANOVA. 
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3.2. Mitochondria are essential for the establishment and 
maintenance of cellular senescence 
 
To definitely determine the importance of mitochondria as potential effectors in 
senescence, we sought to generate mitochondria-deficient cells. Parkin is an 
E3-ubiquitin ligase encoded by the PARK2 gene, that mediates proteasomal 
degradation of proteins (Shimura et al. 2000). When mitochondrial membrane 
potential is lost in mammalian cells, Parkin translocates to mitochondria and 
induces removal of these organelles by autophagy, in a process known as 
mitophagy. Parkin translocation from the cytosol to mitochondria is dependent 
on the PTEN-induced putative kinase 1 (PINK1) (Narendra et al. 2010). The 
exact mechanism through which Parkin interacts with PINK1 to clear 
dysfunctional mitochondria from cells is still not determined. However, it has 
been reported that Parkin mediates polyubiquitination of a subset of 
mitochondrial substrates, which may be part of the mechanism through which it 
triggers mitophagy (Chen et al. 2010, Gegg et al. 2010, Geisler et al. 2010, 
Wang et al. 2011). Moreover, Parkin has been shown to translocate and 
contribute to degradation of depolarised mitochondria following treatment with 
the mitochondrial uncoupler carbonyl cyanide m-chlorophenyl hydrazine (CCCP) 
(Narendra et al. 2008). In order to test the role of mitochondria in senescence, 
we generated human MRC5 fibroblasts stably transfected with YFP-Parkin. We 
induced senescence by X-ray irradiation (20Gy) in controls and YFP-expressing 
Parkin cells, treated them at day 2 with CCCP for 48h and analysed them at 
different time points after irradiation (Figure 3.4). 
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Figure 3.4 | Parkin-mediated clearance of mitochondria in irradiation-induced 
senescent fibroblasts. Scheme illustrating the experimental design: Parkin-
expressing and control MRC5 fibroblasts were irradiated with 20Gy and 2 days later 
were treated with CCCP/DMSO for 48h. Cells were harvested for senescence marker 
analysis 4, 10 and 20 days after irradiation.  
 
 
 
3.2.1. Depletion of mitochondria severely abrogates the senescent phenotype in 
human fibroblasts  
 
Elimination of mitochondria post-induction of senescence led to a remarkable 
rejuvenation of human fibroblasts. These mitochondrial-deficient cells failed to 
develop multiple senescent traits such as increased cell size, Sen-β-Gal activity 
and formation of heterochromatin foci (Figure 3.5). 
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Figure 3.5 | Mitochondrial clearance induces rejuvenation of human senescent 
fibroblast. (A) (top) Histograms illustrating cell size distributions in control and Parkin-
expressing cells 10 and 20 days after X-ray irradiation with or without CCCP pre-
B 
C 
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treatment. Dashed red line represents median cell size. At least 100 cells were 
quantified per condition; (bottom) Representative images of Parkin-expressing cells 20 
days after X-ray irradiation with or without CCCP pre-treatment; Scale bar = 50µm (B) 
(top) Representative images of Senescence associated β-Galactosidase activity (Sen-
β-Gal) 10 days after 20Gy in control and Parkin-expressing fibroblasts with or without 
CCCP treatment; Scale bar = 50µm; (bottom) Quantification of Sen-β-Gal in senescent 
control and Parkin-expressing fibroblasts with or without CCCP treatment. Data are 
mean±S.E.M of 3 independent experiments; (C) (left) Representative images of 
heterochromatin foci observed by DAPI (grey); Scale bar = 20µm; (right) Quantification 
of Senescent-associated heterochromatin foci (SAHF) in senescent control and Parkin 
expressing fibroblasts with or without CCCP treatment. Data are mean±S.E.M of 3 
independent experiments. Asterisk denotes statistical significant P<0.05 One-way 
ANOVA. 
 
The increased ROS and pro-inflammatory mediating factors secretion by 
senescent cells are traits of the senescent phenotype responsible for the 
detrimental effects of these cells on the surrounding tissues (Nelson et al. 2012, 
Acosta et al. 2013). Next, we aimed to understand how mitochondria can 
modulate these two features of senescence. 
 
 
Mitochondria depletion blocks ROS generation in senescence 
 
Mitochondria are the main source of intracellular ROS and have been correlated 
with several markers of senescence as shown previously in this chapter. Parkin-
mediated mitochondrial depletion by treatment with CCCP for 48h in human 
fibroblasts led to a dose- dependent decrease in mitochondrial mass, as well as 
ROS generation (Figure 3.6A). When using a concentration of 12.5µM of CCCP 
we could not detect any mitochondrial proteins from OXPHOS complexes I, II, 
III and IV by western blotting 10 days after irradiation (Figure 3.6B). 
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Immunostaining against the mitochondrial protein SDHA further revealed total 
absence of mitochondria in CCCP treated Parkin-expressing cells (Figure 3.6C). 
 
 
 
 
 
Figure 3.6 | Parkin-mediated mitochondrial clearance reduces ROS levels in 
human senescent fibroblasts. (A) Effect of 2 day treatment with increasing doses of 
CCCP on Mitochondrial mass (measured by NAO fluorescence) and ROS (measured 
by DHE fluorescence) 4 days after irradiation with 20Gy of Parkin-expressing and 
control MRC5 fibroblasts. Data are mean±S.E.M of 3 independent experiments; (B) 
Representative westerns blots confirming absence of proteins from different 
mitochondrial complexes: NDUFB8 (complex I), SDHA (complex II), UQCRC2 
(complex III) and MT-CO1 (complex IV) 10 days after irradiation and 6 days after 
12.5µM CCCP treatment (data are representative of 2 independent experiments); (C) 
Representative image of SDHA fluorescence of Parkin-expressing MRC5 fibroblasts 
with or without CCCP treatment (data are representative of 2 independent 
experiments); Scale bar = 20µm. Asterisk denotes statistical significant P<0.05 One-
way ANOVA. 
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Mitochondria are essential for the development of the senescence-associated 
pro-inflammatory phenotype 
 
The SASP, particularly the pro-inflammatory phenotype, has been associated 
with the deleterious effects of senescent cells on the surrounding tissue (Acosta 
et al. 2013). Elimination of mitochondria in Parkin-expressing human fibroblasts 
with CCCP treatment decreased mRNA expression and severely abrogated 
secretion of the SASP components IL-6 and IL-8 (Figure 3.7). ELISAs were 
performed in collaboration with Jodie Birch in our lab. These findings place 
mitochondria as a putative therapeutic target on strategies aiming to reduce the 
senescence-associated pro-inflammatory phenotype. 
 
 
 
 
Figure 3.7 | Depletion of mitochondria abrogates the senescence-associated 
inflammatory phenotype. (A) Levels of secreted IL-6 and IL-8 proteins (Data are 
representative of 2 independent experiments); (B) Expression of IL-6 and IL-8 mRNA in 
senescent control and Parkin-expressing fibroblasts with or without CCCP treatment 
(Data are mean±S.E.M of 3 independent experiments). Asterisk denotes statistical 
significant P<0.05 One-way ANOVA. 
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3.2.2. Absence of mitochondria in senescence rescues cell proliferation 
 
Despite the cells’ inability to rely on oxidative phosphorylation, a considerable 
percentage of them were able to resume proliferation as demonstrated by 
increased population doublings and expression of the proliferation marker Ki67 
(Figure 3.8A and 3.8B). In fact, we were able to culture human fibroblasts 
without any signs of cell death and no detectable mitochondrial proteins for at 
least a month (not shown). We also observed that depletion of mitochondria 
results in decreased expression of the cyclin-kinase inhibitors p21 and p16 in 
MRC5 fibroblasts induced to senescence with 20Gy X-radiation (Figure 3.8C).  
 
 
 
 
 
Figure 3.8 | Clearance of mitochondria rescues cell proliferation in irradiation-
induced senescent human fibroblast. (A) Representative images of Ki67 (red) with 
DAPI (blue) as a nuclear counterstain in senescent control and Parkin-expressing 
fibroblasts with or without CCCP treatment; Scale bar = 20µm; (B) (top) Quantification 
A B 
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of Ki67 in senescent control and Parkin expressing fibroblasts with or without CCCP 
treatment, (bottom) Population doublings in senescent control and Parkin-expressing 
fibroblasts with or without CCCP treatment. Data are mean±S.E.M of 3 independent 
experiments; (C) Representative western blot showing p21 and p16 expression in 
senescent control and Parkin-expressing fibroblasts with or without CCCP treatment 
(data are representative of n=2 independent experiments). Asterisk denotes statistical 
significant P<0.05 One-way ANOVA. 
 
 
3.2.3. Mitochondria depletion ameliorates the senescent phenotype in replicative 
senescence 
 
In order to test the role of mitochondria in cells where senescence had already 
been established, we cultured Parkin-expressing human fibroblasts until 
replicative senescence (evidenced by around 70% Sen-β-Gal positive cells and 
less than 0.5 Population doublings for at least 4 weeks). Replicative YFP-Parkin 
senescent MRC5 fibroblasts were treated with 12.5 µM CCCP for 48 hours 
(figure 3.9A) resulting in significantly reduced mitochondrial mass and ROS 
generation and absence of mitochondrial proteins (Figure 3.9B and 3.9C). 
Moreover, markers of senescence such as Sen-β-Gal activity, increased cell 
size and expression of p16 and p21 were significantly reduced (Figure 3.9C and 
3.9D). Contrary to X-ray induced senescence, we did not observe increased 
proliferation following mitochondrial depletion (data not shown). 
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Figure 3.9 | Mitochondria elimination ameliorates the senescent phenotype in 
replicative senescent human fibroblasts. (A) Scheme illustrating experimental 
design: Parkin-expressing MRC5 fibroblasts were cultured until replicative senescence 
and then treated with CCCP for 48h; (B) Mitochondrial mass (NAO fluorescence) and 
ROS (DHE fluorescence) with and without CCCP treatment in replicative senescent 
(RS) Parkin-expressing MRC5 fibroblasts. Data are mean±S.D. of n=2 independent 
experiments; (C) Western blots displaying expression of mitochondrial proteins from 
the different mitochondrial electron transport chain complexes, p21 and p16 with and 
A 
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without CCCP pre-treatment in replicative senescent (RS) Parkin-expressing MRC5 
fibroblasts (data from n=1 experiment; (D) (top) Representative images of Sen-β-Gal 
and (bottom) quantification of Sen-β-Gal in replicatively senescent (RS) Parkin-
expressing cells with or without CCCP pre-treatment; Scale bar = 50µm; (E) 
Histograms illustrating cell size distributions in replicatively senescent Parkin-
expressing cells 10 days after treatment with or without CCCP pre-treatment. Dashed 
red line represents median size. At least 100 cells were quantified per condition. 
Asterisk denotes statistical significant P<0.05 One-way ANOVA. 
 
 
3.3. Depletion of mitochondria severely compromises the senescent 
phenotype in mouse fibroblasts  
 
To further extend the significance of our observations on human fibroblasts to 
other mammalian cells, we used 3T3 mouse fibroblasts expressing Parkin 
induced to senesce with 10Gy X-radiation. Similarly to MRC5 human fibroblasts, 
Parkin-expressing mouse fibroblasts (3T3) pre-treated with CCCP had reduced 
mitochondrial mass (Figure 3.10A) and virtually no detectable mitochondrial 
proteins (Figure 3.10B).The western blots showing mitochondrial proteins 
expression on Parkin-expressing 3T3 fibroblasts following CCCP treatment 
were a kind gift of Dr Stephen Tait (Institute of Cancer Sciences, Glasgow 
University, UK). Following X-ray irradiation-induced senescence these cells 
showed no ROS induction, as well as no mRNA expression of p16 and the 
SASP factors IL-6 and CXCL1 (Figure 3.10C-E). These results confirm the 
hypothesis that mitochondria are essential for development of senescence not 
only in human cells but also in other mammalian cells.  
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Figure 3.10 | Mitochondria clearance abrogates the senescent phenotype in 
senescent mouse fibroblasts. (A) Representative flow cytometry histogram of 
mitochondrial mass (NAO staining) in control and Parkin-expressing 3T3 mouse 
fibroblasts with or without treatment with the uncoupler CCCP; (B) Representative 
western blots showing expression of mitochondrial proteins CYTC and HSP60 in 
control and Parkin-expressing 3T3 mouse fibroblasts with or without 2 day treatment 
with CCCP (2 independent experiments); (C) Quantification of ROS levels (DHE 
staining) in 3T3 controls and Parkin-expressing mouse fibroblasts 4 days following 
10Gy irradiation and CCCP; (D) and (E) p16, IL-6 and CXCL1 mRNA abundance in 
3T3 controls and Parkin-expressing 3T3 mouse fibroblasts 10 days following 10Gy 
irradiation and 6 days after CCCP pre-treatment. Data are mean±S.E.M of n=3 
independent experiments. Asterisk denotes statistical significant P<0.05 One-way 
ANOVA. 
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3.4. Mitochondrial DNA depleted cells have diminished expression 
of senescence markers 
 
Cells depleted of mitochondrial DNA (mtDNA), or Rho 0 (0) cells, lack critical 
electron transport chain components (mitochondrial encoded) but still have few 
petit mitochondria. Rho 0 cells by presenting significantly reduced mitochondrial 
mass have largely compromised oxidative phosphorylation and rely solely on 
glycolysis for survival and replication (Chandel et al. 1999). In order to 
understand if low mitochondrial mass content would still impact on senescence, 
we irradiated Rho 0 cells and analysed for senescence markers. When 
compared to parental cells, ROS as well as DNA damage foci only increased 
marginally in Rho 0 cells 3 days after 10Gy Irradiation (Figure 3.11A). 
Furthermore, mRNA levels of the SASP factor IL-6 was significantly reduced in 
Rho 0 cells upon irradiation (Figure 3.11B). Together, these results confirm that 
reduction of mitochondrial content (not only complete elimination of 
mitochondria) impacts on senescent markers. 
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Figure 3.11 | Depletion of mtDNA alleviates the senescent phenotype in human 
cells. (A) (left) Representative flow cytometry histogram of mitochondrial mass staining 
(NAO) in parental and Rho 0 143B osteosarcoma cells and (right) quantification of 
ROS generation in parental and Rho 0 cells 3 days following 10Gy irradiation; (B) (left) 
Quantification of 53BP1 foci in parental and Rho 0 cells 3 days after 10Gy irradiation. 
Data are mean±S.E.M of n=3 independent experiments. (right) mRNA abundance of 
the SASP factor IL-6 in parental and Rho 0 cells following 10Gy irradiation. Asterisk 
denotes statistical significant P<0.05 One-way ANOVA. 
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3.5. Discussion 
 
Despite numerous studies on the impact of mitochondria and the ageing 
process none have really tested directly the necessity of mitochondria for the 
induction of senescence and development of the senescent phenotype. Several 
studies have shown that cellular senescence is characterised by mitochondrial 
dysfunction contributing to metabolic inefficiency and elevated ROS (Allen et al. 
1999, Hutter et al. 2002, Zwerschke et al. 2003, Hutter et al. 2004, Passos et al. 
2007). Increased ROS levels have been associated with replicative, stress- and 
oncogene-induced senescence (Saretzki et al. 2003, Ramsey et al. 2006, 
Passos et al. 2007, Lu et al. 2008). Furthermore, activation of the DDR, a major 
effector of senescence, by genotoxic stress or telomere uncapping (Passos et 
al. 2010), over-expression of activated RAS (Lee et al. 1999), BRAFV600E 
(Kaplon et al. 2013), p53  (Macip et al. 2003), p21 (Macip et al. 2002) and p16 
(Takahashi et al. 2006) all resulted in elevated ROS generation. In most of the 
above reported cases treatment with antioxidants, such as N-acetyl cysteine, 
was able to prevent the cell-cycle arrest supporting a causal role for ROS in the 
process. Nevertheless, non-mitochondrial sources of ROS have also been 
implicated in cellular senescence. Takahashi and colleagues, using human 
fibroblasts, connected p16 with ROS production via protein kinase Cδ signalling 
(Takahashi et al. 2006). Protein kinase Cδ has been shown to activate a non-
mitochondrial source of ROS, generated by NADPH-oxidase through 
phosphorylation of p47phox, an essential component of NADPH oxidase (Talior 
et al. 2005). Consistent with this study, NADPH oxidases have been shown to 
limit the replicative lifespan of human endothelial cells in culture via ROS 
generation (Lener et al. 2009). These observations have placed ROS as 
signalling molecules during cellular senescence (Passos et al. 2006). While 
ROS have been shown to stabilise cellular senescence, the necessity of 
mitochondria in cellular senescence remains to be determined. Here we show 
that mitochondria are required for senescence to occur and for the development 
of the senescence phenotype. 
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First, we showed that there is an increase in mitochondrial mass following DDR 
stimuli and that it correlates with markers of senescence such as increased 
Sen-β-Gal activity, number of DDF and expression of the cyclin-dependent 
kinase inhibitor p21 and absence of proliferation ability, further confirming 
previous reports in our lab (Passos et al. 2007, Passos et al. 2010). We have 
also shown that changes in mitochondrial mass are not an adaptive process 
driven by ROS, but potentially the drivers of ROS generation in senescence as 
demonstrated by: i) unaltered ROS levels following normalisation per unit of 
mitochondria and ii) treatment with the free radical scavenger PBN and the 
antioxidant NAC, where ROS were reduced but mitochondrial mass remained 
unchanged. However, we are aware of the limitations of these dyes in the 
assessment of mitochondrial ROS and mass. DHE measures cellular 
superoxide levels, but it is not mitochondrial specific (Peshavariya et al. 2007). 
Other dyes like MitoSOX, which detects superoxide directly in the mitochondrial 
matrix could have been employed (Mukhopadhyay et al. 2007). However, most 
dyes used to measure ROS are not highly specific and a combination of several 
dyes may be a better approach.  
Our data shows that mitochondrial depletion results in decreased ROS levels 
and SASP factor secretion, both of which have been implicated in the 
stabilisation and reinforcement of senescence via autocrine effects (Acosta et al. 
2008, Passos et al. 2010). We cannot yet exclude that clearance of 
mitochondria rescues senescence via its effect on ROS generation. Our group 
has previously shown that elevated ROS levels in senescent cells as a result of 
signalling through p21 feed back into DNA damage induction and further 
activate the DDR, generating a stable, self-sustaining feedback loop. (Passos et 
al. 2010). In addition, ROS scavengers or antioxidants treatments have been 
shown to rescue the senescent phenotype and in some cases facilitate re-entry 
into the cell cycle (Lee et al. 1999, Macip et al. 2002, Macip et al. 2003, Passos 
et al. 2010). In order to discriminate if ROS is a mediator of the mitochondrial-
dependent cell cycle arrest, cells lacking mitochondria should be treated with 
ROS and assessed for senescence markers. Despite the fact that mitochondrial 
ROS generation increase during senescence could still explain the 
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mitochondrial impact on the induction and maintenance of senescence, it does 
not explain how mitochondrial mass increase in the first place. Another possible 
explanation why mitochondria impact in the induction and maintenance of 
senescence may be related to its effect on the SASP, particularly on the 
inflammatory phenotype. Mitochondria have been described to play a key role 
as mediators of inflammation with ROS playing a major role in host defence 
mechanisms (Tschopp 2011). Elevated ROS levels have been shown to 
activate redox-sensitive transcription factors, such as the nuclear factor-κB (NF-
κB) resulting in increased expression of pro-inflammatory factors (Gloire et al. 
2006). However, ROS-independent mechanisms have also causally implicated 
mitochondria in the induction of inflammatory responses. Mitochondria have 
been identified as key sources of Damage-associated molecular pattern 
molecules (DAMPs) (Krysko et al. 2011). Mito-DAMPs play a role in DAMP-
modulated inflammation in different disorders, such as systemic inflammatory 
response syndrome (SIRS), rheumatoid arthritis (RA), cirrhosis, cancer, and 
heart diseases as well as the aging process (Lopez-Armada et al. 2013). 
Mechanistically, Mito-DAMPs can activate Toll-like membrane receptors (TLRs) 
and cytoplasmic nucleotide-binding oligomerisation domain (NOD)-like 
receptors (NLRs) resulting in the activation of the NF-κB pro-inflammatory 
signalling (Kawai et al. 2009, Krysko et al. 2011). Nevertheless, besides being 
able to induce an inflammatory response, mitochondria can also receive signals 
from inflammatory factors. Evidence has demonstrated that NF-B is present in 
mitochondria of mammalian cells and is able to regulate expression of 
mitochondrial encoded genes (Cogswell et al. 2003). Moreover, the NF-B 
alternative pathway during myogenesis has been shown to be important for 
mitochondrial biogenesis (Bakkar et al. 2008) and to regulate expression of the 
transcription co-activator PGC-1β (a master regulator of mitochondrial 
biogenesis and function) to promote oxidative muscle metabolism (Bakkar et al. 
2012). These last observations could explain why mitochondrial mass increase 
during cellular senescence resulting in elevated ROS generation. Cellular 
energy levels are one other explanation, independent of ROS and SASP levels, 
for the impact of mitochondria in the induction of senescence. It has been 
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shown that the AMP:ATP ratio, a measure of cellular energy charge, increases 
when human fibroblasts reach replicative senescence (Wang et al. 2003, 
Zwerschke et al. 2003), and addition of exogenous AMP to the cell culture 
medium triggers premature senescence in young human fibroblasts (Zwerschke 
et al. 2003). Interestingly, it has been shown that energy failure (reduced levels 
of ATP) resulting from partial mitochondrial uncoupling may contribute to 
cellular senescence in conditions where reducing the rate of oxidative 
phosphorylation induces premature senescence without substantially increasing 
oxidative stress (Stockl et al. 2007). It might be that the reason why we observe 
a decrease in the induction of senescence using the Parkin mediated 
mitochondrial clearance system is due to loss of ATP and is not ROS 
dependent. Although, loss of ATP would impair cells’ proliferating capacity and 
would not explain our observations showing that mitochondrial clearance 
rescues cell proliferation. We hypothesise that the increase proliferation in cells 
depleted of mitochondrial following induction of senescence may be due to an 
energetic replacement from increased glycolysis. We will need to test this 
hypothesis by i) assessing ATP levels in Parkin-expressing MRC5 fibroblasts 
treated with CCCP and ii) by adding ATP or ROS to the Parkin-expressing cells 
and determine if senescence can be restored. 
We have also shown that artificial depletion of mitochondria abrogated the 
development of senescent traits such as increased cell size, Sen-β-Gal activity 
and formation of heterochromatin foci. Emerging studies have demonstrated 
that Krebs cycle intermediates can regulate the level of DNA and histone 
methylation and acetylation. The DNA demethylases and histone lysines 
include members of 2-oxoglutarate-dependent dioxygenases (2-OGDO). These 
enzymes are activated by oxygen, iron and the major Krebs cycle intermediate, 
2-oxoglutarate, whereas they are inhibited by succinate and fumarate. 
(Salminen et al. 2014). Indeed, it is not surprising that mitochondria, an 
organelle with endosymbiotic origin, can regulate gene expression in the host 
cell by modifying the epigenetic landscape of chromatin. This way, changes in 
mitochondrial metabolism during ageing could promote the epigenetic 
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reprogramming underlying the appearance of the senescent phenotype and 
degenerative diseases. 
Elimination of mitochondria rescued proliferation in fibroblasts following 
induction of senescence despite of their inability to rely on oxidative 
phosphorylation. A possible explanation relies on the fact that these cells were 
phenotypically similar to cancer cells presenting high nucleus/cytoplasm ratio 
and being able to grow in low density. Many cancer cells exhibit increased 
glycolysis rather than oxidative phosphorylation as the energy supplier. Majority 
of the pyruvate is converted to lactate, in contrast to entry into the mitochondria 
and conversion to acetyl CoA. (Warburg 1956, Moreno-Sanchez et al. 2009). 
These results suggest mitochondria are required for senescence to occur and 
their absence may contribute to a shift from an irreversible cell cycle arrest 
(senescence) to abnormal proliferation (cancer) in the presence of DNA 
damage. Supporting this hypothesis are reports describing a central role for 
mitochondria in cell proliferation and apoptosis (Antico Arciuch et al. 2012) in 
which levels of hydrogen peroxide are key regulators of the cell cycle fate: lower 
mitochondrial oxidative rates resulting in lower hydrogen peroxide release into 
the cytosol promotes cell proliferation; whereas, stress signals and traffic of pro- 
and antiapoptotic mitochondrial proteins in the intermembrane space, 
modulated by the redox condition determined by mitochondrial O₂ consumption 
and mitochondrial nitric oxide metabolism regulates apoptosis (Antico Arciuch et 
al. 2012). We have also shown that mitochondria are essential for the 
development of the senescent phenotype in fibroblasts that reached 
senescence through replicative exhaustion. Nevertheless, no rescue in cell 
proliferation was observed in replicative senescent fibroblast depleted of 
mitochondria, suggesting that mitochondria are important to restrain cells 
proliferative capacity in the very first states of the development of senescence 
as observed in irradiation-induced senescence (7-10 to develop a senescent 
phenotype) but not when senescence is fully established. Following these 
observations, the extent of mitochondrial elimination should be considered 
when placing mitochondria as a putative therapeutic target in senescence; the 
impact of mitochondrial content on the tumour-suppressive/promoting ability in a 
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cell is dependent on the “state” of cellular senescence (whilst developing or in 
the presence of a full developed senescent phenotype). 
The impact on the senescent phenotype observed as a consequence of 
mitochondrial clearance in humans cells is extended to mouse cells and cells 
harbouring petit mitochondrial (unable to perform oxidative phosphorylation) 
resulting from mtDNA depletion, indicating that mitochondrial content impact on 
cellular senescence is a broader process existing (at least) in mammalian 
organisms. 
Here we showed that the mitochondrial mass increase was accompanied by 
increased expression of the mitochondrial regulators PGC-1α and β in 
senescent cells. Experimental evidence supporting a role for these co-
transcriptional factors regulating mitochondrial biogenesis in senescence was 
performed by Francisco Marques in our lab. PGC-1-/- mouse embryonic 
fibroblasts (MEFs) presented lower mitochondrial mass, mtDNA copy number 
and mitochondrial protein expression than wild-type MEFs. Similarly to 
mitochondrial depleted human fibroblasts, mouse fibroblasts with compromised 
mitochondrial biogenesis (lower mitochondrial content) have also reduced 
expression senescence markers (DDF, p21, p16, ROS and SASP factors). 
Furthermore, when cultured at normal atmospheric (21% O2) oxygen MEFs 
acquire a senescent phenotype after a small number of passages, while when 
grown at low oxygen (3%O2) MEFs show negligible expression of senescent 
markers and divide at faster rates (Parrinello et al. 2003). We found that at 21% 
oxygen, absence of PGC-1 delayed senescence and at 3% O2 PGC-1
-/- had 
higher proliferative rates when compared to wild-types. In contrast, 
overexpression of PGC-1 led to an increase in mitochondrial mass and loss of 
cell proliferation, increased Sen--Gal activity and frequencies of 53BP1 foci 
both in non-irradiated and irradiated fibroblasts. MEFs senescence has been 
associated with oxidative damage (Parrinello et al. 2003). One possibility to 
explain our observations is that PGC-1 mediated mitochondrial biogenesis 
increases oxidative stress, thereby activating a DDR and p21 and p16 mediated 
cell-cycle arrest. 
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Further to the autocrine role of ROS and the SASP in cellular senescence, 
these two features of the senescent phenotype also impact on surrounding 
tissues by induction of paracrine senescence (Nelson et al. 2012, Acosta et al. 
2013) and stimulation of tumour progression when in a tumour context (Davalos 
et al. 2010, Costa et al. 2014). Our observations showing that decreased 
content (PGC-1-/- MEFs) or depletion of mitochondria (Parkin-expressing cell) 
in cells decreases both ROS and the SASP are of great therapeutic interest, 
since manipulation of mitochondrial content would diminish/abrogated the 
deleterious effects of senescence cells in organism. 
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Chapter 4. mTORC1 integrates DDR signalling towards 
mitochondrial biogenesis during senescence 
 
The mechanistic (previously the mammalian) target of rapamycin (mTOR) 
pathway is involved in central cellular functions including cell growth and has 
been widely implicated in the control of pathways regulating mitochondrial 
turnover such as biogenesis and mitophagy. mTOR complex 1 (mTORC1) has 
been shown to integrate inputs from growth factors, stress, energy status and 
amino-acid availability to regulate protein and lipid synthesis and autophagy all 
of which are involved in the complex pathways mediating mitochondrial 
homeostasis (Laplante et al. 2012). Regulation of cell growth (mass), 
proliferation and stress management by mTOR is tightly controlled and requires 
co-integration of this kinase in other major cellular pathways, including the DNA 
damage response to ensure that no damage is transmitted to other cells during 
proliferation (Reiling et al. 2006). DNA damaging stressors such as UV light, 
ROS (e.g. H2O2) and some carcinogens (eg. arsenide) have been reported to 
activate mTORC1. UV light stimulates S6K activity shortly after exposure (<7 
hours), being this effect of UV light over mTORC1 activity sensitive to 
rapamycin (Brenneisen et al. 2000, Ding et al. 2002, Huang et al. 2002). 
Factors involved in DDR pathways such as p38MAPK, ERK1/2, JNK and PI3K 
may also affect S6K phosphorylation via mTORC1 activation (Zhang et al. 2001) 
downstream of exposure to UV light. ROS generation in response to UV 
exposure is one possible explanation, since pre-treatment with ROS 
scavengers or antioxidants prevents S6K activation (Ding et al. 2002, Huang et 
al. 2002). Arsenide, a human carcinogen, has also been found to promote S6K1 
activation via increased H2O2 production (Jung et al. 2003). Given that mTOR is 
activated upon DNA damage and that it is a key regulator of mitochondrial 
homeostasis, we questioned whether mTOR was a mechanistic factor in the 
pathways that lead to mitochondrial mass increase following a persistent DDR 
in senescence. 
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4.1. mTOR drives mitochondrial mass increase during senescence 
 
Following induction of a DDR using X-ray irradiation, we observed a progressive 
increase in phosphorylation of the mTORC1 target p70S6K starting at 6 hours 
in both human (Figure 4.1) and mouse fibroblasts (not shown).  
 
 
 
Figure 4.1 | mTOR activity increases following activation of a 
DDR. Representative western blot of mTORC1 activity measured 
by phosphorylated p70S6K (T389) from 6 to 72 hours after 20Gy 
(data are representative of 3 independent experiments).  
 
In order to understand mechanistically how mitochondrial mass content 
increases in senescence we inhibited mTORC1 with rapamycin in irradiated 
MRC5 fibroblasts. Consistent with a role for mTORC1 in DDR-dependent 
mitochondrial protein expression, expression of mitochondrial proteins 
belonging to OXPHOS complexes I, II, III and IV (NDUFB8, SDHA, UQCRC2, 
and MT-CO1) and the mitochondrial import receptor subunit TOMM20 
(Translocase of outer mitochondrial membrane 20) were significantly reduced 
by rapamycin treatment (Figure 4.2A). In collaboration with Michele Charles and 
Alina Merz in our lab, we further confirmed by morphometric analysis using 
T.E.M that mTOR inhibition by rapamycin decreases mitochondrial volume 
fraction and number in irradiated human fibroblasts (Figure 4.2B). Furthermore, 
Mitotracker Green fluorescence (marker of mitochondria) was also reduced in 
human (Figure 4.2C) and mouse (not shown) irradiated fibroblasts treated with 
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rapamycin. Rhys Anderson in our lab, have also shown that rapamycin 
treatment decreases mtDNA copy number in human (Figure 4.2D) and mouse 
fibroblasts (not shown) following induction of senescence by X-radiation. 
Similarly, in replicatively senescent cells we observed that rapamycin treatment 
greatly reduced mtDNA copy number and mass (not shown). In collaboration 
with Rhys Anderson and Francisco Marques in our lab, we aimed to test the 
robustness of our findings and screened mitochondrial mass as before (see 
Figure 3.1A) following induction of senescence with different known DDR 
activators in a variety of human and mouse cell types treated with rapamycin. In 
all cases, the increased mitochondrial mass could be partially rescued by 
rapamycin (Figure 4.1E). Together these results show that mTOR is an 
essential factor in the pathway(s) leading to mitochondrial mass increase in 
senescence.  
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Figure 4.2 | mTOR inhibition by rapamycin rescues mitochondrial mass content 
in senescence. (A) (top left) Representative western blots of mitochondrial proteins 
TOMM20, NDUFB8 (complex I), SDHA (complex II), UQCR2 (complex III) and MT-
CO1 (complex IV) following 20Gy irradiation with or without rapamycin treatment (data 
are representative of 3 independent experiments); (top right and bottom) Quantification 
of mitochondrial proteins 1 and 3 days after 20Gy in the presence or absence of 
rapamycin. Data are mean±S.E.M. of n=3 independent experiments; (B) (top) 
Representative electron micrographs of human young proliferating MRC5 fibroblasts 
(0Gy) and 3 days after 20Gy with or without rapamycin (Rap) treatment; mitochondria 
are labelled in pink; (bottom) Quantification of mitochondrial volume fraction %Vv and 
mitochondrial number per cross section (T.E.M mitochondrial analyses are 
mean±S.E.M of 24 electron micrographs per condition); Scale bar = 2µm (C) 
Representative images of human fibroblasts stained with Mitotracker green 
(mitochondrial marker) 3 days after 20Gy X-ray irradiation with and without rapamycin; 
Scale bar = 10µm; (D) mtDNA copy number analysis, by Real-Time PCR, of human 
MRC5 fibroblasts 3 days after 20Gy with or without rapamycin treatment. Data are 
mean±S.E.M of 3 independent experiments; (E) Effect of Rapamycin on mitochondrial 
mass (NAO fluorescence) 2-4 days following genotoxic stress (generated by X-ray 
irradiation, Etoposide, Neocarcinostatin (NCS), H2O2 or telomere dysfunction 
(TRF2BM) in a variety of cell lines (data are from 3 independent experiments per cell 
line or treatment). Asterisk denotes statistical significant P<0.05 One-way ANOVA. 
 
 
In collaboration with Berni Carroll in the Korolchuk lab and Francisco Marques 
in our lab, we have overexpressed a constitutively active mutated form of Rheb 
(N153T) (Urano et al. 2007). Rheb overexpression resulted in both increased 
mTORC1 activity (Figure 4.3A) and mitochondrial mass (Figure 4.3B and 4.3C)  
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Figure 4.3 | mTOR hyperactivation stimulates mitochondrial mass increase. (A) 
Representative western blot showing the effect of activated Rheb N153T on 
phosphorylation of p70S6K; (B) Overexpression of activated Rheb (pcDNA3-flag-Rheb-
N153T) increases mitochondrial mass measured by NAO fluorescence in HeLa cells. 
Data are mean±S.E.M of n=3 independent experiments; (C) (left) Representative 
western blot of the effect of activated Rheb on mitochondrial proteins TOMM20 and 
VDAC in MEFs following 10Gy irradiation, (right) Quantification of western blots 
showing expression of mitochondrial proteins TOMM20 and VDAC in controls and 
RhebN153T expressing mouse fibroblasts (2 days following 0 or 10Gy irradiation). 
Data are mean±S.E.M. of n=3 independent western blots. Asterisk denotes statistical 
significant P<0.05 One-way ANOVA. 
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4.2. mTOR-dependent mitochondrial biogenesis in senescence 
 
Experimentally, it is complex to dissect the intricate pathways by which mTOR 
regulates mitochondrial mass. Mitochondrial biogenesis is a multi-factorial 
process which involves the integration of tightly regulated transcriptional events, 
lipid membrane, protein biogenesis and assembly as well as replication of 
mtDNA (Zhu et al. 2013). Several studies indicate that mTORC1 can exert 
regulatory effects on mRNA expression of PGC-1α and β master regulators of 
mitochondrial biogenesis and function, by complex interactions with the 
transcription factors YY1 and NF-κB (Cunningham et al. 2007, Bakkar et al. 
2012). In accordance with a transcriptional regulated process, we found that 
activation of a DDR resulted in a rapamycin sensitive increase in PGC-1α and β 
mRNA abundance (Figure 4.4A) as well as downstream OXPHOS genes 
ATP5G1, COX5A and NDUFS8 (Figure 4.4B).  
 
 
 
 
Figure 4.4 | mTOR-dependent mitochondrial biogenesis in cellular senscence. (A) 
mRNA abundance of PGC-1α (right) and PGC-1β (left) and (B) mitochondrial genes 
ATP5G1, COX5A and NDUFS8 after 20Gy with or without rapamycin treatment. 
Expression was normalised to mRNA levels of GAPDH. Data are mean±S.E.M of n=3 
independent experiments. Asterisk denotes statistical significant P<0.05 One-way 
ANOVA. 
A B 
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Another mTORC1–dependent mitochondrial homeostatic regulatory mechanism 
is mitophagy, a selective type of autophagy, known to be negatively regulated 
by mTORC1 (Zhu et al. 2013). In order to investigate the impact of mitophagy 
following a DDR, we used autophagy-deficient MEFs from ATG5-/- mice (kind 
gift from Dr Viktor Korolchuk from the IAH, Newcastle University, UK). The 
autophagy-related protein 5 (Atg5) when in conjugation complex with Atg12 acts 
as an ubiquitin-protein ligase (E3)-like enzyme necessary for the formation of 
autophagic vesicles, hence ATG5-/- mice have impaired autophagy (Ohsumi 
2001). Work done by Francisco Marques and Graeme Hewitt in our lab have 
shown that while ATG5-/- MEFs experienced increased mitochondrial mass, 
ROS and DDR foci when compared to wild-type, they were still responsive to 
the effects of rapamycin supplementation (Figure 4.5). This suggested that 
mTORC1 mediated effects on mitochondrial mass after a DDR are autophagy-
independent. 
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Figure 4.5 | Autophagy-independent mTOR mediated mitochondrial mass 
increase in senescent MEFs. (A) (left) Representative images of LC3 expression 
(red) in ATG5+/+ and ATG5-/- MEFs; Scale bar = 10µm; (right) Representative western 
blot showing absence of expression of ATG5-12 in ATG5-/- MEFs; (B) Effect of 10Gy 
irradiation and rapamycin treatment on 53BP1 foci number, mitochondrial mass and 
ROS generation in ATG5+/+ and ATG5-/- MEFs. Data are mean±S.E.M. of n=3-4 
independent experiments. Asterisks denote statistical significant P<0.05 using one-way 
ANOVA. 
 
 
Together the results suggest that the mTOR-dependent mitochondrial mass 
increase in senescence occurs as a result of mitochondrial biogenesis 
programme activation via PGC1-α and β rather than impaired mitophagy. 
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4.3. mTOR-inhibition alleviates the senescent phenotype without 
rescuing cell proliferation 
 
Corroborating our previous results showing that mitochondrial clearance 
alleviates the senescent phenotype (Chapter 3), in collaboration with Rhys 
Anderson in our lab, we found that mTOR inhibition-dependent mitochondrial 
mass decrease by rapamycin was accompanied by reduced Sen-β-Gal activity 
in various models of stress-induced and replicative senescence (Figure 4.6A). 
Consistent with reports affirming a central role for a persistent DDR in the 
development of senescence and the emergence of the SASP (Rodier et al. 
2009), we found that rapamycin suppressed the senescence-associated 
secretion of several pro-inflammatory cytokines and mRNA expression of IL-6 
(Figure 4.6B) following induction of a DDR. However, despite decreasing Sen-β-
Gal and the SASP, rapamycin treatment did not rescue cell-cycle arrest in 
senescent fibroblasts (work done in collaboration with Alina Merz in our lab), 
owing these results to the potent anti-proliferative effect of mTOR inhibition 
already shown in not irradiated fibroblasts (Figure 4.6C). Consistent with our 
previous data that mTORC1 acts on mitochondrial biogenesis via PGC-1β, data 
from Francisco Marques in our lab shows that rapamycin decreases Sen-β-Gal 
in wild-type MEFs but has no effect in PGC-1β-/- MEFs (not shown). 
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Figure 4.6 | mTORC1 inhibition decreases Sen-β-Gal activity and SASP 
expression without rescuing cell proliferation in senescence. (A) (left) 
Representative images of Sen-β-Gal activity (Sen-β-Gal – cytoplasmic blue; nucleus – 
pink) with or without rapamycin treatment in MRC5 fibroblast induced senescence 
using X-ray irradiation, Etoposide, Neocarcinostatin (NCS), H2O2 and replicative 
exhaustion (RS); Scale bar = 50µm; (right) Quantification of Sen-β-Gal positive cells. 
Data are mean±S.E.M, n=10 randomly analysed fields (at least 150 cells were 
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analysed per condition); (B) (top) Secreted protein array of a variety of inflammatory 
proteins following X-ray induced senescence in MRC5 fibroblasts treated with 
rapamycin (3 and 10 days after 20Gy); Data are mean of 3 independent experiments; 
(bottom) mRNA abundance of IL-6 up to 10 days after 20Gy with or without rapamycin. 
Data are mean±S.E.M of n=3 independent experiments; (C) (left) Representative 
images of Ki67 immunostaining 3 days following X-ray irradiation with or without 
rapamycin; Scale bar = 40µm; (right) Quantification of Ki67 positive cells at 3 and 10 
days following 20Gy. Data are mean±S.E.M of n=4 independent experiments. Asterisk 
denotes statistical significant P<0.05 by two-tailed t-test or One-way ANOVA. 
 
 
4.4. mTOR-dependent mitochondrial biogenesis maintains ROS-
driven DNA damage foci (DDF) and cellular senescence 
 
A DNA damage response (DDR) is a prominent initiator of senescence and 
persistence of a DDR during senescence has been shown to be essential for 
the stability of stress-induced (Passos et al. 2010), replicative (d'Adda di 
Fagagna et al. 2003) and oncogene-induced senescence (Suram et al. 2012) 
and the development of a SASP (Rodier et al. 2009). Initially we observed that 
rapamycin supplementation immediately following X-ray irradiation had no 
impact on DNA damage repair capability up to 24 hours. However, we found a 
significant reduction of DNA breaks from 24 hours onwards in human fibroblasts 
assessed by alkaline comet assay (Figure 4.7A), and confirmed by frequencies 
of γH2AX foci (immunofluorescence staining) in human (Figure 4.7B) and 
mouse fibroblasts (not shown). γH2AX Immunofluorescence staining was 
performed by Francisco Marques in our lab. 
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Figure 4.7 | mTOR inhibition reduces DNA breaks during senescence. (A) Alkaline 
comet assay on proliferating (0Gy) or 20Gy irradiated MRC5 fibroblasts treated with or 
without rapamycin. To quantify DNA damage, the tail moment (TM) was calculated as 
the product of the tail length and the fraction of DNA in the comet tail. Data are 
Mean±S.E.M of n=3 independent experiments. (B) Kinetics of DDF (H2AX repair in 
MRC5 fibroblasts after 20Gy in the presence or absence of rapamycin. Asterisk 
denotes statistical significant P<0.05 One-way ANOVA. 
 
 
To test whether foci were driven by elevated ROS, we first knocked-down 
mTOR using siRNA (Figure 4.8A) and found that it reduced both DDF and ROS 
2 days after 20Gy (Figure 4.8B). The reduction of DDF was accompanied by 
decreased abundance of p21 protein and mRNA levels (Figure 4.8C). 
Furthermore, we supplemented cells after irradiation with both rapamycin and 
the antioxidant NAC. In collaboration with Graeme Hewitt in our lab, we found 
that NAC, rapamycin or both compounds resulted in a non-cumulative reduction 
of both DDF and ROS (Figure 4.8D). To investigate the role of mitochondrial 
biogenesis in mTORC1-dependent activation of a DDR, Francisco Marques in 
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our lab together with Berni Carrol in the Korolchuk lab, increased or decreased 
mTORC1 activity in wild-type and PGC-1-/- MEFs by overexpression of 
activated Rheb or rapamycin supplementation respectively. We observed that 
following a DDR, Rheb-dependent increase in number of DDF was suppressed 
in PGC-1-/- MEFs. Furthermore, rapamycin was unable to further decrease 
DDF in PGC-1-/- MEFs (Figure 4.8E), suggesting that mTORC1 and PGC-1 
are in the same pathway that regulate ROS-dependent DDF formation and 
activation of a DDR. 
 
Further supporting the idea that mTOR is activated downstream of a DDR 
(Reiling et al. 2006) and that ROS are major inducers of DNA damage, hence 
contributors of a persistent DDR that stabilises senescence (Passos et al. 2010), 
we found that mitochondrial deficient cells, possibly via lower ROS levels, have 
decrease mTOR activity (Figure 4.8F). Based on previous data showing 
dependence between DDR and the SASP (Rodier et al. 2009) and our own 
observations, we hypothesize that maintenance of DDR via mTOR driven 
mitochondrial biogenesis impacts on the development of cellular senescence 
and the SASP (Figure 4.8F). 
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Figure 4.8 | mTOR-dependent mitochondrial biogenesis maintains ROS-driven 
DNA damage foci (DDF) and cellular senescence. (A) Western blot showing the 
knockdown efficiency of 2 different siRNA against mTOR and its effects on p70S6K 
phosphorylation (T389) 2 days after 20Gy (data are representative of 2 independent 
experiments); (B) (left) Quantification of H2A.X and (right) ROS levels (measured by 
DHE) after mTOR knockdown 2 days after 20Gy. Data are Mean±S.E.M of n=3 
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independent experiments; (C) (top) Representative western blot showing inhibition of 
p21 protein expression with rapamycin at different time points (days) after 20Gy (data 
are representative of 3 independent experiments); (bottom) p21 mRNA levels 3 days 
after 20Gy with or without rapamycin treatment. Data are Mean±S.E.M of n=3 
independent experiments; (D) (left) Quantification of H2A.X foci and (right) ROS 
generation (measured by DHE) with or without rapamycin and the antioxidant NAC 3 
days after 20Gy. Data are Mean±S.E.M of n=3 independent experiments; (E) (top) 
Effect of overexpression of mutated Rheb (N153T) on the number of 53BP1 foci in 
wild-type and PGC-1-/- MEFs, 3 days after 0Gy or 10Gy; (bottom) Effect of Rapamycin 
on the number of 53BP1 foci in in wild-type and PGC-1-/- MEFs, 3 days after 0Gy or 
10Gy. Data are Mean±S.E.M of n=3 (at least 125 cells were analysed per condition); (F) 
(top) Representative western blots of mTOR activity in mitochondrial-depleted MRC5 
fibroblasts 10 days after 20Gy and in replicative senescence (RS). C= control and P= 
Parkin expressing cells (data are representative of 2 independent experiments); 
(bottom) Scheme representing the hypothesis that maintenance of DDR via mTOR 
driven ROS is dependent on mitochondria and contributes to the development of the 
senescent phenotype (including the SASP). Asterisk denotes statistical significant 
P<0.05 One-way ANOVA. 
 
 
4.5 The DDR induces mitochondrial biogenesis by activating ATM, 
AKT and mTORC1 phosphorylation cascades 
 
Two lines of evidence suggested that DDR could converge into the mTOR 
signalling pathway via protein kinase B (Akt/PKB) phosphorylation: Firstly, Akt 
has been shown to activate mTORC1 by directly phosphorylating the 
TSC1/TSC2 complex (Inoki et al. 2002) or by dissociation of PRAS40 from the 
essential mTORC1 component RAPTOR (Thedieck et al. 2007). Secondly, Akt 
has been shown be a direct phosphorylation target of ATM (Viniegra et al. 
2005). The serine/threonine kinase ATM is a primary sensor and transducer of 
DNA double strands breaks (DSBs). Following a DSB, ATM is activated and 
phosphorylates numerous key players of the DDR (Derheimer et al. 2010). To 
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test the relation between ATM, Akt and mTOR, we induced a DDR in human 
fibroblasts derived from mutated Ataxia Telangiectasis (AT) patients or treated 
with an ATM inhibitor. In both cases we were able to significantly reduce Akt 
(S473) and p70S6K (T389) phosphorylation induced by DDR when compared to 
controls (Figure 4.9A-C). Moreover, we observed that increased expression of 
the mitochondrial protein NDUFB8 following activation of DDR was significantly 
suppressed in both AT patient fibroblasts and in fibroblasts treated with an ATM 
inhibitor (Figure 4.9A and 4.9B). 
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Figure 4.9 | mTORC1 integrates DDR signalling towards mitochondrial 
biogenesis during cellular senescence. Representative western blots showing 
expression of phosphorylated p70S6K (T389) and AKT (S473), mitochondrial protein 
NDUFB8 and the DDR downstream target p21 in (A) normal fibroblasts and from a 
patient with AT and (B) in MRC5 human fibroblasts treated with or without the ATM 
inhibitor KU55933 at different time points after 20Gy irradiation (data are representative 
of 2 independent experiemnts); (C) Western blot showing effect of ATM inhibitor 
KU55933 on H2A.X and AKT phosphorylation and p21 expression in MRC5 human 
fibroblasts after 20Gy irradiation (1 independent experiment). 
 
Having established that ATM, AKT and mTOR are activated following a DDR, 
we aimed to test whether they would be part of the same pathway regulating 
mitochondrial content during senescence. For this purpose we treated irradiated 
fibroblasts with an ATM inhibitor and/or rapamycin and assessed for 
mitochondrial mass and its correlation with senescence markers (Figure 4.10A). 
In support of a role for ATM, AKT and mTORC1 in the same pathway that 
regulates mitochondrial mass in senescence, we observed that chemical 
inhibition of ATM and mTORC1 activity: i) reduced mitochondrial mass with no 
additive effect when both inhibitors were applied simultaneously (Figure 4.10B), 
ii) had non-synergistic effects on DDF and p21 expression (Figure 4.10C and 
4.10D) and iii) decreased Sen-β-Gal activity with no cumulative effect compared 
to single inhibitions (Figure 4.10E) (work performed in collaboration with Rhys 
Anderson in our lab). 
 
 
 
 
 
 Chapter 4. mTORC1 integrates DDR signals towards mito biogenesis during senescence 
 
122 
 
 
 
Figure 4.10 | Epistatic pathway involving ATM and mTOR in mitochondrial mass 
regulation during senescence. (A) Scheme illustrating experimental design: human 
MRC5 fibroblasts were irradiated with 20Gy and treated with the ATM inhibitor 
KU55933 (ATMi) and/or Rapamycin (Rap); (B) Effect of Rapamycin and/or ATM 
inhibitor KU55933 on mitochondrial mass in human MRC5 fibroblasts 3 days after 
20Gy. Data are mean±S.E.M of n=3 independent experiments; (C) Combined inhibition 
of ATM and mTORC1 effects on p21 expression at day 10 after 20Gy X-radiation 
(western blot is representative of 3 experiments); (D) Combined inhibition of ATM and 
mTORC1 effect on H2A.X (left) and Sen-β-Gal (right) at day 10 after irradiation in 
MRC5 fibroblasts. Data are mean±S.E.M of 3 independent experiments. Asterisk 
denotes statistical significant P<0.05 One-way ANOVA. 
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4.6 Discussion 
 
Mitochondria have been widely associated with cellular senescence and ageing. 
In the previous chapter we have demonstrated that more than associated with, 
mitochondria are necessary for senescence to occur. However the exact 
mechanisms regulating mitochondrial homeostasis in senescence are still 
unclear. Uncovering the pathways that lead to mitochondrial deregulation (e.g. 
mass increase) during senescence are important for the development of 
interventions targeting mitochondria and aiming to decrease senescence “side 
effects” in the located tissues. In this chapter we have demonstrated that 
interventions that reduce the load of mitochondria in cells such as inhibition of 
mTORC1 (and ablation of PGC-1β, in collaboration with Francisco Marques in 
our lab) have a beneficial impact on the senescent phenotype by decreasing 
ROS and SASP factor secretion. Firstly, we showed that mTOR activation 
progressively increases following induction of a DDR using X-ray irradiation in 
human and mouse fibroblasts. This observation is supported by previous 
reports showing that DNA damage stressors such as UV light, ROS and some 
carcinogens can indeed activate mTORC1. (Bae et al. 1999, Brenneisen et al. 
2000, Zhang et al. 2001, Ding et al. 2002, Huang et al. 2002). Consistent with a 
role for mTORC1 in DDR-dependent mitochondrial protein expression, we 
observed that expression of mitochondrial proteins belonging to OXPHOS 
complexes and the mitochondrial import receptor subunit TOMM20 is 
significantly reduced when mTOR is inhibited by rapamycin in irradiated 
fibroblasts. In addition to mitochondrial protein expression analysis, mtDNA 
copy number and mitochondrial mass assessed by flow cytometry (NAO 
intensity), fluorescence microscopy (MitoTracker Green) and T.E.M were also 
reduced upon mTORC1 inhibition in senescent cells. On the other hand, mTOR 
hyperactivation resulting from Rheb overexpression induced an increase in 
mitochondrial content in senescence. Together these results show that mTOR 
is an essential factor in the pathway(s) leading to mitochondrial mass increase 
in senescence and are supported by the idea that mTOR plays a role in the 
complex pathways mediating mitochondrial homeostasis (Laplante et al. 2012).  
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Corroborating our previous results showing that mitochondrial clearance 
alleviates the senescent phenotype, we found that mTORC1 inhibition-
dependent mitochondrial mass decrease by rapamycin was accompanied by 
reduced Sen-β-Gal activity and SASP factor secretion (particularly inflammation 
mediating factors) in senescence, consistent with the reported 
immunossupressive effects of rapamycin (Abraham et al. 1996). There are 
several possible explanations our observations. Sen-β-gal is thought to be a 
result of increased β-galactosidase activity coming from higher lysosomal 
activity demands during senescence (Kurz et al. 2000). It was suggested that 
senescence is accompanied by lysosomal changes including increased size 
and number (Robbins et al. 1970, Lee et al. 2006) which attempt to deal with 
increased molecular damage. Increased molecular damage in senescence has 
been associated with elevated levels of ROS and oxidative damage (Sitte et al. 
2001, Passos et al. 2007, Ahmed et al. 2010), which stimulate degradation 
mechanisms, namely lysosomal degradation. This way mTOR inhibition, by 
decreasing mitochondrial content and subsequent ROS formation, may 
decrease oxidative damage and reduce demands for lysosomal degradation 
during senescence. Alternatively, it has been shown that expression of the 
GLB1 gene, which encodes β-galactosidase, is increased in senescent cells 
(Kurz et al. 2000), thus it might be that by downregulating protein translation, 
mTORC1 inhibition also decreases expression of β-galactosidase. Regarding 
the effect of mTORC1 inhibition on the SASP, it could be that an mTORC1 
inhibition-dependent mitochondrial mass decrease would result in lower ATP 
levels compromising mTORC1 activity with decreased SASP translation. 
However, our results show that inhibition of mTORC1 activity also impacts on 
the mRNA levels of SASP factors. Consistent with our results are reports 
showing that rapamycin affects transcriptional programs controlling proliferative 
and inflammatory properties in smooth muscle cells (Zohlnhofer et al. 2004). 
Nevertheless, reduced transcriptional activity could still be a consequence of 
the loss of S6K mediated protein translation (downstream of mTORC1 inhibition) 
resulting in translation downregulation of major transcriptional regulators. 
Mechanisms independent of mitochondria have also been implicated in the 
 Chapter 4. mTORC1 integrates DDR signals towards mito biogenesis during senescence 
 
125 
 
activation of inflammatory pathways. It has been shown that activation of mTOR 
downstream of Akt regulates NF-B activity in PTEN-null/inactive prostate 
cancer cells via interaction with and stimulation of IKK (Dan et al. 2008), which 
may also explain the control of mTOR over the SASP, particularly the pro-
inflammatory phenotype. 
 A DNA damage response (DDR) is the most prominent initiator of senescence 
and persistence of a DDR during senescence has been shown to be essential 
for the stability of stress-induced (Passos et al. 2010), replicative (d'Adda di 
Fagagna et al. 2003) and oncogene-induced senescence (Suram et al. 2012) 
and the development of a SASP (Rodier et al. 2009). mTOR downregulation 
impacted on ROS-driven DDF, while overexpression of mutated Rheb resulted 
in increased number of DDF in senescent cells, further supporting the role of 
mTOR in ROS generation following a DDR. In this context we have shown that: 
i) mTOR regulates mitochondrial content in senescence and concomitant 
mitochondrial-ROS production; ii) mitochondrial-ROS are an important 
generator of DNA damage during senescence; iii) both mitochondrial (Chapter 3) 
and mTOR (possibly via mitochondria) regulate the SASP and iv) mitochondria, 
possibly via ROS levels and consequent impact on the DDR, regulate mTOR 
activity. Our findings are consistent with a model by which mTOR signalling 
impacts on mitochondria content and by doing so, affects the persistence of a 
DDR and the development of the SASP. We have assumed that mitochondrial 
ROS induces DNA damage and activates a DDR that stabilises senescence. 
However, ROS has been shown to impact on mechanisms leading to 
senescence independently of the DDR. Several studies have reported that ROS 
can activate directly p53, p38MAPK and NF-B activity (Gloire et al. 2006, Liu 
et al. 2008, Wang et al. 2011). Additionally, ROS can activate ATM 
independently of DNA damage (Ditch et al. 2012). It may be that ROS impact 
on the stabilisation of cellular senescence involves regulation of pathways other 
than the positive feedback loop that we have previously reported (Passos et al. 
2010), and that integration of not one but several pathways ensure stabilisation 
of the permanent cell cycle arrest. We can also not exclude direct modes of 
interaction between mTORC1 and targets of the DDR such as p53, 
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independently of mitochondria (Lee et al. 2007, Lai et al. 2010). However, while 
these studies report dynamic interactions between the mTOR and p53 
pathways very shortly after a DDR, they do not explain how the cell-cycle arrest 
is maintained and contributes to the development of senescence which is a 
lengthier process usually taking between 7-10 days post-DDR (Coppé et al. 
2008). Regarding the inhibitory effect of mitochondrial depletion on mTORC1 
activity it could also be that a possible loss of ATP (we still don’t know if 
mitochondrial depleted cells have lower ATP levels) compromises mTORC1 
activity. To exclude ROS-independent effects of mitochondria on mTOR via 
energy levels (ATP) or other direct interaction we would need to perform further 
experiments including supplementation of ATP to mitochondria depleted cells 
and assess for mTORC1 activity and senescence markers. 
mTOR is a master regulator of pathways controlling mitochondrial turnover such 
as biogenesis and mitophagy (Laplante et al. 2012). Mitochondrial biogenesis is 
a multi-factorial process which involves the integration of tightly regulated 
transcriptional events, including lipid membrane and protein biogenesis and 
assembly as well as replication of mtDNA (Zhu et al. 2013). mTORC1 has been 
shown to exert regulatory effects on the mRNA expression of PGC-1α and β 
master regulators of mitochondrial biogenesis and function, by complex 
interactions with the transcription factors YY1 and NF-κB (Cunningham et al. 
2007, Bakkar et al. 2012). In accordance with a transcriptionally regulated 
process, we found that mTORC1 regulates PGC-1α and β mRNA expression 
following activation of a DDR as well as downstream OXPHOS genes. 
mTORC1 has also been implicated in mitochondria homeostasis via mitophagy, 
a selective type of autophagy, known to be negatively regulated by mTORC1 
(Zhu et al. 2013). However, contrary to what was expected, mTORC1 mediated 
effects on mitochondrial mass after a DDR seem to be autophagy-independent, 
at least in the early time points of the development of the senescent phenotype. 
However, we do not discard the hypothesis that autophagy may be impaired 
later on when senescence is fully established and may contribute to its 
maintenance. The impact of autophagy in cellular senescence remains poorly 
defined. A number of reports have provided indirect or circumstantial evidence 
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for the induction of autophagy and senescence (Gewirtz 2013). Young et al. 
have shown that induction of autophagy promotes fibroblast entry into 
senescence (Young et al. 2009). While, Kang et al. has reported that autophagy 
impairment induces premature senescence through a ROS- and p53-dependent 
manner, possibly via mitochondrial dysfunction in primary human fibroblasts 
(Kang et al. 2011). The studies on autophagy and senescence are contradictory 
and further studies are necessary to clarify the role of autophagy and mitophagy 
during senescence. 
Regulation of cell growth (mass), proliferation and stress management by 
mTOR is tightly controlled and requires co-integration of this kinase in other 
major cellular pathways, including the DNA damage response (Reiling et al. 
2006). Here, we report that mechanistically, the mTOR-dependent 
mitochondrial mass increase in senescence follows activation of the DDR 
proteins ATM and AKT. ATM is involved in a wide spectrum of biological 
processes including cell cycle control, genome stability, apoptosis and response 
to genotoxic stress (Shiloh 2003). Beside phosphorylating numerous key 
players of the DDR (Derheimer et al. 2010), ATM has also been shown to 
directly phosphorylate Akt (Viniegra et al. 2005) a serine/threonine kinase that 
has been implicated in pathways related to survival by inhibition of apoptotic 
signals and promotion of cell cycle progression (Nicholson et al. 2002). Despite 
not having chemically or genetically interfered with Akt to assess mTORC1 
activity, we have indirect evidence via ATM inhibition that lower Akt 
phosphorylation correlates with reduced phosphorylation of p70-S6K. Further 
supporting our results, Akt has been shown to activate mTORC1 by directly 
phosphorylating the TSC1/TSC2 complex (Inoki et al. 2002) or by dissociation 
of PRAS40 from the essential mTORC1 component RAPTOR (Thedieck et al. 
2007). Performing double chemical inhibition of ATM and mTORC1 we found 
that these two kinases are part of an epistatic pathway regulating mitochondrial 
mass in senescence. 
In summary, our data suggest that ATM, Akt and mTOR phosphorylation 
cascades downstream of a DDR promote mitochondrial biogenesis and 
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mitochondrial-ROS production that contributes to a persistent DDR that keeps 
cells locked in the cell cycle.  
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Chapter 5. mTORC1-PGC-1β regulate mitochondrial content 
and contribute to senescence in vivo 
 
 
In the previous chapters we have demonstrated that mitochondrial mass 
increase is necessary to senescence to occur in a process co-regulated by 
mTORC1 and the mitochondrial regulator PGC-1β. In this chapter, we 
hypothesised that the mitochondrial mass increased observed during cellular 
senescence in vitro is also a feature of cellular ageing in vivo.  
 
5.1 Mitochondrial mass increase with age in vivo 
 
In order to understand if in vivo cellular ageing is accompanied by an mTORC1-
PGC-1β dependent mitochondria mass increase, we analysed mouse liver 
samples from young (3 months) and old (12 months) animals. Similarly to our 
observations in vitro, in collaboration with Dr Viktor Korolchuk (IAH-Newcastle 
University), we found an age-dependent increase in mTORC1 activity 
(measured by p-S6/S6 ratio) associated with increased p21, PGC-1β and 
OXPHOS components in wild-type mice (Figure 5.1A). Furthermore, we also 
found that a mouse hepatocyte cell line (MIH) cultured in vitro also experienced 
increased mitochondrial mass and ROS generation after activation of a DDR 
and that this increase could be partially suppressed by the mTORC1 inhibitor 
rapamycin (Figure 5.1B). 
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Figure 5.1 | Mitochondrial mass increase with age in mouse liver tissues. (A) (left) 
Representative westerns of pS6, S6, p21, PGC-1β, MT-CO1 and NDUFB8 proteins in 
mouse livers at 3 and 12 months of age (n=3 mice per group); (top right and bottom) 
Quantification of pS6/S6, p21, PGC-1β, MT-CO1, and NDUFB8 protein expression in 
liver tissue from wild-type C57BL/6 mice at 3 and 12 months of age. Data are 
mean±S.E.M n=3 mice per group; (B) Mitochondrial mass and ROS (measured by 
NAO and DHE fluorescence respectively) quantifications of in vitro cultured mouse 
hepatocytes (MIH) 3 days after 10Gy irradiation treated with or without rapamycin. Data 
are mean±S.E.M n=3 independent experiments. Asterisks denote statistical 
significance P<0.05 using two-tailed t-test and one-way ANOVA. 
A 
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5.2 Mitochondrial mass increase with age positively correlates with 
DNA damage in vivo 
 
Following the observation that expression of the DDR effector p21 and 
mitochondrial proteins are simultaneously increased with age in mouse livers, 
we aimed to understand the correlation between mitochondrial content and 
DNA damage in vivo. For this purpose, we performed dual immunofluorescence 
staining against the mitochondrial protein MT-CO1 (a marker of mitochondrial 
content) and H2A.X (a marker of DNA damage) in livers from 12 month old 
mice. We found that hepatocytes containing more MT-CO1 intensity had in 
general higher number of H2A.X foci (Figure 5.2A and 5.2B), indicating a 
positive correlation between mitochondrial mass increase and DNA damage in 
vivo. 
 
 
 
 
Figure 5.2 | Mitochondrial content correlates with DNA damage foci in vivo. (A) 
Representative image of double staining for the mitochondrial protein MT-CO1 and 
H2A.X; Scale bar = 10µm; (B) Quantification of MT-CO1 intensity vs number of 
H2A.X foci in hepatocytes from 12 months old mice (n=3 mice were analysed). 
Asterisks denote statistical significance P<0.05 using one-way ANOVA. 
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5.3 Age-dependent mTORC1 upregulation promotes mitochondrial 
biogenesis in vivo 
 
In order to test the impact of mTORC1 inhibition on mitochondrial mass in vivo, 
mice were fed with rapamycin using the same conditions as Harrison et al. 2009 
(Harrison et al. 2009) and sacrificed at different ages (Figure 5.3).  
 
 
 
 
Figure 5.3 | Rapamycin diet study: experimental design. (A) Scheme 
representative of mice experiments invoving rapamycin diet supplementation; (B) 
Representative western blot of the expression of pS6 and S6 in 16 months old mice 
liver with or without 4 months rapamycin supplementation. 
 
Further investigating the impact of rapamycin on mitochondrial content, Rhys 
Anderson in our lab found that rapamycin prevented the age-dependent 
increase in mtDNA (Figure 5.4A). We also found, through mitochondrial 
morphometric analysis using T.E.M, lower mitochondrial volume fraction and 
mitochondrial numbers per cross-section in rapamycin-supplemented animals 
when compared to controls (Figure 5.4B). In order to investigate the role of 
A B 
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mTORC1 on mitochondrial activity in vivo, in collaboration with Satomi Miwa in 
the von Zglinicki lab, we performed Seahorse XF24 analysis of mitochondrial 
function in liver tissues from control and rapamycin supplemented animals. We 
found no significant changes in mitochondrial function. State III (ADP-
stimulated), state IV and respiration uncoupled from ATP synthesis (using 
uncoupler FCCP) remained unchanged using pyruvate/malate as substrates 
(Figure 5.4C). Supporting a role for mTORC1 in the regulation of mitochondrial 
biogenesis in vivo, in collaboration with Dr Viktor Korolchuk (IAH-Newcastle 
University), we observed that rapamycin treated animals have decreased 
expression of PGC-1β (Figure 5.4D). Together these observations suggest that 
increased mTORC1 activity with age promotes mitochondrial mass increase via 
the mitochondrial regulator PGC-1β. 
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Figure 5.4 | mTORC1 regulate mitochondrial content in vivo. (A) mtDNA copy 
number by qPCR at 3, 12, 16 months and at 16 months after 4 months rapamycin 
treatment. Data are mean±S.E.M of n=3-4 mice per group; (B) (top) Representative 
electron micrographs of hepatocytes from 16 months old mice with or without 4 months 
rapamycin diet, mitochondria are labelled in pink; Scale bar = 5µm; (bottom) 
Quantification of mitochondrial volume fraction %Vv and mitochondrial number per 
cross section (T.E.M mitochondrial analyses are mean±S.E.M of n=3 mice per group; > 
16 electron micrographs (cells) were analysed per mouse); (C) Oxygen consumption 
rates (OCR) in liver mitochondria, from 16 months old mice with or without 4 months 
rapamycin diet, in the presence of pyruvate/malate. Data are mean ± S.E.M of n = 5 
mice per group). State III was induced by injection of ADP. State IV was induced by 
inhibition of the ATP synthase with oligomycin and uncoupled respiration rates were 
A B 
C 
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determined by injection of CCCP. Antimycin A (AA) was used to determine background, 
non-mitochondrial OXPHOS, OCR; (D) (left) PGC-1β expression in 16 months old mice 
fed with of rapamycin supplemented diet  for 4 months (n=3 mice per group); (right) 
Quantification of PGC-1β expression in 16 months old mice fed with of rapamycin 
supplemented diet  for 4 months. Data are mean±S.E.M n=3 mice per group. Asterisks 
denote statistical significance P<0.05 using two-tailed t-test and one-way ANOVA.
  
 
 
5.4 mTORC1 inhibition reduces senescence markers in vivo 
 
5.4.1 mTORC1 inhibition prevents Telomere-associated foci (TAF) in vivo 
 
A recent report in our lab has shown that Telomere-associated foci (TAF), one 
of the important effectors of cellular senescence, increase in mice tissues with 
age (Hewitt et al. 2012). In order to test if mTORC1 inhibition impact on 
Telomeres-associated senescence in vivo we analysed mouse liver tissues of 
rapamycin treated mice as described previously (see Figure 5.3), and found that 
rapamycin was able to prevent the age-dependent increase in TAF. 
Interestingly, the 4 months rapamycin supplemented diet was as effective in 
preventing TAF formation as 12 months treatment (Figures 5.5A). TAF could 
not be attributed to changes in telomere length (Figures 5.5B) or telomerase 
activity (not shown). These results together with the fact that mitochondria 
increase with age positively correlates with DDF and p21 expression, suggests 
that mitochondrial mass increase (via mTORC1 upregulation) is a promoter of 
senescence associated DNA damage in vivo. 
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Figure 5.5 | mTORC1 inhibition prevents TAF formation in liver mouse tissues 
during ageing. (A) (top) Representative immunoFISH images of hepatocytes from 3 
and 15 old mice with or without rapamycin diet. Co-localising foci are amplified in the 
right panel (amplified images are from single Z-planes where co-localisation was found); 
(bottom) Dot plot of Telomere-associated foci in 3, 9.5, 15 and 16 months old control 
mice. 9.5, 15 and 16 months old mice were fed with rapamycin for 6.5, 12 and 4 
months respectively. Quantification of TAF was done in collaboration with other lab 
colleagues (Rhys Anderson, Graeme Hewitt and Francisco Marques) to ensure 
unbiased analysis; at least 50 cells were analysed per mice. Data are mean ± S.E.M of 
n=3-9 mice per group. Asterisks denote statistical significance P<0.05 using one-way 
ANOVA. (B) (left) Representative image of mouse hepatocyte stained for H2A.X and 
telomere-FISH. Two telomeres of equal intensity are shown (a and b), one co-localising 
with H2A.X and the other not; (right) Histograms showing telomere intensity for 
telomeres co-localising (TAF) or not co-localising (non-TAF) with DNA damage foci in 
liver from 16 months old mice with or without 4 months rapamycin treatment (n=4); red 
dotted line represents median intensity. Mann-Whitney test shows no significant 
difference in the telomere intensities distribution between TAF and non-TAF. Intensity 
of 1000 telomeres was analysed per condition. 
 
 
5.4.2 mTORC1 inhibition reduces Sen-β-Gal activity, p21 and SASP factors 
expression in vivo 
 
Consistent with a role for mTORC1 in senescence, we found decreased Sen-β-
Gal (Figure 5.6A) and mRNA expression of components of the SASP (Figure 
5.6B) in the liver of rapamycin fed animals. In collaboration with Rhys Anderson 
in our lab also, we found that Sen-β-Gal positive hepatocytes were generally 
positive for TAF (Figure 5.6C). Further supporting a role for mTORC1 in 
suppressing the DDR in senescence, we found decreased expression of p21 in 
rapamycin fed mice (Figure 5.6D). 
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Figure 5.6 | mTORC1 inhibition reduces senescence markers in vivo. (A) 4 months 
old and 15 months old mice livers [control (-) or rapamycin (+)] stained with Sen-β-Gal 
solution (n=3 mice per group), (B) Dot plots of mRNA expression of the SASP 
components CXCL1, CXCL5 and Inhibin A (normalised to 18S) in livers of 15 months 
old mice fed with rapamycin for 12 months (n=5 mice per group). Data are mean of n=5 
mice per group. Asterisks denote statistical significance P<0.05 using two-tailed t-test; 
(C) Representative image showing Sen-β-Gal staining in hepatocytes (scale bar=10µm) 
and corresponding ImmunoFISH (arrows represent co-localising foci - TAF); (D) 
Representative western blot showing effect of 4 months rapamycin feeding on p21 
expression in 16 months old mice (data are representative of n=3 mice per group). 
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5.5 PGC-1β deficiency diminishes senescence markers in vivo 
 
In order to test in vivo if expression of PGC-1β would have an impact on 
telomere-associated DNA damage, we analysed liver samples from aged PGC-
1β-/- mice. These mice have decreased expression of mitochondrial proteins and 
decreased mtDNA copy number in liver tissues (Figure 5.7A). Consistent with 
our hypothesis that mitochondrial content impact on the DDR and our data 
revealing a role for PGC-1β in senescence in vitro, PGC-1β-/- mice show 
decreased numbers of TAF (Figure 5.7B). Antonio Vidal-Puig in the Rodriguez-
Cuenca Lab (University of Cambridge) has observed (and kindly shared with us) 
that PGC-1β-/- mice show lower energy expenditure than wild-type litter-mates 
and absence of PGC-1β ameliorates age-dependent decline in glucose and 
insulin tolerance (unpublished). Altogether, these results support a causal link 
between the DDR, mTOR and mitochondria in the development of senescence 
in vivo. 
 
 
 
Figure 5.7 | PGC-1β deficiency reduces senescence markers in vivo. (A) (left) 
Quantification of the mitochondrial protein SDHA in wild-type and PGC-1β-/- mice. Data 
are mean ± S.E.M of n = 5 per group; (right) mtDNA copy number comparison between 
wild-type and PGC-1β-/- mice at 7 months of age. Data are mean±S.E.M n=4 mice per 
group; (B) Mean number of Telomere-associated foci (TAF) at 18 months of age in 
PGC-1β-/- when compared to age-matched wild–type mice. Data are mean ± S.E.M of n 
= 4 per group. Asterisks denote statistical significance P<0.05 using two-tailed t-test. 
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5.6 Mitochondrial mass increase may be a tumour-suppressor factor 
and promoter of senescence in vivo 
 
To test the hypothesis that mitochondrial mass increase stabilises the 
senescent arrest and helps maintain tumour suppression, in collaboration with 
Derek Mann’s lab (Institute of Cellular Medicine-Newcastle University), we 
induced liver cancer in mice by intraperitoneal (IP) injection of N-
Nitrosodiethylamine (den) in wild-type mice. Dissection of tumour vs. adjacent 
non-tumour tissue revealed that liver tumours had significantly lower mtDNA 
copy number (Figure 5.8A), reduced expression of PGC-1β and mitochondrial 
proteins SDHA and MT-CO1 (Figure 5.8B and 5.8C). Strikingly, we found that 
the lipid peroxidation marker 4-HNE intensity was markedly reduced in tumour 
regions as were H2A.X foci (Figure 5.8D and 5.8E). These observations 
suggest that mitochondria might be a tumour-suppressor factor and promoter of 
senescence in vivo. 
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Figure 5.8 | Mitochondrial mass is decreased in mouse liver tumours. 
Diethylnitrosamine (den) induced liver tumours were dissected and analysed for: (A) 
mtDNA copy number by qPRC. Data are mean±S.E.M n=3 mice (tumour and non-
tumour) per group and (B) Expression of mitochondrial protein SDHA and PGC-1β 
measured in tumour and adjacent non-tumour tissue (n=5 mice per group); C) 
Histograms show MT-CO1 fluorescence intensity (by immunofluorescence staining) 
comparison between tumour and adjacent non-tumour tissue (n=2 mice were analysed; 
50 cells per area); D) Quantification of number of H2A.X per hepatocyte in tumour and 
adjacent non-tumour regions. Data are mean ± S.E.M of n=3 mice per group; (E) 
Representative image of the lipid peroxidation marker 4-HNE staining in tumour and 
non-tumour regions (data is representative of n=3 mice); Scale bar = 50µm. Asterisks 
denote statistical significance P<0.05 using two-tailed t-test. 
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5.7 Discussion 
 
The role of mitochondria in animal physiology has been the subject of extensive 
investigation with mitochondrial dysfunction being considered a major hallmark 
of ageing, underlining the significance of appropriate mitochondrial activity for 
survival (López-Otín et al. 2013). A rigorous regulation of mitochondrial mass, 
distribution and activity is fundamental for cellular homeostasis and 
maintenance. Mitochondrial dynamics during ageing are subject of controversy. 
What was initially proposed in the MTA has been later questioned, with several 
reports suggesting an inverse relationship between mitochondrial biogenesis 
and ageing. It has been shown that mitochondrial density in skeletal muscle 
gradually declines during age (Crane et al. 2010), suggesting a decrease in 
mitochondrial biogenesis possibly via an age-dependent reduction in levels of 
PGC-1α (Wenz et al. 2009). Additionally, studies on mitochondrial-myopathy 
mouse models have suggested that a compensatory mitochondrial mass 
increase is beneficial by partly compensating for the reduced function of the 
respiratory chain and maintaining overall ATP production in skeletal muscle 
(Wredenberg et al. 2002) However, what seems to be beneficial in skeletal 
muscle may be detrimental in other tissues. The same group has later reported 
that mitochondrial mass increase in heart muscle of the same mouse model 
may contribute to aggravate heart failure progression (Hansson et al. 2004). 
Furthermore, mice studies addressing the role of oxidative damage on ageing 
have proven to be inconclusive. While heterozygous deletion of the 
mitochondrial superoxide dismutase, an enzyme able to convert superoxide 
anion into hydrogen peroxide and water, showed that increased oxidative stress 
does not accelerate ageing in mice (Van Remmen et al. 2003), another study 
showed that overexpression of catalase targeted to mitochondria increased 
lifespan in mice (Schriner et al. 2005). Additionally, interventions promoting 
longevity, namely CR and sirtuin activators, have been linked with increased 
mitochondrial biogenesis (Baur et al. 2006, Lopez-Lluch et al. 2006). 
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In previous chapters we have demonstrated that mitochondrial mass increases 
in senescence via a process co-regulated by mTORC1 and the mitochondrial 
regulator PGC-1β. Therefore we hypothesised that the mitochondrial mass 
increase observed during cellular senescence in vitro could also be a feature of 
cellular ageing in vivo. Here we show that in vivo cellular ageing is 
accompanied by an mTORC1-PGC-1β dependent mitochondrial mass increase. 
Our results demonstrate that there is an age-dependent increase in mTORC1 
activity associated with increased expression of p21, PGC-1β and OXPHOS 
components in wild-type mice. We have shown that age-dependent mTORC1 
hyperactivation promotes mitochondrial biogenesis in vivo. Mice fed with a 
rapamycin supplemented diet (Harrison et al. 2009) have lower mitochondrial 
content shown by decreased mtDNA copy number, mitochondrial volume 
fraction and numbers per cross section (T.E.M), but showed no significant 
changes in mitochondrial function. Further supporting a role for mTORC1 in the 
regulation of mitochondrial biogenesis in vivo, mTORC1 inhibition by rapamycin 
partially supressed expression of PGC-1β. Together these observations 
suggest that increased mTORC1 activity with age promotes mitochondrial mass 
increase via the mitochondrial regulator PGC-1β. Supporting our results 
showing increased mTORC1 activity with age are numerous studies 
demonstrating that mTOR is a key modulator of ageing and age-related 
diseases (Johnson et al. 2013), with mTOR inhibition being the major 
contributor to extension of lifespan in several organisms (Fabrizio et al. 2001, 
Vellai et al. 2003, Jia et al. 2004, Kapahi et al. 2004, Kaeberlein et al. 2005, 
Harrison et al. 2009, Bjedov et al. 2010). Furthermore, we have also shown that 
mTORC1-dependent mitochondrial mass increase positively correlates with 
DNA damage in vivo with age. Our observations are in accordance with 
previous reports showing that mitochondrial oxidative damage is a conserved 
process, accumulating with age in organisms ranging from worms to humans 
(Golden et al. 2001, Yui et al. 2003), resulting in macromolecule oxidation, 
particularly DNA oxidation (Harman 1972, Oliver et al. 1987, Fraga et al. 1990, 
Hamilton et al. 2001). 
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Our in vivo data is consistent with reports in hematopoietic stem cells in which 
mTORC1 activity increases mitochondrial biogenesis, contributing to ROS-
dependent decreased stemness and hematopoiesis (Chen et al. 2008) and that 
mTOR inhibition can alleviate mitochondrial disease (Johnson et al. 2013). The 
reduced mitochondrial content in liver following mTOR inhibition is in 
accordance with various reports of reduced protein synthesis and mitochondrial 
transcriptional regulation observed in mice with impaired mTORC1 activity 
(Cunningham et al. 2007, Romanino et al. 2011). Moreover, it has been recently 
shown by whole-genome expression profiling and large-scale proteomic 
analysis, that mice under CR have less mitochondrial protein synthesis (Lanza 
et al. 2012). This latter study, together with other more recent reports (Hancock 
et al. 2011, Lanza et al. 2012, Price et al. 2012) have questioned early 
associations between DR and enhanced mitochondrial content (Nisoli et al. 
2005). In addition, despite evidence suggesting that increased mitochondrial 
abundance can be an advantageous adaptive response to energy deficit, 
genetically induced mitochondrial biogenesis has been associated with age-
related diseases such as cardiomyopathy (Lehman et al. 2000), renal fibrosis 
(Hickey et al. 2011) and diabetes (Sawada et al. 2014), all of which have been 
associated with cellular senescence (Sussman et al. 2004, Testa et al. 2007, 
Yang et al. 2010). Increased mitochondrial content has also been associated 
with osteoarthritis, particularly Kashin-Beck Disease (KBD), where articular 
chondrocytes present increased mitochondrial mass, but reduced activity of 
complexes II, III, IV and V in patients samples when compared to controls (Liu 
et al. 2010). Alternatively, our results showing increased mTOR activity with age 
could also impact on mitochondrial content via a decrease in autophagy. 
Several reports have suggested that autophagy is down-regulated during 
ageing (Pyo et al. 2013). It has been shown that protein turnover slows down 
with accumulation of protein aggregates with age (Levine et al. 2008). 
Autophagy related proteins, including ATG5, ATG7, and BECN-1, expression 
was shown to be down-regulated in aged human brains (Lipinski et al. 2010). 
Increased autophagy via mTOR inhibition by rapamycin has been shown to 
boost the clearance of mutant huntingtin fragments and attenuates toxicity in 
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cells (Ravikumar et al. 2006), and to reduce tau toxicity and the appearance of 
protein aggregates in D. melanogaster and mammals (Ravikumar et al. 2002, 
Ravikumar et al. 2004, Berger et al. 2006). Additionally, chaperon-mediated 
autophagy has been shown to decline with age in rat liver tissues (Cuervo et al. 
2000). An alternative explanation for our observation is that increased mTORC1 
activity in mouse livers with age could result in decreased autophagic activity, 
namely mitophagy, and explain why we observe an increase in mitochondrial 
mass in this organ during mice ageing, which is partially rescued by treatment 
with rapamycin. Increased PGC-1β expression could be a compensatory 
mechanism in response to accumulation of dysfunctional mitochondria with age 
(possibly resulting from impaired mitophagy). 
Recently, our lab has shown that Telomere-associated foci (TAF), an important 
effector of cellular senescence, increase in mice tissues with age (Hewitt et al. 
2012). Consistent with a role for mTORC1 in senescence in vivo, we found that 
rapamycin treatment prevents the age-dependent increase in TAF. We have 
further shown that mitochondria increase with age positively correlates with 
DDF and p21 expression. The observation of a key role for mTORC1 in the 
maintenance of a DDR in vivo is supported by reports that calorie restriction 
(CR) reduces DDR positive cells in vivo in several tissues (Wang et al. 2010, 
Jurk et al. 2012) as well as ROS (Lanza et al. 2012). Further supporting a role 
for mTORC1 in senescence, we also found decreased Sen-β-Gal activity, p21 
and SASP factor expression in rapamycin fed mice. Together these data 
suggests that mitochondrial mass increase, via mTORC1 hyperactivation, is a 
promoter of senescence associated DNA damage in vivo and contributes to 
secretion of major deleterious senescence factors (ROS and the SASP). 
In order to understand the role of the mitochondrial biogenesis regulator PGC-
1β in vivo we analysed liver samples from PGC-1β-/- mice. We found that PGC-
1β deficiency diminishes senescence markers in vivo. PGC-1β-/- mice present 
lower mitochondrial content (mtDNA copy number and expression of 
mitochondrial proteins) and decreased telomere-associated foci. Moreover, 
absence of PGC-1β ameliorates age-dependent decline in glucose and insulin 
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tolerance. Altogether, our results support a causal link between PGC-1β-
dependent mitochondrial mass increase and the DDR in the development of 
senescence in vivo. To test the physiological relevance of these observations, it 
would be important to perform lifespan experiments in mice lacking PGC-1β 
with an assessment of further senescence and age-related parameters. 
Consistent with the hypothesis that mitochondrial mass increase stabilises the 
senescent arrest and helps maintain tumour suppression in vivo, we found that 
mouse liver tumours have significantly lower mtDNA copy number and reduced 
expression of PGC-1β and mitochondrial proteins. We also found that the lipid 
peroxidation marker 4-HNE intensity was markedly reduced in tumour regions 
as were DDF. Similarly, a persistent DDR at telomeres has been recently 
associated with the tumour suppressor properties of cellular senescence in nevi 
melanocytes but absent in malignant melanoma (Suram et al. 2012). These 
observations suggest that mitochondria might be a tumour-suppressor factor by 
promoting senescence in vivo. Indeed, it is long known that many cancer cells 
present enhanced glycolysis and diminished oxidative phosphorylation capacity 
when compared to their normal counterparts (Warburg 1956, Zheng 2012). This 
shift from mitochondrial oxidative phosphorylation to glycolysis is known as the 
Warburg effect (Warburg 1956). Our results are suggestive of mitochondria as a 
putative tumour suppressor factor by inducing senescence in vivo (Figure 5.9). 
Nonetheless, despite being promising, these observations require further 
experiments to prove tumour suppressor qualities of mitochondria, for instance 
longitudinal studies on PGC-1β-/- mice aiming to assess tumour formation with 
age. 
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Figure 5.9 | Mitochondria as a key promoter of senescence in vivo. Scheme 
represents overall hypothesis: feedback loop between DDR, mTOR and mitochondrial 
biogenesis are involved in the tumour suppressor properties of senescence 
(stabilisation of the arrest), but they also impact on ROS and the SASP which can lead 
to tissue impairment via paracrine effects. 
 
 
The exact mechanisms by which mitochondria contribute to the lengthier 
process of ageing are complex. Our results suggest that there is a mTORC1 
upregulation-dependent mitochondrial mass increase with age via PGC-1β. We 
consider that mitochondrial density is an important factor on cellular ageing, 
however we do not exclude that other mitochondrial changes occur during 
ageing namely a decline in mitochondrial function.  
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Chapter 6. Pro-inflammatory cytokines impact on cellular 
senescence via mitochondrial dysfunction 
 
Considering the multiple factors secreted by senescent cells, pro-inflammatory 
cytokines are amongst the most prominent SASP factors. At the same time that 
they are necessary to restrain tumour progression by stabilising cellular 
senescence both in vitro (Acosta et al. 2008, Kuilman et al. 2008) and in vivo 
(Xue et al. 2007), they also influence the neighbouring environment in a pro-
tumorigenic manner by promoting cell growth, angiogenesis and metastasis 
(Coppé et al. 2006, Campisi et al. 2007). Interleukin-8 (IL-8), also known as 
CXCL8, belongs to the CXC amino acid motif family of pro-inflammatory 
chemokines that are highly secreted by senescent cells (Coppé et al. 2010). IL-
8 is a chemotactic factor whose main functions are to stimulate cell proliferation, 
angiogenesis and migration (Waugh et al. 2008, Ning et al. 2011). This 
chemotactic factor was first described to promote the directional migration and 
activation of neutrophils in response to inflammatory and infectious diseases 
(Baggiolini et al. 1989, Baggiolini et al. 1997). More recent studies have 
recognised IL-8 as an important factor in cancer by promoting tumorigenesis 
(cell proliferation), its maintenance (angiogenesis) and 
progression/invasiveness (migration) (Waugh et al. 2008). IL-8 expression is 
mainly regulated by the nuclear factor-B (NF-B); its promoter contains a NF-
B element that is required for its transcriptional activation in all cell types. 
Although, IL-8 promoter can also be recognised by the activator protein (AP)-1 
and the CAAT/enhancer-binding protein (C/EBP), these sites have been 
described to participate in the transcriptional activation of IL-8 only in some cells 
types (Hoffmann et al. 2002). Once IL-8 expression is inducted by these 
transcription factors, it can activate a variety of signalling pathways through 
binding to two membrane receptors, CXCR1 (IL-8RA) and CXRC2 (IL-8RB). 
(Holmes et al. 1991, Murphy et al. 1991, Holmes et al. 2009). CXCR1 and 2 are 
promiscuous G-protein coupled receptors with affinity for several CXC 
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chemokines. Besides binding to IL-8, CXCR1 can also bind to GCP-2 (CXCL6) 
and to the neutrophil-activating protein (NAP)-2 (CXCL7), whereas CXCR2 can 
additionally bind to CXCL1, 2 and 3 (GRO α, β and γ), CXCL5 (ENA-78), GCP-
2 and NAP-2 (Brat et al. 2005). Both IL-8 and CXCR2 have been shown to 
reinforce cellular senescence (Acosta et al. 2008, Kuilman et al. 2008) but the 
mechanisms through which this cytokine and its receptor contribute to a 
permanent cell cycle arrest are still not clear. 
Previous and my own work have shown (Passos et al. 2010; see Chapters 3 
and 4) that mitochondria and resulting ROS production are key factors in the 
establishment and maintenance of cellular senescence. It is also known that 
pro-inflammatory cytokines, namely IL-8, can reinforce senescence (Acosta et 
al. 2008, Kuilman et al. 2008). However, how these two main features of 
senescence act together to induce and preserve a permanent cell cycle arrest is 
still not clear. In this chapter we examined the links between IL-8 and its 
receptors and mitochondrial dysfunction and ROS generation. Moreover, we 
tested the involvement of the mTOR pathway in the process. 
 
 
6.1 IL-8 expression increases during cellular senescence 
 
Consistent with previous reports (Coppe et al. 2008, Davalos et al. 2010), we 
have observed increased secretion of several pro-inflammatory cytokines in 
senescent (10 days after 20Gy) MRC5 fibroblasts (Figure 6.1A). Performing an 
independent ELISA, in collaboration with Jodie Bitch in our lab, we confirmed 
that IL-8 secretion gradually increases with the development of the senescent 
phenotype in irradiation-induced senescent fibroblasts. 
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Figure 6.1 | IL-8 highly expressed by senescent cells. (A) Secreted protein array of 
a variety of inflammatory proteins following X-ray induced senescence in MRC5 
fibroblasts (3 and 10 days after 20Gy); Data are mean of 3 independent experiments; 
(B) Levels of secreted IL-8 detected by ELISA on proliferating and irradiated MRC5 
fibroblasts at the indicated time-points. (n=1 experiment). 
 
To understand the impact of IL-8 in senescence, we reduced IL-8 signalling by 
either knocking down IL-8 and its receptors (CXCR1 and CXCR2) or using 
neutralising antibodies against IL-8 receptors in irradiated-induced or replicative 
senescent MRC5 fibroblasts (Figure 6.2). 
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Figure 6.2 | Inhibition of IL-8 signalling in irradiation-induced and replicative 
senescent fibroblasts. Scheme illustrating the experimental design: 1. MRC5 
fibroblasts were irradiated (20Gy X-ray) and immediately treated with neutralising 
antibodies against CXCR1 and CXCR2 for 3, 6 or 9 days; 2. MRC5 fibroblasts were 
treated with siRNA against IL-8, CXCR1 and CXCR2 24 hours before irradiation (20Gy 
X-ray), cells were harvested 2 days after irradiation (72 hours of siRNA); 3. Replicative 
senescent MRC5 fibroblasts were treated with neutralising against CXCR1 and CXCR2 
for 3 days. 
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6.2. IL-8Rs Inhibition alleviates the senescent phenotype 
 
Senescent cells can be distinguished from their young proliferating counterparts 
by their cellular morphology characterised by increased cellular volume, loss of 
the original cellular shape and a flattened cytoplasm. To analyse whether 
inhibition of IL-8 receptors would abrogate cell size increase we treated both 
irradiation-induced and replicative senescent MRC5 fibroblasts with CXCR1 
and/or CXCR2 neutralising antibodies. Treatment with IL-8Rs neutralising 
antibodies significantly decreased cell size in both irradiation-induced and 
replicative senescent MRC5 fibroblasts when using a combination of the two 
(CXCR1/2) antibodies (Figure 6.3). The results support the idea that IL-8 
receptors signalling inhibition can reduce cell size increase during induction of 
cellular senescence. 
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Figure 6.3 | IL-8Rs inhibition rescues cell size in senescent cells. (A) Phase 
contrast images of senescent MRC5 fibroblasts showing a rejuvenated phenotype 
upon IL-8Rs neutralisation in both irradiation-induced (3 and 6d IR) and replicative 
senescence (RS); (B) Quantitative analysis of cellular size upon IL-8Rs neutralisation 
both in irradiation-induced and replicative senescence (left and right respectively). Data 
are median cell size at the indicated time points after irradiation or duration of antibody 
incubation in replicative senescent cells. Statistical analysis were performed using 
Mann-Whitney Test, n=100 cells/treatment.  
A 
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To further characterise the impact of IL-8Rs inhibition on cellular senescence, 
we assessed for Sen β-Gal activity. We found that treatment with IL-8Rs 
neutralising antibodies significantly decreased Sen-β-Gal activity in irradiation 
induced senescent fibroblasts (Figure 6.4).  
 
 
  
 
Figure 6.4 | IL-8Rs inhibition decreases Sen-β-Gal activity in senescence. (A) 
Representative images of Sen-β-Gal cytochemistry staining in irradiated MRC5 
fibroblasts upon IL-8Rs neutralisation. Sen-β-Gal positive cells are stained dark blue, 
whereas light blue fluorescence (DAPI) indicates DNA content; Scale bar = 20µm; (B) 
Quantitative analysis of Sen-β Gal activity in MRC5 fibroblasts at 9 days after 
irradiation following IL-8Rs neutralisation. Data are Mean ± SEM, n=3 independent 
experiments (200 cells were analysed per treatment per experiment). Statistical 
analysis was performed using One Way ANOVA Test. 
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6.3 Inhibition of IL-8 activity ameliorates the senescent phenotype 
by improving mitochondrial function in cellular senescence 
 
Mitochondria are central players in oxidative energy metabolism. As a 
consequence of mitochondrial dysfunction, senescent cells have been 
described to generate higher levels of ROS when compared to their young 
proliferating counterparts (Passos et al. 2007). Mitochondrial dysfunction in 
senescence has been characterised by an increase in mitochondrial mass (as 
described on Chapters 3 and 4) and a decrease in the mitochondrial membrane 
potential (depolarization of the membrane potential) with subsequent increased 
ROS formation (Passos et al. 2007). To evaluate the role of IL-8Rs in 
mitochondrial function in senescence, irradiated MRC5 fibroblasts were treated 
with CXCR1 or 2 neutralising antibodies for 3 and 6 days after irradiation. To 
assess for mitochondrial mass cells were stained with NAO and fluorescence 
intensity was measured by flow cytometry. Induction of senescence by 
irradiation led to an increase in mitochondrial mass which was reduced 
following IL-8Rs inhibition (Figure 6.5A). 
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Figure 6.5 | IL-8Rs inhibition improves mitochondrial function in cellular 
senescence. (A) Mitochondrial Mass (Mito Mass) in irradiation-induced senescence. 
NAO intensity in non-irradiated (Prol) and irradiated (3d after 20 Gy) MRC5 fibroblasts 
treated with neutralising antibodies as indicated. Data are Mean ± SEM, n=3 
independent experiments. Statistical analysis was performed using One way ANOVA. 
(B) Mitochondrial Membrane Potential (MMP) in irradiation-induced senescent MRC5 
fibroblasts. Quantification of TMRM/Mito Tracker Green ratios. Box plots represent 
median, upper and lower quartiles, percentiles and outliers; n=3 independent 
experiments (100 cells were analysed per treatment per independent experiment). 
Statistical analysis was performed using ANOVA on Ranks Test. (C) Representative 
TMRM (red) and Mito Tracker Green (green) fluorescence images of irradiated MRC5 
fibroblasts following CXCR1 and CXCR2 neutralisation; Scale bar = 10µm .  
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Mitochondrial Membrane potential (MMP) was measured using the fluorescent 
dye Tetramethylrhodamine methyl ester (TMRM), a cationic and mitochondria 
selective probe that can be assessed by several fluorescence analysis methods 
(including fluorescence microscopy) (Floryk et al. 1999). Because TMRM 
changes the intensity but not the emission spectra in response to membrane 
potential it is a good marker of mitochondrial membrane potential in 
combination with Mito Tracker Green, a marker of mitochondrial mass 
(TMRM/MT Green). Mitochondrial membrane potential (MMP) was significantly 
decreased following induction of senescence and rescued upon neutralisation 
of CXCR1 or 2 in senescent MRC5 fibroblasts 6 days after irradiation (Figure 
6.5B and 6.5C). Following the observation that neutralisation of CXCR1 or 2 
improved mitochondrial function, we questioned whether compromised IL-8 
signalling would affect ROS generation in senescence. For this purpose, we 
decreased IL-8 activity either by small interference RNA (siRNA) knockdown of 
IL-8 and its receptors or using neutralising antibodies against IL-8Rs in both 
irradiation-induced and replicative senescent cells (see Figure 6.2). To measure 
ROS levels (superoxide levels), cells were stained with Dihydroethidium (DHE) 
and fluorescence intensity was measured by flow cytometry. In all cases 
(knockdown of IL-8 and IL-8Rs or neutralisation of IL-8Rs), decreased IL-8 
activity resulted in significantly reduced ROS generation in senescent cells 
(Figure 6.6).  
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Figure 6.6 | Reduced IL-8 signalling decreases ROS generation in senescent cells. 
(A) Inhibition of IL-8Rs decreases ROS levels in irradiated (20Gy X-radiation) MRC5 
human fibroblasts upon short term (3 days) and long term (6 and 9 days) incubation 
with IL-8Rs neutralising antibodies (left and right graphs respectively). Data are Mean ± 
SEM n=3 on the left and Mean ± SD, n=2 on the right. (B) ROS levels in replicative 
senescent MRC5 fibroblasts following inhibition of CXCR1 and CXCR2 with 
neutralising antibodies (3 days antibody incubation). Data are from one experiment 
(n=1). (C) IL-8 and IL-8Rs knockdown using siRNA (72h) in MRC5 fibroblast 2 days 
after Irradiation (20Gy X-radiation). Data are Mean ± SEM n=3 independent 
experiments. Statistical analysis was performed using One Way ANOVA Test. 
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6.4 IL-8 signalling inhibition reduces ROS-dependent DNA damage 
foci in senescence 
 
Our group has previously shown that elevated ROS levels during senescence 
contribute to DNA damage and are responsible for the stability for the 
permanent cell cycle arrest in senescent cells (Passos et al. 2010). Having 
observed that decreased IL-8 signalling reduced ROS generation during 
senescence, we question whether decreased IL-8 activity would also impact on 
DNA damage. For this purpose, irradiated fibroblasts treated for 72 hours with 
siRNA against IL-8 and its receptors were immunostained for γH2AX, a marker 
of DNA double strands breaks. Knockdown of IL-8 and IL-8Rs significantly 
decreased the number of DNA damage foci per cell compared to that of the 
scrambled control (Figure 6.7A and 6.7B). Additionally, an alkaline comet assay 
was performed as an independent method to assess DNA damage (single and 
double strand breaks). Data shows that CXCR1 and 2 neutralisation 
significantly decrease DNA breaks at 3 days after 20Gy in MRC5 fibroblasts 
(Figure 6.7C). Interestingly, CXCR1 and 2 neutralisation had no impact on DNA 
damage repair capability immediately following X-ray irradiation (up to 6 hours). 
We have previously shown that ROS levels in senescence increase 2-3 days 
following a DDR and can induce more DNA damage in a positive feedback loop 
that stabilises cellular senescence (Passos et al. 2010), supporting the idea that 
the later (3 days after X-radiation) increase in DNA is ROS driven and the 
decrease on DDF following IL-8Rs neutralisation may result from ROS 
generation repression. Together our results show that decreased IL-8 signalling, 
by either neutralisation or knockdown of IL-8 and its receptors, reduces DNA 
damage in senescence possibly as a result of decreased ROS levels. 
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Figure 6.7 | IL-8 and IL-8Rs inhibition decreases DNA damage in cellular 
senescence. (A) Representative γH2AX foci immunofluorescence images of irradiated 
MRC5 fibroblasts following siRNA knockdown of IL-8 and IL-8Rs, 2 days after 
irradiation. γH2AX is indicated by red fluorescent foci whereas blue fluorescence (DAPI) 
indicates DNA content; Scale bar = 10µm;  (B) Quantitative analysis of numbers of 
γH2AX foci per nucleus by immunofluorescence staining in irradiated MRC5 following 
knockdown of IL-8 and IL-8Rs. Data are Mean ± SEM, n=3 independent experiments. 
(C) Alkaline comet assay showing DNA breaks fold change (FC) following IL-8Rs 
inhibition using neutralising antibodies in irradiated MRC5 fibroblasts. Data are Mean ± 
SEM, n=3 independent. Statistical analysis was performed using One Way ANOVA 
Test. 
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6.5 IL-8 and IL-8Rs inhibition does not rescue cell proliferation in 
Irradiation-induced senescence 
 
Consistent with a function for IL-8 as a pro-proliferation cytokine (Waugh et al. 
2008), we found that IL-8 signalling inhibition significantly decreased cell 
proliferation in non-irradiated cells (Figure 6.8A) and did not rescue cell 
proliferation upon induction of senescence with 20Gy X-radiation in MRC5 
fibroblasts (Figure 6.8B). Lawless et al. proposed that absence of a proliferation 
marker (e.g. Ki-67) and the presence of more than 5 DDF (e.g. γH2A.X) is a 
robust marker of senescence (Lawless et al.). We have performed Ki-
67/γH2A.X double immunostaining on MRC5 fibroblasts following IL-8 and IL-
8R knockdown in irradiation-induced senescent fibroblast. We found that a 
small percentage of non-irradiated cells (0Gy) were positive for γH2A.X >5 foci 
and Ki-67, possibly as a result of replication stress (DNA replication). 
Nevertheless, knockdown of IL-8 and IL-8Rs significantly reduced the 
proportion of cells negative for Ki67 with more than 5 γH2A.X foci (Figure 6.8C), 
indicating that despite still being locked in the cell cycle, these cells harbour less 
DNA damage. 
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Figure 6.8 | Inhibition of IL-8 signalling does not rescue cell proliferation in 
irradiation-induced senescence (A) Representative Ki-67 immunofluorescence 
images of non-irradiated (0Gy) MRC5 fibroblasts upon 6 and 9 days of CXCR1 
neutralising antibody incubation; Scale bar = 20µm; (B) Quantitative analysis of Ki-67 
positive cells at the indicated times points after 0Gy or 20Gy X-radiation following (top) 
neutralisation of IL-8Rs and (bottom) knockdown of IL-8 and its receptors in MRC5 
fibroblasts. Data are Mean ± SEM of n=3 independent experiments; (C) Quantitative 
analysis of percentage of Ki-67 (positive and negative), and number of γH2A.X foci (<5 
foci or >5 foci) upon IL-8 and IL-8Rs knockdown in 0Gy or 20 Gy X-radiation treated 
MRC5 fibroblasts. Data are mean ± SEM of n=3 independent irradiation. Statistical 
analysis was performed using One way ANOVA Test. 
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6.6 IL-8 stabilises cellular senescence via mitochondrial dysfunction 
and ROS generation through mTOR  
 
In previous chapters we have shown that mTOR is a central mediator of 
mitochondrial biogenesis in cellular senescence by regulating PGC-1β co-
transcription factor. We have also shown that repression of mTOR abrogates 
the senescent phenotype in a similar fashion to that observed following IL-8 
signalling inhibition. In addition, it is well-established that mTOR can be 
activated downstream of G protein-coupled receptors (O'Hayre et al. 2014). 
This way we hypothesised that IL-8/IL-8Rs and mTOR may be involved in the 
same pathway that regulates mitochondrial function in senescence. To explore 
our hypothesis, we started by neutralising both CXCR1 and CXCR2 and assess 
for mTOR activity upon induction of senescence. We found that treatment with 
neutralising antibodies against CXCR1/2 decreased phospho-p70S6K in 
senescent MRC5 fibroblasts (Figure 6.9A), indicating that mTOR activity is 
reduced when IL-8Rs are repressed. Following these observations, we double 
knocked down IL-8/IL-8Rs and mTOR in MRC5 fibroblasts and assessed for 
ROS production in senescence. Individual knockdowns of IL-8, IL-8Rs and 
mTOR significantly decrease ROS generation in MRC5 fibroblasts 2 days after 
20Gy as previously shown. Double knockdown of IL-8/IL-8Rs and mTOR also 
significantly decreased ROS generation in irradiated fibroblasts but with no 
cumulative effect (Figure 6.9B), suggesting that IL-8 and mTOR may act 
together in the same pathway that regulates mitochondrial function to stabilise 
cellular senescence. A similar non-cumulative effect was observed when 
assessing DNA damage foci following double knockdown of IL-8 and mTOR 
(Figure 6.9C). 
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Figure 6.9 | IL-8 impacts on mitochondrial function via mTOR during senescence. 
(A) Representative western blots of mTOR activity measured by phosphorylation levels 
of p70S6K (T389) 3 days after 20 Gy X-radiation (data are representative of 2 
independent experiments); (B) ROS (DHE intensity) levels following double knockdown 
of IL-8/IL-8Rs and mTOR in irradiated MRC5 fibroblasts (2 days after 20Gy X-ray). 
Data shows Mean ± SEM, n=3 independent experiments; (C) Quantitative analysis of 
γH2AX immunofluorescence staining in irradiated MRC5 following double knockdown 
of IL-8 and mTOR. Data are Mean ± SEM, n=3 independent experiments. Statistical 
analysis was performed using One way ANOVA statistical test.  
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6.7 Discussion 
 
Reports have shown that SASP factors can trigger and reinforce senescence in 
a paracrine and autocrine fashion, among these factors interleukins encompass 
some of the most prominent SASP factors. A recent report showed that the IL-8 
receptor CXCR2 and its ligands are upregulated during senescence forming a 
chemokine network reinforcing senescence in a p53-dependent manner (Acosta 
et al. 2008). It has also been reported that mitochondria become dysfunctional 
during senescence, with increased mitochondrial mass and decreased 
mitochondrial membrane potential being the source of higher ROS in this 
cellular state (Passos et al. 2010). There is some evidence on ROS and SASP 
regulation in senescence, but little is known about how ROS and SASP interact 
during senescence. To explore the impact of pro-inflammatory cytokines on 
mitochondrial function in senescence, IL-8 (a pro-inflammatory cytokine highly 
secreted by senescent cells) signalling was inhibited in senescent fibroblasts. 
The results shown in this chapter are preliminary and require further 
experimental confirmation, which will be highlighted during this discussion. 
Our results show that neutralisation of IL-8Rs significantly decreased 
mitochondrial mass and improved mitochondrial membrane potential (MMP) in 
irradiation-induced senescent MRC5 fibroblasts. Despite being promising, our 
results on MMP using TMRM should be further confirmed with analysis of 
oxygen consumption rates in whole cells and isolated mitochondria using the 
Seahorse technology, and the IL-8 impact on mitochondrial mass should also 
be confirmed by mtDNA copy number, electron microscopy and mitochondrial 
protein expression analysis. The improvement in mitochondrial function 
following IL-8 signalling inhibition was accompanied by decreased ROS 
generation. Consistent with our results are previous observations that CXCR2 
downregulation decreases ROS levels in senescence (Acosta et al. 2008). 
Furthermore, previous reports have shown that generation of superoxide in 
response to IL-8 is selectively mediated by CXCR1 in neutrophils (Jones et al. 
1996, Jones et al. 1997). However, the CXCR1-dependent ROS generation in 
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neutrophils has been attributed to non-mitochondrial sources such as NADPH 
oxidases (Jones et al. 1996). To discriminate the source of ROS generation 
downstream of CXCR1 and CXCR2 activation we would need to: 1. analyse 
expression of mitochondrial regulatory proteins such as PGC-1α and β following 
inhibition of IL-8 signalling; 2. analyse expression of NADPH oxidases and other 
non-mitochondrial enzymes capable of producing ROS during senescence and 
assess whether IL-8 signalling inhibition downregulates expression of these 
enzymes; 3. treat mitochondrial depleted cell (e.g. Parkin-expressing MRC5 
fibroblasts) with IL-8 and assess for ROS production and expression of non-
mitochondrial enzymes capable of ROS production following induction of 
senescence. 
Senescent cells have been described to contain increased numbers of DNA 
damage foci which seem to remain constant overtime (Passos et al. 2010, 
Hewitt et al. 2012). A persistent DNA damage response is a central mediator of 
cellular senescence and has been shown to play a role in the maintenance of 
the cell cycle arrest (d'Adda di Fagagna et al. 2003, Passos et al. 2010). Our 
data showing that Inhibition of IL-8 signalling simultaneously decreases DDF 
and ROS levels in senescent MRC5 fibroblasts are consistent with previous 
reports (Acosta et al. 2008) and further supports the positive feedback loop 
described by Passos et al. (2010). We have observed that after X-radiation 
induced DNA damage cells quickly repair the majority of the damage (within 6 
hours as shown in the comet assay Figure 6.6C), new DNA damage is then 
generated most probably due to increased ROS production resulting from 
mitochondrial mass increase during senescence (shown in the previous 
chapters and Figure 6.6C). In this context, we hypothesise that IL-8 signalling 
inhibition prevents DNA damage formation by reducing mitochondrial mass and 
ROS generation. To support our hypothesis we would need to perform 
experiments where downregulation of IL-8 signalling is combined with 
antioxidant treatments and assess for DNA damage during senescence. We 
should also analyse expression of other DDR markers such as phosphorylated 
p53, p21 and p16 to support a role for IL-8 in the induction of a DDR during 
senescence. Furthermore, interpretation of experiments involving knockdown of 
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IL-8 and its receptors is limited. Despite several attempts, determination of the 
knockdown efficiency of siRNA against IL-8 and IL-8Rs was not possible by 
western blotting or qPCR (we could not see a signal by western blotting and 
values by qPCR were close to undetectable). We believe that at 2 days after 
irradiation, expression of these proteins are still too low, yet able to produce an 
effect. We will need to repeat and confirm these experiments by improving our 
methodology regarding siRNA efficiency analysis (e.g. increasing protein 
loading for western blotting; increasing cDNA amount for qPCR or performing 
another method of protein visualisation  such as immunofluorescence). 
Further characterising the role of IL-8 inhibition in the senescence process, we 
found that neutralisation of IL-8Rs decreases Sen-β-Gal activity and cell size in 
senescent fibroblasts with no rescue in cell proliferation in irradiated fibroblasts 
following neutralisation or knockdown of IL-8 and its receptors. Consistent with 
our results is the fact that IL-8 is a potent pro-proliferating chemokine (Waugh et 
al. 2008). Although absence of cell proliferation is not an intrinsic marker of 
senescence but in combination with other markers of senescence it is a reliable 
marker of senescence. Consistent with our results showing a role for IL-8 in 
senescence, particularly on DNA damage, knockdown of IL- 8 and IL-8Rs 
significantly reduced the proportion of cells negative for Ki-67 with more than 5 
γH2A.X foci (senescent cells). Once more, siRNA efficiency needs to be 
confirmed in these experiments. 
In order to mechanistically understand how IL-8 regulates mitochondrial function 
in senescence, we correlated our previous data showing that mitochondrial 
mass increase in senescence is mTOR dependent and assessed for mTOR 
activity following IL-8 signalling inhibition. Consistent with previous reports 
showing that G-protein coupled receptors, such as CXCR1 and CXCR2 (IL-
8Rs), can activate mTOR (O'Hayre et al. 2014), we found that IL-8Rs 
neutralisation results in reduced p70S6K phosphorylation, hence reduced 
mTOR activity, following induction of senescence. Further supporting our 
observations, IL-8 has been shown to induce changes in protein expression 
through regulation of translation associated proteins: IL-8 signalling promotes 
 Chapter 6. Pro-inflammatory cytokines impact on cellular senescence via mito dysfunction 
 
168 
 
multisite phosphorylation of the ribosomal S6 kinase as a consequence of 
mTOR activation (MacManus et al. 2007). Consistent with a role in the same 
pathway regulating mitochondrial function on senescence, we found that double 
knockdown of IL-8/IL-8Rs and mTOR significantly decrease ROS generation 
and DDF in senescent fibroblasts in a non-cumulative fashion. We have indirect 
evidence that IL-8 impacts on mitochondrial mass via mTOR during senescence, 
however we would need to perform double inhibition of IL-8 and mTOR 
signalling to analyse the effect of downregulation of these pathways on 
mitochondrial content during senescence (e.g using fluorescence dyes and/or 
EM). 
We have shown that IL-8 impacts on ROS, bioactive molecules involved in 
autocrine and paracrine induction of senescence (Passos et al. 2010, Nelson et 
al. 2012), via a pathway that seems to be dependent on mTOR. Nevertheless, 
we still need to understand the impact of reduced pro-inflammatory stimuli via 
downregulation of IL-8 signalling on SASP activation, also known to promote 
autocrine and paracrine effects during senescence (Acosta et al. 2008, Acosta 
et al. 2013). Previously in this thesis (Chapter 4) we show that mTOR inhibition 
alleviates the senescence-associated inflammatory phenotype. It may be that 
inhibition of IL-8 signalling through its regulatory control over mTOR activity, 
results in downregulation of the SASP. However, these speculations need 
experimental confirmation. 
To summarise, we had previously shown that mTOR stimulates mitochondrial 
biogenesis and ROS generation leading to DNA damage and the stabilisation of 
cellular senescence. Furthermore, at the same time that mTOR is activated 
downstream of IL-8 and its receptors, it is also a key factor in the pathways 
regulating protein translation and inhibition of mTORC1 by rapamycin represses 
the SASP. These observations, together with the fact that IL-8 may affect 
mTOR-dependent mitochondrial function during senescence suggest that IL-8 is 
part of the positive feedback loop that reinforces the growth arrest. In this 
context our preliminary results are suggestive of a model where inflammatory 
cytokines promote mTOR-dependent mitochondrial biogenesis leading to 
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increased ROS production and SASP factor secretion (e.g. pro-inflammatory 
cytokines), which continuously contribute to DNA damage and induce a 
persistent DDR able to activate mTOR (Figure 6.10). 
 
 
 
 
Figure 6.10 | IL-8 stabilises cellular senescence via mTOR-dependent 
mitochondrial dysfunction. IL-8 activates mTOR-dependent mitochondrial biogenesis. 
Higher mitochondrial content results in increased ROS production and ROS-driven 
DNA damage, which is in turn able to activate mTOR closing this way a positive 
feedback loop (Correia-Melo and Marques et al. unpublished). Persistent DNA 
signalling can also trigger the senescence-associated secretory phenotype (SASP) 
including secretion of IL-8 (Rodier et al. 2009). IL-8 and its receptors can reinforce 
senescence in an autocrine fashion (Acosta et al. 2008), closing this way another 
positive feedback loop that stabilises cellular senescence. 
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The implications of senescence in physiological and pathological settings, such 
as ageing and cancer, have gained firm ground. It is therefore important to learn 
more about the mechanisms underpinning the establishment and maintenance 
of senescence. Autocrine and paracrine effects of senescence are dependent 
on the development of the so-called senescent phenotype, which involves over-
production of pro-inflammatory and pro-oxidant signals. However the exact 
mechanisms underlying induction of such a phenotype remain incompletely 
understood. In this thesis we aimed to comprehend how mitochondria and pro-
inflammatory factors interact during senescence and how they contribute to the 
severity of the senescent phenotype.   
Despite being numerous, the studies on the impact of mitochondria on the 
ageing process have so far failed to establish the fundamental importance of 
these organelles on cellular senescence. The work done in this PhD thesis has 
first shown that there is an increase in mitochondrial mass following DDR stimuli 
and this correlates with markers of senescence, including increased Sen-β-Gal 
activity, number of DDF and expression of the cyclin-dependent kinase inhibitor 
p21 and absence of proliferation ability. It was also demonstrated that changes 
in mitochondrial mass are not an adaptive process driven by ROS, but 
potentially the driver of ROS generation in senescence. Secondly, by artificially 
depletion of mitochondria, we demonstrate that these organelles are necessary 
for the development of the aging-promoting characteristics of the senescent 
phenotype (including ROS and the SASP). Our observations are of great 
therapeutic interest, since manipulation of mitochondrial content would 
diminish/abrogate the deleterious effects of senescent cells in an organism. 
However, elimination of mitochondria rescued proliferation in fibroblasts 
following induction of senescence despite their inability to rely on oxidative 
phosphorylation. A possible explanation relies on the fact that these cells 
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shared phenotypic traits of cancer cells. Interestingly, no recue in cell 
proliferation was observed in replicative senescent fibroblasts depleted of 
mitochondria, suggesting that mitochondria is important to restrain cells 
proliferative capacity in the very first states of the development of senescence 
as observed in irradiation-induced senescence (7-10 to develop a senescent 
phenotype), but not when senescence is fully established. Furthermore, our 
work showed that interventions which reduce the load of mitochondria in cells, 
such as inhibition of mTOR and depletion of PGC-1, have similar impact on 
the senescent phenotype. Considering these observations, the extent of 
mitochondrial elimination should be taken into account when placing 
mitochondria as a putative therapeutic target in senescence; the impact of 
mitochondrial content on the tumour-suppressive/promoting ability in a cell is 
dependent on the “state” of cellular senescence (whilst developing or in the 
presence of a fully developed senescent phenotype). Mechanistically, we 
showed that ATM, Akt and mTOR phosphorylation cascades, downstream of a 
DDR, promote mitochondrial biogenesis and mitochondrial-ROS production 
which contributes to a persistent DDR that keeps cells locked in the cell cycle. 
The role of mitochondria in animal physiology has been the subject of extensive 
investigation with mitochondrial dysfunction being considered as a major 
hallmark of ageing, underlining the significance of mitochondrial homeostasis 
for survival (López-Otín et al. 2013). A rigorous regulation of mitochondrial 
mass, distribution and activity is fundamental for cellular homeostasis and 
maintenance. Despite evidence proposing a role for mitochondria in ageing and 
age-associated diseases (Vafai et al. 2012, Malpass 2013), mitochondrial 
dynamics during ageing is still controversial, owing to the fact that interventions 
promoting longevity, namely DR and sirtuin activators, have been linked with 
increased mitochondrial biogenesis (Baur et al. 2006, Lopez-Lluch et al. 2006). 
Here we showed that in vivo cellular ageing is accompanied by an mTORC1-
PGC-1β dependent mitochondrial mass increase. First we showed that there is 
an age-dependent increase in mTORC1 activity associated with increased p21, 
PGC-1β and OXPHOS components in wild-type mice. Secondly, we have 
demonstrated that the age-dependent mTORC1 hyperactivation promotes 
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mitochondrial biogenesis via the mitochondrial regulator PGC-1β in vivo. 
Consistent with the hypothesis that mitochondrial mass increase stabilises the 
senescent arrest and helps maintain tumour suppression in vivo, we found that 
mouse liver tumours have significantly reduced mitochondrial content, 
suggesting that mitochondria might be a strong tumour-suppressor factor by 
promoting senescence in vivo. Corroborating this hypothesis are reports 
showing that many cancer cells present enhanced glycolysis and diminished 
oxidative phosphorylation capacity when compared to their normal counterparts 
(Warburg 1956, Zheng 2012).  
SASP factors can trigger and reinforce senescence in a paracrine and autocrine 
fashion, among these factors interleukins encompass some of the most 
prominent SASP factors (Acosta et al. 2008, Acosta et al. 2013). A recent report 
showed that the IL-8 receptor CXCR2 and many of its ligands are upregulated 
during senescence and that they form part of a chemokine network reinforcing 
cellular growth arrest in a p53-dependent manner (Acosta et al. 2008). 
Considering these observations, we aimed to understand how SASP factors 
interact with mitochondria during senescence. We showed that inhibition of IL-8 
decreases ROS generation possibly by improving mitochondrial function in 
cellular senescence via the intermediate action of mTOR. Owing to IL-8 pro-
proliferating signalling, inhibition of this pro-inflammatory cytokine did not rescue 
cell proliferation upon induction of senescence, placing IL-8 as putative 
therapeutic target in senescence as it eases the senescent phenotype without 
rescuing proliferation of cells harbouring DNA damage.  
Bringing together our findings, young proliferating cells are continuously 
exposed to a plethora of stressors eventually causing irreparable DNA damage. 
Cells containing irreparable DNA damage undergo a permanent cell cycle arrest 
(senescence), as a result of a persistent DDR. The DDR induces mTOR-
dependent mitochondrial biogenesis resulting in higher ROS production and 
additional induction of DNA damage (feedback loop 1). The DDR also triggers 
the senescence-associated secretory phenotype (SASP), particularly the 
inflammatory phenotype (Rodier et al. 2009). The inflammatory phenotype, 
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particularly IL-8 and its receptors reinforce senescence in an autocrine fashion 
(Acosta et al. 2008) (feedback loop 2). Activation of mTOR via IL-8 - CXCR1/2 
is the linking factor between the two main circle pathways (feedback loop 1 and 
2) that stabilise cellular senescence (Correia-Melo et al. unpublished). Both 
ROS and the SASP contribute to tissue impairment by inducing paracrine 
senescence (Nelson et al. 2012, Acosta et al. 2013) and cancer progression 
when in a tumour context (Wu 2006, Davalos et al. 2010). Inhibition of IL-8 
signalling reduces activation of the pathways maintaining and stabilising cellular 
senescence, resulting in decreased ROS- and SASP factors-dependent tissue 
impairment (Figure 7.1). 
 
 
 
Figure 7.1 | Interactions between mitochondria and inflammatory factors during 
cellular senescence.. Young proliferating cells are continuously exposed to a myriad 
of stressors eventually causing irreparable DNA damage. Cells containing irreparable 
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DNA damage undergo a permanent cell cycle arrest, senescence, as a result of a 
persistent DNA damage response (DDR). The DDR induces mTOR-dependent 
mitochondrial biogenesis with higher ROS production and additional induction of DNA 
damage (feedback loop 1). The DDR also triggers the senescence-associated 
secretory phenotype (SASP), particularly the inflammatory phenotype (Rodier et al. 
2009). The inflammatory phenotype, particularly IL-8 and its receptors reinforce 
senescence in an autocrine fashion (Acosta et al. 2008) (feedback loop 2). Activation of 
mTOR via IL-8 - CXCR1/2 is the linking factor between the two main circle pathways 
(feedback loop 1 and 2) that stabilise cellular senescence (Correia-Melo et al. 
unpublished). Both ROS and the SASP contribute to tissue impairment by inducing 
paracrine senescence (Nelson et al. 2012, Acosta et al. 2013) and cancer progression 
when in a tumour context (Wu 2006, Davalos et al. 2010). Inhibition of IL-8 signalling 
reduces activation of the pathways maintaining and stabilising cellular senescence, 
resulting in decreased ROS- and SASP factors-dependent tissue impairment. 
 
 
The work developed on this thesis may be of potential interest in therapeutically 
combating the pro-oxidant and pro-inflammatory effects of cellular senescence, 
given their suggested role as drivers of age-related disease (Tchkonia et al. 
2013, Correia-Melo et al. 2014). Our data demonstrating that mitochondria are 
required for these features of senescence has very important implications for 
our understanding of the origins and mechanisms underlying the senescence 
phenotype and suggests mitochondria as major putative therapeutic targets for 
interventions impacting on the senescent phenotype. 
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